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Abstract 
Newly emerging infectious agents along with already existing ones, extended life­
span and increased population in the modern age, and the threat of biological warfare 
increase the demand for high amounts of pharmaceutical/diagnostic recombinant protein 
production. Plants are safe and cost efficient for production of recombinant pharmaceuticals 
for humans and livestock. This work investigated potential of corn to serve as a production 
and delivery vehicle for subunit vaccines and vaccine components. Highly immunogenic 
antigens LT-B and CT-B from enterotoxigenic strains of Escherichia coli (E. coli) and Vibrio 
cholera (K cholera) were used in this study as vaccine/component candidates. 
This study indicated that corn derived LT-B is capable of inducing immune memory 
formation. Mice were immunized with LT-B corn through feeding when they were young. 
They showed a rapid immune memory response in the form of elevated levels of LT-B 
specific IgG and IgA antibodies upon receiving a booster dose 11 months after initial 
immunization. This work provided evidence that immunization through feeding with 
antigens produced in palatable parts of plants would be effective as conventional subunit 
vaccines in terms of immune memory formation. 
The B subunit of cholera toxin (CT-B) was expressed in transgenic com seeds at high 
levels. Biochemical and immunological analysis indicated that com derived CT-B, like the 
bacterial protein, is assembled into pentamers and binds to Gmi gangliosides. Although the 
bacterial signal peptide of CT-B appears to not cleaved in com seed tissue, unlike its counter 
part LT-B, it is able to induce murine immune system to produce CT-B specific antibodies. 
This work also provided evidence that administration of a mixture of com derived CT-B and 
LT-B together has potential to induce higher levels of specific antibodies than when they 
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were administered alone. This finding opens the possibilities of using these two corn derived 
antigens in combination and may lead to more efficacious vaccines against both cholera and 
enderotoxigenic E. coli induced diarrhea. 
To use the potential adjuvant and carrier molecule properties of the B-subunits, we 
attempted to produce the LT-B and CT-B subunit fusion protein with an epitope that may 
function as a vaccine. A 42 amino acids epitope of amyloid beta (A(3), a protein involved in 
pathogenesis of Alzheimer's disease (AD), was used as a case study. Two strategies, LT-
B/A(3 C-terminal fusion and CT-B internal fusion, were used. LT-B/Ap fusion resulted in 
pentameric assembly of LT-B alone in corn callus tissue, but the fusion protein was not 
detected. On the other hand, the CT-B internal fusion resulted in no detection of CT-B or the 
fusion protein. While these B-subunit protein fusion strategies were successful in producing a 
number of B-subunit/epitope fusions in bacteria and some plants, this study taught us that 
current ability to predict a successful fusion is limited and there is a need to evaluate each 
fusion on a case by case basis in their host organisms. 
The immunogenic potential of corn derived LT-B in pigs was also investigated. Oral 
administration of corn derived LT-B to newly weaned pigs resulted in elevation of LT-B 
specific IgG and serum IgA in 50% of the subjects. This result expands possibilities for 
utilization of corn derived LT-B to prevent E. coli induced diarrhea in pigs and as a mucosal 
adjuvant for unrelated antigens. 
This work indicated that a major food and feed crop corn holds great potential to be 
utilized as a production and delivery vehicle for production of vaccine antigens and 
components which could be used for prevention of both human and animal diseases. 
1 
Chapter 1 : Introduction 
1.1 General Introduction 
More than 10,000 years ago, descendants of highly advanced apes started to utilize 
other living organisms through domestication of plants and animals. Knowledge regarding 
functioning of living organisms, accumulated since then, allowed modern man to use 
organismal and cellular paradigms as part of agriculture, medical sciences, industrial 
applications, environmental and wild life management, forensic science and paleontology. 
Plants have been used for making clothing and shelter and in medicine since ancient times in 
addition to being a primary source of food for survival (Gurib-Fakim, 2006). Today, as a 
result of advancements in biotechnology, plants are used to produce pharmaceuticals 
including antibodies, antigens and diagnostics, veterinary and industrial products. As of 
2005, there are four plant-derived vaccines that are close to commercialization for treatment 
of diarrhea, hepatitis B and rabies (Ma et al, 2005). Following initial introduction of the 
concept by Mason et al (1992), a number of antigens have been produced in plants including 
tobacco, spinach, potato, carrot, lettuce, alfalfa, tomato, and corn (Mason et al, 1992, 
Tregoning et al, 2005, Karasev et al, 2005, Tacket et al, 2005, Dong et al, 2005, Chikwamba 
et al, 2002). Seeds are attractive organs in which to produce antigens because they store high 
amounts of proteins allowing a high level of recombinant protein expression. Seeds also 
provide stable dry environment which is a major advantage for long term storage and long 
distance delivery. Also, seeds are used as feed and food; they can readily be used as delivery 
vehicles for the antigens. In addition to being produced worldwide, com is an attractive 
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expression system for plant-derived vaccine production among other seed crops. In this work, 
we used com as a vehicle for production of vaccine and vaccine components and also 
addressed related issues regarding long term analysis of immune response to oral 
administration of corn-derived antigen and also assessment of allergenic potential of 
genetically modified corn. 
Infectious diseases are responsible for one quarter of all deaths worldwide annually. 
Most mortality occurs among children in developing countries who are not adequately 
immunized (Arntzen 2005). Cholera is an enteric disease which is considered to be endemic 
in Sub-Saharan Africa, South East Asia and South and Central America. Enterotoxigenic E. 
coli (ETEC) is another enteric disease with similar pathology and symptoms; which also has 
high morbidity. Production of plant-derived vaccines for enteric diseases is desirable because 
antigens produced in edible parts of the plants can be administered orally which could 
provide immediate protection at the site of infection. 
Pathogenesis of both cholera and ETEC involves intestinal colonization followed by 
release of toxins; LT (labile toxin) and CT (cholera toxin). Both LT and CT are made of two 
subunits; toxic A subunit which is internalized by binding of nontoxic B subunit to GM1 
gangliosides residing on intestinal epithelial cells. The B subunit is highly immunogenic. 
Vaccines made of B subunit could elicit immune response and anti-XB (X: LT or CT) could 
interfere with entry of the toxin to epithelial cells. In addition to being potent immunogens, 
CT-B and LT-B also non-specifically activates the immune system therefore they could serve 
as adjuvants in vaccine preparations targeting other diseases. Moreover, CT-B and LT-B 
could serve as carriers for other antigens through translational fusions. 
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In this study, we investigated different aspects of production of vaccines in corn. Our 
first project assessed long term and booster effects of orally administered LT-B corn with a 
pre-clinical trial conducted on mice. Anti-LT -B antibodies were detectable over an eleven 
month period in sera of mice fed with LT-B corn when they were young and booster 
administration of LT-B com resulted in rapid and strong memory reaction in the form of 
antibody production. 
Our next project focused on production of a transgenic maize line expressing a non­
toxic subunit (CT-B) of cholera toxin in its kernels. This was achieved by expression of 
synthetic CT-B gene under control of the seed specific 27 kDa y-zein promoter. To ensure 
expression, possibly at high levels, the synthetic CT-B gene was formulated based on maize 
preferred codon usage. Expression and native conformation of CT-B in maize kernels were 
demonstrated by ELISA and immunogenicity was determined by feeding experiments in 
mice. 
In order to test the carrier potential of CT-B and LT-B, fusion genes with gene 
sequence encoding for amyloid beta protein which is involved in pathogenesis of 
Alzheimer's disease were created. Even though correctly folded CT-B pentamers with the 
fusion were not detected, pentameric LT-B were detectable. However, in either case, 
expression of amyloid beta protein and its epitopes were not achieved. 
Although genetic modification of food crops holds great promise for the society in 
terms of better agricultural management, increased yield and enhanced nutritive quality, all 
of which could help to ensure food security, the technology also raised fundamental human 
health concerns. These include potential toxicity and allergenicity of the transgene product 
(Malarkey, 2003), the use of suicide genes and the possible risk of transmission of resistance 
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genes to neighboring plants (Metcalfe, 2003). In this study, a preliminary work was also 
conducted to determine a strategy for complete analysis of transgenic corn lines used and 
generated in this work. 
The last project described in this dissertation evaluated antibody induction potential 
of LT-B corn in a preliminary pig feeding trial. 
1.2 Dissertation organization 
This dissertation aims at exploring different aspects of plant-derived vaccines. The 
following chapters describe projects conducted in my PhD study. Dr. Kan Wang, my major 
professor, has provided overall supervision to the program. Dr. Joan Cunnick, one of my 
POS committee members provided the guidance on experiments involving immunization. 
Chapter 1 is a literature review. It focuses on achievements and challenges in the 
production of plant-derived vaccines and the unique advantages that they promise. Rationale 
of using corn to generate plant-derived vaccines, role of mucosal immunization in 
development of novel drugs against different classes of diseases, introduction to LT and CT 
structure and functioning and their potential as mucosal adjuvant and carriers are also given. 
A neurodegenerative disorder Alzheimer's disease is given as a case study as an introduction 
to our attempt to generate a plant-derived vaccine for AD. Finally, this chapter is concluded 
by human health concerns, and allergenic potential in particular, raised by genetically 
modified crops. 
Chapter 2 is the analysis of long term immune response of mice to orally 
administered LT-B and effect of booster administration. This work has been published in the 
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journal Molecular Biotechnology. Dr. Joan Cunnick provided hands-on training on animal 
handling methods. Jennifer McMurray provided technical assistance for sample collection. 
In Chapter 3 expression of CT-B in corn seeds is described. This manuscript 
reporting complete analysis of corn-derived CT-B including a mice feeding experiment 
indicating its immunogenic activity is in preparation for submission to a peer-reviewed 
journal. Throughout this work undergraduate assistant Chad Niederhuth and graduate 
assistant Swetha Gottimukkula assisted me on routine analysis. Jennifer McMurray and Chad 
Niederhuth helped with sample collection during feeding experiment in mice. 
Chapter 4 presents our efforts to generate a plant-derived vaccine against Alzheimer's 
disease by using LT-B and CT-B as carriers. 
Chapter 5 presents analysis of the allergenic potential of transgenic corn lines used 
and generated in this study (LT-B corn and CT-B corn). Results of this analysis were used to 
determine a strategy for complete analysis of these transgenic lines. 
Work presented in Chapter 6 is carried out as an initial testing of LT-B-corn in pigs 
for its ability to induce immune response. This work is the collaboration between Dr. Wang, 
Dr. Cunnick and Dr. Harris from Animal Science. I carried out the initial experimental 
design of the pig feeding test. This involved determining treatment groups, dose administered 
and feeding days. I also analyzed sera for determining levels of LT-B specific IgG and IgA 
antibodies. The pig feeding and sample collection was done by Dr. Mathew Erdman. 
1.3 Literature Review 
1.3.1 Why Plants 
In the past, therapeutics were relatively small molecules produced by chemical 
synthesis or produced in microorganisms. These pharmaceuticals include antibiotics, 
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hormones, diagnostics and others. Recently, much attention has focused on small peptides 
and proteins of varying sizes. Due to their inherent physiological and structural roles 
in organisms, utilization of proteins as therapeutics holds great promise for treatment 
and prevention of a number of diseases. Over 20 years after commercialization of the 
first peptide therapeutic agent, insulin, more than 40 out of 200 best selling drugs 
were made of peptides or proteins in 2004 (http://www.srinstitute.com). These include the 
recently commercialized 36-amino-acid synthetic peptide drug Fuzeon® (enfuvirtide) that 
has been approved by FDA (Food and Drug Administration) for treatment of HIV infection 
(Jamjian and McNicgoll 2004). 
Recombinant proteins can be produced in a variety of systems. Cultured mammalian 
cells (Derouazi et al., 2004), insect cells (Altmann et al., 1999), bacteria (Eko et al., 2004), 
yeast (Porro and Mattanovich, 2004), moss (Decker and Reski, 2004), recombinant animals 
(Dalyrymple and Garner 1998) and plants (Wang et al., 2004) have been widely used. Each 
of these systems has inherent advantages and disadvantages. Microbial systems are well 
established however, they are expensive to meet the increasing demand for peptide/protein 
therapeutics. They can not produce complex eukaryotic proteins. Mammalian cell cultures 
and transgenic animals have the machinery for producing complex proteins However using 
these systems involves therapeutic risk because even after purification, the product might be 
contaminated with viruses, oncogenes and endotoxins. Furthermore, it takes longer time to 
obtain products with these systems (Goldstein and Thomas, 2004). 
A number of recombinant proteins have been synthesized in plants. These include a 
variety of antibodies and vaccine antigens, adjuvants and blood substitutes (Goldstein and 
Thomas, 2004). Plants have unique advantages over other expression systems. One of the 
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main advantages of using plants to express peptides and proteins is that; plants can synthesize 
short peptides, longer polypeptides and also form multimers (Ma et al, 2003). In addition as 
their eukaryotic counterparts, plants also perform posttranslational modifications such as 
phosphorylation and glycosylation which enable transgene products to have their native 
structure and function. Allowing multimer formation and posttranslational modifications are 
particularly important for antibody production. 
The most important advantage of using plants as bioreactors is that plants essentially 
are free of human and animal pathogens. In addition, plants are easy to produce and bulk up, 
which reduces cost of production. In addition to ease in scaling up, being able to be 
administered orally could also decrease the cost of production by eliminating downstream 
processes such as purification. In the case of plant-derived vaccine administration, this 
property offers a special benefit; oral immunization (Freytag and Clements, 2005). Orally 
administered antigens could elicit both mucosal and systemic immune response which 
provides dual protection (Berinstein et al, 2005). Moreover, availability of specific promoters 
and signals to target the expression of the transgene to desired organ and organelles makes 
utilization of plants as expression vectors for recombinant proteins more attractive. Among 
other organs, seeds are particularly practical due to their inherent role as protein storage unit. 
In addition, they provide stable and dry environment for the proteins making long term 
storage easier. This is important in that it might eliminate the need for refrigeration of the 
vaccine during delivery or storage in underdeveloped and developing countries where 
refrigeration is not always readily available. 
Proteins can be expressed in stably transformed plants or transiently transformed 
plant cells. Due to difficulties in scaling up, transient systems are usually used only for 
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testing of the constructs. Agroinfiltration, plant viral vectors and biolistic techniques are 
commonly used for transient expression. Agroinfiltration is relatively a simple procedure. 
Agrabacterium tumafaciens with its T-DNA containing a recombinant gene is infiltrated into 
plant tissues. This method provides milligram quantities of the target protein in a few days 
(Vaquero et al, 1999). Plant viral vectors provide rapid and systemic invasion of the plant 
tissue enabling expression of the desired protein in a large amount of cells transiently in a 
very short time. This method can not be used as a stable transformation technique, because 
the viral genome does not integrate itself to the nuclear genome of the host plant. However, 
the technique is feasible as a screening method for gene constructs for complex proteins 
which requires assembly. For example, full length monoclonal antibodies can be produced in 
plants by co-infection with two plant viruses carrying light and heavy chains of the antibody 
to be produced. Assembly of the chains can be successfully carried out in planta (Verch et al, 
1998). Gene delivery with biolistic method for transient expression in plants is also 
commonly used. Leaves, callus, immature embryo end endosperm cells of corn (personal 
experience), leaves and calli of rice (Morello et al, 2005), shoot epidermal cells of barley 
(Douchkov et al, 2005) and strawberry and tomato fruits (Agius et al, 2005). 
Stable transformation refers to integration of the foreign gene into nuclear, plastid or 
mitochondrial genome. Each cell in a transgenic plants produced with this method has the 
foreign gene in them. New generations obtained from these plants are also transgenic because 
the germ cells also contain the recombinant gene. Agrobacterim tumafaciens and biolistic 
method are used to generate stably transformed plants. Currently pea, soybean, tobacco and 
Arabidopsis plants are routinely transformed with Agrobacterium infection (Schillberg et al, 
2005). Com and rice can be transformed with both methods (Zhao et al, 1998, Dai et al, 
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2001). It has been recently indicated that Agrobacterium mediated transformation leads 
mostly to single or low transgene copy numbers (Zhao et al, 1998, Dai et al, 2001, Shou et al, 
2004). This is likley to stabilize expression of the transgene in subsequent generations 
(Meyer and Saedler 1996). Therefore the Agrobacterium method is becoming more 
preferred for maize transformation (Shou et al, 2004). 
After two decades of recombinant protein production in plants, the technology is 
coming close to bearing fruits. As of 2005, there have been eight Phase I and three Phase II 
clinical trials conducted to test the efficacy and safety of plant made pharmaceuticals 
(PMPs). Out of these eleven trials, two of them were antibodies, one was a therapeutic 
enzyme, two were dietary supplements and three were vaccine candidates two of which are 
against enteric disease while one of them were against rabies (Ma et al, 2005). 
Commercialization of PMPs will depend on resolving issues regarding formulation of the 
final product, homogeneity and consistent dosing, regulation, biosafety and social and 
political concerns. 
1.3.2 Selection of the plants and plant tissues 
Recombinant proteins can be produced in a large number of plant species. Besides 
model organisms Arabidopsis and tobacco, fruits (tomato, strawberry, watermelon, and 
banana), vegetables (spinach, lettuce, potato and carrot), legumes (soybean, pea, and alfalfa), 
and grains (corn, barley, rice, and wheat) are widely used as host for production of target 
proteins. The choice of plant to be used depends on certain parameters; production, scale up 
and delivery cost, time required for generating the fully characterized transgenic line, 
palatability, requirement for downstream processing and related expenses, regulatory steps to 
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be followed for field releases and geographical location (Schillberg et al, 2005). Therefore, 
there is no single host species which is superior to others in terms of all the parameters listed. 
Tobacco is the most widely used host species among other plant species for 
production of recombinant proteins and proof of concept. It is easy to transform and 
propagate, thereby has high biomass yield. Both nuclear and plastid transformation is 
possible. In some cases with chloroplast transformation very high levels of expression have 
been achieved (up to 25% of total soluble proteins). One major disadvantage is that even with 
low alkaloid varieties, the final product will require a certain level of processing to eliminate 
toxic alkaloids (Ma et al, 2003). Also, high levels of proteolytic and microbial activity in 
green tissue makes tobacco less practical for post-harvest stages of the process (Menkhaus et 
al, 2004). Arabidopsis per se has also been used for proof of concept and as a model to 
express proteins with pharmaceutical value (Schillberg et al, 2005). However, in addition to 
possessing all the obstacles regarding green tissue as a system to produce recombinant 
proteins, its low biomass makes it unlikely that it will be utilized for mass production. 
A number of fruit and vegetable species have been successfully transformed. One 
advantage of using fruits and vegetables is the relatively short time required for generation. 
Fruits and vegetables are also suitable for production of plant derived pharmaceuticals 
because they can be fed raw or after minimal processing. Among this class of plants, most of 
the studies including Phase I clinical trials have been carried out with potato. Antibodies, 
antibody-fusion proteins, milk proteins and cytokines have been successfully produced in 
potatoes (Ma et al, 2003, Ohya et al, 2001). Another transgenic vegetable that reached 
clinical trials is lettuce transformed with gene encoding for hepatitis B surface antigen 
(Kapusta et al, 2001). Transgenic spinach plants that express antigens of HIV (human 
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immunodeficiency virus), the anthrax bacterium (.Bacillus anthracis) and rabies virus have 
also been produced. All three spinach-derived antigens have been shown to be highly 
immunogenic (Karasev et al, Sussman, 2003, Modelska et al, 1998). Tomatoes also received 
attention due to their palatability. A tomato-derived rabies vaccine has also been 
immunogenic in laboratory animals (Ma et al, 2003). However, low levels of transgenic 
protein accumulation, due to low levels of proteins in fruit, leaves and tubers of vegetables 
makes utilization of them to produce bulk quantities of target proteins less desirable. Another 
disadvantage of fruits and vegetables is their short shelf life which makes partial processing 
necessary. Powder formulations produced by homogenizing and freeze drying would 
surmount this obstacle and also enable more homogenous preparations for feedings. 
As mentioned before, tissues with a high level of moisture such as leaves and fruits 
do not provide a stable environment for production and storage of recombinant proteins. 
However, seeds provide dry, stable environment for proteins during long term storage at 
ambient temperature. Previous studies indicated that antibodies produced in seeds remain 
stable for three years (Ma et al, 2003). In addition to lack of toxic phenolic compounds, rapid 
scaling up makes seeds practical for production of PMPs (plant made pharmaceuticals). 
Currently there are five commercial pharmaceutical products obtained from food crops which 
are used in research, diagnostics and manufacturing. These are avidin, (3-glucorunidase and 
trypsin (http://www.prodigene.com/pdf/TrypZean('tm)%20Backgrounder.pdf) produced in 
corn and lactoferrin and lysozyme produced in rice (Humphrey et al, 2002). Research 
conducted with soybean, peas and alfalfa also have shown to promise. One major advantage 
of using legumes is minimal need for chemical support in the form of fertilizers due to their 
innate ability to fix atmospheric nitrogen (Ma et al, 2003). 
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1.3.3 Selection of the host species: crops or non-crop plants? 
Corn is a common grain produced world-wide. It can readily be transformed to 
produce recombinant proteins. It has been shown to be an ideal production and delivery 
vehicle for PMPs, in particular plant-derived vaccines, by different studies (Streatfield et al, 
2003). Further investigation of possibilities in the area of PMPs with corn and assessment 
and resolution of safety concerns will enable commercialization of PMPs for human and 
veterinary medicine. 
The major concern about using food crops for pharmaceutical production is the 
possibility of contaminating the plants grown for food production. This might result from 
pollen drift or accidental mixing of modified crops not intended for human consumption with 
stocks used for human food supply. Using male sterile lines and plastid transformation are 
two systems to surmount this concern. Currently, field release of PMPs with open pollination 
system is regulated by United States Department of Agriculture-Animal and Plant Health 
Inspection Services (USDA-APHIS). APHIS requires temporal and spatial confinement for 
field release of PMP crops. Temporal confinement prevents pollination between PMP crops 
and nearby conventional crop of the same species. Open pollinated PMP com lines are 
required to be planted 28 days earlier or later than commercial varieties planted nearby. Also, 
test plots must be at minimum of 1 mile distance from commercial com fields. In addition, 50 
feet of perimeter fallow zone around the test plot is required 
(http://www.bio.org/healthcare/pmp/factsheet4.asp). 
1.3.4 Mucosal immunization, oral tolerance and mucosal adjuvants 
Infectious diseases continue to be a major cause of death globally. Vaccination is still 
the most successful way of prevention of communicable diseases. Increased rates of foreign 
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travel and international trade of foodstuff has changed the perception and reality for 
endemics to become pandemics. Today, an infectious disease encountered in one country is a 
global threat. Emergence of two new diseases; SARS in 2003 and avian flu in 2004 created 
an intense global response and preparation for preventing pandemics, and it continues to be a 
concern. Along with rapid rate of evolution of resistant varieties of related pathogens and 
immense global population, development of effective, cheap and easily distributable vaccines 
is more important than ever. 
There has been an enormous effort to change traditional vaccine preparations as well 
as using alternative routes of delivery. Traditionally vaccines were made of killed or 
attenuated pathogens and the standard route of delivery was parenteral administration. Recent 
efforts have focused on subunit vaccines. This class of vaccine is made of non-pathogenic yet 
immunogenic elements of microorganism causing the disease. This approach is safer and in 
some cases more effective. Producing these elements in edible parts of the plants and oral 
administration might be advantageous. The linings of mucosal surfaces are the entry site for 
many pathogens and therefore play an important role for rendering microorganisms harmless 
and preventing disease. These mucosal surfaces are respiratory, genitourinary, nasal, 
oropharyngeal and gastrointestinal mucosa (Freytag and Clements, 2005). The main 
advantage of mucosal administration of a vaccine is the ability to induce both systemic and 
local mucosal response in the form of serum IgG and secretory IgA production, respectively 
(Eriksson and Holmgren, 2002). Secretory IgA antibodies can prevent entry of pathogens to 
mucosal cells and neutralize bacterial toxins. In addition, the ability of the mucosal immune 
system to relay information to distant sites, through common mucosal immune system 
(CMIS), expands the possibilities for administration of the antigens. For example, the oral 
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route may be effective to induce sufficient amount of secretory IgA production in lungs and 
may be chosen as a route of delivery for respiratory diseases as well as GI related diseases. 
Mucosal administration also offers hope for treatment of autoimmune diseases such 
as multiple schlerosis (MS), diabetes, rheumatoid arthritis (RA) and allergies (Faria and 
Weiner, 2005). In autoimmune diseases, a component in the body, in the case of allergies a 
protein from outside source (food, plants or animals which is tolerated in majority of human 
population) are attacked by immune system of the individual with the disease. Induction of 
oral tolerance (a phenomenon which allows human and animals not to attack ingested 
proteins) to such components have been tested as a means of therapy. Treatment of such 
diseases has been tested by oral administration of a related protein, in the case of MS myelin 
basic protein (MBP) for example, through a specific feeding regimen. Although promising, 
the results of such efforts are not conclusive yet. A significant placebo effect was observed in 
clinical trials testing the efficacy of such treatment for MS and RA. New trials with 
modifications in administration regimen are ongoing (Faria and Weiner, 2005). 
Although promising there are challenges regarding mucosal administration of 
antigens. High acidity and digestive enzymes inactivate the majority of the antigens before 
they reach Peyer's patches which are T-cell and B cell rich immune structures of 
gastrointestinal tract (Rigano and Walmsley, 2005). In some cases with oral vaccination 
systemic tolerance has been observed (Simmons et al, 2001). In order to protect orally 
administered antigens a variety of strategies have been developed. One strategy uses 
biodegradable antigen carriers including liposomes, chitosan particles, polyacrylamide starch 
particles, virosomes, immune stimulating complexes (ISCOMs) and latex microspheres 
(Foster and Hirst, 2005). In addition to all of the advantages of using plants for 
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pharmaceutical production, plants also offer an advantage for encapsulation of the 
recombinant proteins in sub-cellular compartments thereby providing better antigen 
preservation in harsh environment of the digestive tract (Chikwamba et al, 2002). 
Co-administration with mucosal adjuvants can enhance immunogenicity of plant 
derived antigens. Some mucosal adjuvants can also be used as carriers for antigens. Two 
bacterial enterotoxins LT from Escherichia coli and CT from Vibrio cholerae, and their 
subunits LT-B and CT-B, have received a great deal of attention due to their ability to serve 
as mucosal adjuvants (Freytag and Clements, 2005). In this work, plant derived LT-B and 
CT-B have been studied for their antigenic, adjuvant and carrier potential, and are discussed 
below. 
1.3.5 E.coli heat labile toxin and cholera toxin as mucosal adjuvants and carriers 
E. coli and V. cholerae colonize the intestinal system of humans and animals and 
cause severe diarrhea through similar mechanisms. Both LT and CT are potent 
immunomodulators. LT and CT share 82% homology in terms of their amino acid sequences 
(Williams et al, 1999). They are multimeric proteins with approximate sizes of 84 kilodalton 
(kDa). A 27 kDa toxic A subunit is non-covalently linked to a ring shaped pentamer made of 
five identical non-toxic B subunits. A 55 kDa B pentamer binds to the toxin receptor, 
ganglioside GM1 (galactosyl-N-acetylgalactosaminyl-sialyl galactosyl glucosyl ceramide), 
residing on the surfaces of intestinal epithelial cells. Upon binding, exogenous enzymes 
proteases cleave A subunit into A1 and A2 fragments. Following transport from ER to 
cytosol, the A1 fragment catalyzes ADP-ribosylation of a G protein which results in chloride 
ion (CI ) efflux. Activated G protein triggers adenylate cyclase leading to increased levels of 
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cyclic AMP (cAMP). High amounts of cAMP results in opening of a transmembrane CI" 
channel which is followed by efflux of water along with ions into the intestinal lumen which 
results in the characteristic diarrhea of the disease (Williams et al, 1999). 
Potential of LT and CT as mucosal adjuvants was indicated for the first time in the 
late 1980s (Clements et al, 1988, Elson, 1989). Due to toxicity of holotoxins, the B subunit of 
both toxins received attention for utilization as mucosal adjuvants. Several other studies 
investigated separating toxicity from immunogenicity by creating mutant toxins (Verweij et 
al, 1998). In addition to their adjuvant properties, B subunits can be used as vaccines against 
toxin induced diarrhea because they induce secretory IgA and serum IgG that protect against 
subsequent challenge (Millar et al, 2001). CT-B and LT-B have been produced in a variety of 
plant species. Transgenic potato, tomato and tobacco plants producing recombinant CT-B 
(Arakawa et al, 1997, Jani et al, 2002, Wang et al, 2001) and transgenic com, tobacco, potato 
and ginseng plants (Chikwamba et al, 2002, Streatfield et al, 2001, Kang(a) et al, 2004, 
Mason et al, 1998, Kang(b) et al, 2005) producing recombinant LT-B formed the basis for 
plant-derived vaccines against diarrhea induced by these two toxins. 
In order to use CT-B and LT-B as carriers for targeting unrelated antigens to mucosal 
surfaces, a number of fusion proteins were produced in plant and non-plant systems. 
These include CT-B fusions with anthrax lethal factor protein (Kim et al, 2004a), simian-
human immunodeficiency vims 89.6p Tat protein (Kim et al, 2004b), simian 
immunodeficiency virus mac Gag p27 capsid protein (Kim et al, 2004c), and rotavirus VP7 
protein (Choi et al, 2005). Similarly, a few LT-B-antigen fusion proteins have been produced 
in plants. These include neutralizing epitope of porcine epidemic diarrhea virus expressed in 
tobacco (Kang(c) et al, 2005) and a tuberculosis antigen produced in Arabidopsis thaliana 
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(Rigano et al, 2004). In this study, a human protein amyloid beta was chosen to produce 
fusion proteins with LT-B and CT-B due to its potential to treat and prevent Alzheimer's 
disease (Schenk et al, 1999). 
1.3.6 Case study: Alzheimer's disease 
Alzheimer's disease is a severe neurodegenerative disorder seen in elderly. It affects 
more than 12 million people worldwide (Gelinas et al, 2004). Symptoms of the disease are 
progressive loss of memory and cognitive decline, behavioral changes and language 
problems. Current therapies are mainly aimed at symptom control. Five classes of drugs used 
in AD treatment are cholinesterase inhibitors, glutamatergic neurotransmission suppressers, 
vitamins and antioxidants, non-steroidal anti-inflammatory drugs (NSAIDs), and drugs that 
are used to manage neuropsychiatrie symptoms (Lleô et al, 2005). All of these drugs provide 
cognitive, behavioral and motor function benefits to a certain extent; however they do not 
affect disease progression. Therefore the search for AD treatments that are going to prevent 
and also slow down the progression of the disease are still continuing. 
Morphological hallmarks observed in AD patient's brains are amyloid beta plaques 
and neurophirillary tangles. Lesions caused by amyloid beta plaques and neurophibrillary 
tangles lead to death of neurons. Amyloid beta plaques are formed of 40 and 42 amino acid 
long peptides called amyloid beta. The 42 amino acid long version is more fibrillogenic and 
is the product of improper cleavage of amyloid beta precursor protein (APP) by P-secretases 
and y-secretases. Unlike amyloid beta deposits, neurofibrillary tangles are observed 
intracellularly, located mostly around the nuclei of neurons. They result from 
hyperphosphorylation of a structural protein, tau, which normally functions in assembly of 
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microtubules. Mutations in APP and components of the enzymes processing APP lead to 
formation of both amyloid beta plaques and tau tangles. However mutations in tau only result 
in formation of tangles (Walker et al, 2005). This indicates a primary role for amyloid beta 
in disease pathogenesis, which is referred as 'amyloid beta cascade'. This hypothesis implies 
that accumulation of fibrillar amyloid beta is followed by neurofibrillary tangle formation, 
inflammation, death of neurons which then triggers formation of other lesions observed in 
AD brains. Therefore, much of the recent efforts for treatment of AD have focused on 
reducing the amount of amyloid beta plaques. 
Current strategies targeting prevention of amyloid beta deposition are; inhibition of 
amyloid beta protein generation, inhibiting formation of multimers and induction of 
degradation of the plaques via immune system involvement. The first approach involves 
inhibition of enzymes (secretases) that generate the fibrillar form of amyloid beta. Even 
though this method has been shown to be successful in terms of reducing the amount of 
amyloid beta in experimental animals, severe side effects of the inhibitors make their 
utilization as drugs impossible. Due to their central role in AD pathogenesis, highly toxic 
oligomeric forms of Amyloid beta have also been targeted in the search of finding a cure for 
the disease. However, difficulties involved in inhibition of protein interactions in vivo slow 
down the progress that can be achieved with this approach (Walker et al, 2005). The last 
strategy has been shown to be promising through. Parenteral immunization with aggregated 
amyloid beta prevented occurrences of the plaques and also removed already existing ones 
when tested in transgenic mice (PDAPP mice) showing AD pathology (Schenk et al, 1999). 
In addition, further studies carried out following different immunization schemes indicated 
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that immunization with amyloid beta also improves cognitive abilities of mice as the plaques 
are removed (Weksler, 2004). 
Given these encouraging results a human clinical trial was commenced in 2001. The 
Phase I trials with 100 AD patients indicated that injections induced antibody response and 
they were well tolerated. However, Phase II clinical trials conducted by Elan Pharmaceuticals 
Inc. had to be stopped due to brain inflammation observed in 6% of the 300 subjects (Haas et 
al, 2003, Walker, 2005). Complications due to aging are likely to cause unexpected results. 
In aged individuals, the immune system undergoes certain changes that lead to slower 
immune response, increased autoimmunity following immunization with a foreign antigen 
(Weksler, 2004) and chronic stimulation of macrophages leading to a 'pro-inflammatory 
status' (Kipar et al, 2005). Moreover, evidence indicating induction of innate immune 
response in AD pathology might suggest that inflammation observed following amyloid beta 
administration may not be a direct result of the immunization. 
It has been postulated that amyloid beta plaques stimulate the innate immune 
response involving activation of microglia, astrocytes and the complement system and free 
radical formation, as well as release of pro-inflammatory cytokines such as TNF-a and IL-P 
(Weiner and Selkoe, 2002) and formation of acute-phase proteins (Akiyama et al, 2000). 
Support for the validity of this hypothesis came from the studies showing that these 
molecules, which are suggestive of inflammation, are present in AD patient's brain (Akiyama 
et al, 2000). On the contrary, nonappearance of immunoglobulins in the brain regions 
suggests that the humoral immune response is not involved in amyloid beta plaque formation 
(Eikelenboom et al, 1994). Given the fact that inflammation may play a role in the 
neuropathological injury observed in AD (Weiner and Selkoe, 2002), the exact reason for 
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inflammation in Phase II clinical trials is unknown. Hence, complications observed in a small 
percentage of subjects in the trial should not negate the potential of amyloid beta 
immunization for preventing and treat AD. Modifying immunization schemes and adjuvant 
combinations could help overcome some of the severe side effects observed with parenteral 
immunization. 
T-helper cells that secrete cytokines that induce macrophage production are 
classified as Thl cell, and those releasing cytokines that induce B-cells are classified as Th2 
cells. The Thl response is characterized by cellular cytotoxicity and local inflammation 
whereas the Th2 response involves induction of opsonizing antibody formation and 
suppression of the Thl response thereby inhibiting inflammation (Janeway et al, 2001). 
Therefore, one modification that could overcome inflammation is testing different routes of 
delivery. Intranasal and oral administration of antigens preferentially induces Th2 rather than 
Thl type immune response (Constant et al, 2000, Itoh et al, 1999). Encouraging results with 
mucosal immunization have already been observed. A 50 to 60% reduction in amyloid beta 
burden was indicated in PDAPP mice which were intranasally immunized with the short 
form of amyloid beta protein (AP42) for seven months (Lemere et al, 2002). Not surprisingly, 
antibody response was found to be low (26 ng/ml). Further study conducted by the same 
group in wild type mice used LT and a non-toxic version of LT (R1192G) as adjuvant. 
Antibody levels were found to be dramatically increased, especially with non-toxic LT. 
Based on these findings, and with the carrier and adjuvant properties of LT-B and 
CT-B in mind, in the search for a safe and effective vaccine against Alzheimer's disease, we 
aimed at producing a plant-derived vaccine against AD by transforming corn with fusion 
genes. 
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1.3.7 Age related changes in immune reaction and immune memory 
Aging leads to deterioration of both innate and specific immune responses through 
alterations at the organism and single cell levels (Frasca et al, 2004, Nikolich-Zugich, 2005). 
These changes are altogether named as immunosenescence. Immunosenescence results in 
reduced response to vaccination and increased vulnerability to infections. Accordingly, 
morbidity and mortality rates in aged individuals due to diseases, which are not fatal in 
healthy young adults, are substantial (Miller et al, 1996, Peterson et al, 2003). As well as 
changes that occur in immune system, functional and structural modifications observed at the 
port of entry (skin and respiratory surfaces) and destination organs (circulatory and nervous 
system) and also contribute to this susceptibility seen in elderly (Wick et al, 2000). 
At the cellular level, the changes occurring in systemic immunity observed in aged 
individuals are as follows; decreased antigen presentation, increased constitutive cytokine 
release, reduced response to antigen and pathogens, impaired macrophage activation, 
dendritic cell (DC) migration and Toll-like receptor mediated activation, and alterations in T-
cell and B-cell regulation (Frasca et al, 2004, Nikolich-Zugich, 2005). Recent research 
indicates that intestinal mucosal components also undergo deterioration which accounts for 
increased incidences of gastrointestinal infections seen in elderly (Beharka et al, 2001). 
In this regard, it is essential to study the potential of plant-derived vaccines in elderly. 
Investigating long term efficacy of mucosal administration following initial sensitization 
early in life and booster response is also critical. 
1.3.8 Allergy concerns 
Nutritional quality and yield of food crops can be increased via genetic modification. 
Biotechnology also enables production of vitamins, antigens and hormones in plants. 
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Genetically modified food crops with natural pesticides and increased resistance to drought 
are already part of common agricultural practice (Metcalfe, 2003). Food crops with their 
allergenic components rendered inactive could also be produced through genetic 
modification. 
In spite of the great promise that it offers, application of biotechnology to food crops 
initiated concerns regarding potential toxicity of recombinant proteins and unintended 
environmental consequences of the technology in the long run. Major health concerns 
regarding GM food crops are potential toxicity and allergenicity of the recombinant protein 
and the risk involved in rendering any endogenous component of the food crop being 
modified to be toxic or allergenic. 
Symptoms of food allergies involve classic allergy reactions: hives, swelling of parts 
of body, usually lips, tongue and eyes, vomiting, diarrhea and asthma are observed shortly 
after ingestion of the allergenic food. Such reactions to foods can be IgE mediated or non-
IgE mediated. Since IgE mediated reactions are more common and severe, research regarding 
allergenic potential of GMO foods has been focused on IgE mediated reactions (Metcalfe, 
2003). 
No single predictive test is available to test allergenic potential of a given protein. 
The International Food Biotechnology Counsel and the International Life Sciences Allergy 
and Immunology Institute formed a decision tree approach to identify allergens in GMOs 
either before or after production. Final version of the strategy was determined by Food and 
Agriculture Organization of the United Nations (FAO) and the World Health Organization 
(WHO) (Poulsen, 2004). The first step is to perform a homology search against amino acid 
sequences of known allergens. Currently, there are a number of allergen databases. Efforts 
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are under way to unite these to create a high validity public allergen database (Poulsen, 
2004). The second step involves specific or targeted serum screening. Specific serum 
screening is testing of a protein extract of the GMO food with sera of individuals known to 
be allergenic to the source of the gene. Positive results of such testing indicate that the newly 
introduced gene encodes for an allergenic protein. If the result is negative, further testing 
with a panel of sera that are raised against different groups of organisms is performed. This 
testing is called as 'targeted serum screening' and provides more broad screening of all 
potential allergens. Positive result of this test also indicates that the protein is an allergen. 
The third level of testing is required if targeted serum screen yields negative results. One 
common property of allergenic proteins is their resistance to digestion. Therefore, a pepsin-
resistance test is performed. If an extract from transgenic product is found to be more 
resistant than its non-transformed counterpart, it might indicate allergenicity. In order to 
reach a final conclusion, animal models are used to test immunogenicity of the transgenic 
product. 
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Chapter 2: Analysis of immune response in young and aged mice 
vaccinated with corn-derived antigen against E. coli heat labile 
enterotoxin 
Molecular Biotechnology 2006: 32; 31-42 
Sule Karaman, Joan Cunnick and Kan Wang 
2.1 Abstract 
Enterotoxigenic strains of E. coli produce a heat labile holotoxin (LT), which causes 
diarrhea. We engineered corn seeds to produce LT-B, the non-toxic subunit of LT, to serve as 
a plant-derived vaccine to traveler's diarrhea and as an adjuvant for co-administered proteins. 
We previously demonstrated that a strong mucosal and systemic antibody response is elicited 
in young mice upon oral administration of corn-derived LT-B. The present study examined 
systemic and mucosal antibody responses to LT-B in young and aged mice, and recall 
responses to oral administration and injection of LT-B in aged mice. Specific IgA and IgG 
antibodies were detectable over an 11-month period even though the concentration of antigen 
specific antibodies declined gradually. Booster by feeding or injection dramatically increased 
the concentration of specific IgA over that seen in young mice. Specific IgG levels were 
boosted to concentrations similar to those in young mice. This effect may be age-dependent 
and related to prior immunization exposure. Analysis of the antibody response of naïve aged 
mice against com derived LT-B demonstrated an age related suppression in specific IgG 
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production, but not specific IgA. These results may provide important information for edible 
vaccine strategies for young and aged individuals. 
2.2 Introduction 
Mammals are exposed to a vast majority of infectious agents that enter the body 
through the mucosal surfaces of the upper respiratory, gastrointestinal and urogenital tracts. 
To protect the animal from pathogens at this first line of contact, mucosal surfaces are armed 
with immune structures: mucosal-associated lymphoreticular tissues (MALT) including 
Peyer's Patches in intestines and nasopharyngeal-associated lymphoreticular tissue (NALT) 
in the upper respiratory tract. Immune stimulation at these locations induces memory B cells 
and T cells to the common mucosal immune system (CMIS) resulting in increased levels of 
antigen-specific secretory IgA both at the inductive site where the pathogen is encountered 
first and in the effector sites throughout the CMIS (McGhee et al, 1998). 
The ability of the mucosal system to produce antigen-specific responses is the driving 
force for attempts to develop edible vaccines by which antigenic proteins are synthesized in 
edible parts of plants and administered orally to animals. Many studies show that 
recombinant proteins produced in plants are immunogenic when given orally and also 
provide protection in animal models of infectious disease (Wang et al, 2004). Phase 1 human 
clinical trials using three different recombinant antigens produced in plants show similar 
results as evidenced by the induction of a systemic and secretory antibody response (Tacket 
et al, 1998, Tacket et al, 2000, Kapusta et al, 1999). 
While oral vaccines may stimulate a mucosal response, the extreme low pH and 
presence of gastric peptidases in the stomach present a challenge for the use of small proteins 
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as oral vaccines when administered alone. Co-administration of adjuvants can increase 
immunogenicity of mucosally administered antigens (Fujihashi et al, 2000, Kanellos et al, 
2000, Choi et al, 2002). Two such mucosal adjuvants, heat labile enterotoxin (LT) from 
enterotoxinogenic strains of Escherchia coli and its homologue cholera toxin (CT) from 
Vibrio cholera, are strongly immunogenic when administered via the intestinal tract, 
respiratory tract, or parenteral route (Elson and Balding, 1984, Clements et al, 1998, Xu-
Amano et al, 1993). Both toxins cause diarrhea by a mechanism involving binding of the B-
subunit of the toxin to the Gmi receptors on intestinal epithelial cells. Binding of the B-
subunit enables entry of the enzymatically active A-subunit to the cytosol. This results in 
secretion of water and chloride ions from epithelial cells to the intestinal lumen due to over 
activation of adenyl cyclase (Haan et al, 1996). Because neither of the holotoxins is suitable 
for use as a mucosal adjuvant in humans, much effort has focused on the utilization of the 
nontoxic B subunit (LT-B and CT-B) and attempts to dissociate toxicity from adjuvanticity 
[Millar et al, 2001, Pizza et al, 1994, Verweij et al, 1998). Besides potential use as mucosal 
adjuvants, the two B-subunits can also serve as vaccines against diarrhea caused by LT and 
CT as the B-subunit induces high levels of anti-LT-B and anti-CT-B secretory IgA that 
provide protection against subsequent toxin challenge (Haan et al, 1996, Verweij et al, 1998, 
Mason et al, 1998, Chikwamba et al, 2002, Guidry et al, 1997). In addition, our previous 
studies indicate that oral administration of LT-B corn can induce significant concentrations 
of anti-LT-B IgG in serum (Chikwamba et al, 2002). 
Immunogenicity and adjuvanticity of LT-B and CT-B have been studied extensively 
in young mice. However, immune responses in aged individuals can be different due to 
cellular and molecular alterations associated with aging. Examples of age-related changes 
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include: dysfunctional alterations in mitogenic responses, phenotype, and cytokine 
expression of T cells. Changes in T-cell responses can result in an altered mode of help for B 
cells, ultimately leading to impaired antibody responses (Fujihashi et al, 2000). For example, 
vaccines against influenza and tuberculosis are less efficient in aged individuals when 
compared to young adults (Mayer, 2000, Czerkinsky et al, 1999). Aged mice that were given 
CT and CT-B as an adjuvant for the co-administered antigen ovalbumin demonstrate a 
diminished capacity to produce antigen specific antibodies mucosally (IgA) and systemically 
(IgG) when compared to young mice (Fujihashi et al, 2000, Nagler-Anderson et al, 1986). 
However, immunogenicity and adjuvanticity of LT and its components in aged mice remains 
to be elucidated. Even though LT-B and CT-B share 80% homology in terms of amino-acid 
sequence, they have distinct biochemical and immunological features. For example, LT-B is 
more potent than CT-B in terms of induction of an antibody response. This could be due to 
the greater stability of LT-B at low pH and high temperature (Nedrad and Sigmund, 1991). 
Therefore administration of LT-B to aged mice could result in a different outcome than that 
of CT-B and CT. 
Earlier studies of recombinant LT-B and CT-B produced from transgenic plants 
report antibody responses with efficacy in protecting animals from toxin challenge. However, 
these studies measured antibody responses over a short time interval in young mice 
(Chikwamba et al, 2002, Brennan et al, 1999, Tuboly et al, 2000, Yu and Langridge, 2001, 
Lauterslager et al, 2001, Yu and Langridge, 2003). In the present work, we aimed at 
investigating immune responses to corn derived LT-B in young and aged mice. Our 
objectives were to carry out a kinetic assay to determine the time interval in which anti-LT-B 
antibody levels remain significantly elevated after feeding in young mice and to investigate 
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the effect of booster administration of LT-B using both oral and intraperitoneal injection 
methods in aged mice. In addition, we measured the systemic and mucosal immune response 
against LT-B in elderly naive mice when fed with corn-derived LT-B antigen. 
2. 3 Materials and Methods 
Preparation of feeding pellets 
Transgenic maize seeds (R4 generation) expressing LT-B were used for making food 
pellets as described previously (Chikwamba et al, 2002). Each pellet made of ground 
transgenic maize seeds and phosphate buffered saline (PBS) weighed 1.87 grams and 
contained 10 |ug of LT-B. Pellets were allowed to air-dry overnight. Non-transgenic maize 
seed powder was used to make pellets of similar weight to serve as a negative control. For 
each feeding, one extra pellet was prepared to serve as an LT-B dose control to be analyzed 
at the end of the experiment. 
Immunization of mice-young mice study, aged mice study, recall study 
All animal procedures were approved through the Iowa State University (ISU) 
Committee on Animal Care. Ten-week-old female BALB/c mice were obtained from Harlan 
(Indianapolis, IN, USA). Prior to start of the experiment, mice were allowed a two-week 
adjustment period with a reverse light-dark cycle (lights-off at 9AM) in the ISU animal 
facility where they were housed throughout the experiment. 
The design of the overall study is given in Figure 1. Mice were fed a basic diet of 
mouse chow with water ad libitum. The mouse chow was removed overnight (during the 
light phase) prior to feeding corn pellets on days 0, 7, 21 and 35 of the study. Initial LT-B 
immunization was done when the mice were three months old (young mice study). They 
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were divided into two groups: the initial control group mice were fed with non-transgenic 
corn pellets (NT Corn) while the LT-B corn group mice were fed with LT-B corn pellets. 
Throughout the study two mice were housed in each cage. However, during feeding of 
control or vaccine pellet they were caged individually and one maize pellet was placed in 
each cage (without bedding) 30 min before lights off. Mice were allowed to eat the maize 
pellet in the dark cycle for 3 hours until the pellet was completely consumed and then 
returned to their home cage with their normal mouse chow. 
At 14 months of age, 12 mice from the initial LT-B corn group were divided equally 
into three feeding groups for the recall study: 1) the Recall/Control group was fed with non-
transgenic maize pellets, 2) the LT-B Corn group was fed with transgenic maize pellets 
containing 10 p,g LT-B and 3) the Recall/Injection group was also fed with non-transgenic 
maize pellets and was injected intraperitoneal^ (IP) with 10 fig of purified bacterial LT-B 
(kindly provided by John Clements, Tulane University, LA, USA) in 100 jul of PBS 
(phosphate buffered saline). All the mice in this study, which did not have LT-B injections, 
were injected with sterile PBS to ensure consistency of handling for each subject in the 
experiment. 
In the aged mice study, 6 mice (aged 14 months) not previously immunized with LT-
B were assigned to two groups (N=3/group), a negative control group and an LT-B corn 
group. Food pellets from LT-B corn or NT-corn were administered on days 0, 7, 21 and 35 of 
the study. 
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Preparation of plasma and fecal samples and determination of anti-CT-B and anti-LT-B 
antibodies 
For the initial LT-B immunization study, fecal and blood samples (approximately 100 
jal) were obtained from mice over an 11-month period (days -1, 6, 13, 20, 27, 34, 41, 51, 63, 
94, 270 and 320). In the recall study, samples were collected prior to feeding (day 336) and 
on days 343 and 350 (6 and 13 days post feeding) of the study. For analysis of LT-B 
immunization in naïve 14-month-old mice, fecal and blood samples were collected weekly 
from day -1 to day 41. Mice were bled via the sephanous vein. Plasma and fecal samples 
were stored at -20°C until analysis by ELISA as described before (Chikwamba et al, 2002). 
Briefly, plates were coated with 5 ng of mixed gangliosides (G2375, Sigma, St. Louis, MO, 
USA) per well diluted in coating buffer [15 mM Na^CO^, 35 mM NaHCOg, 3 mM NaNg 
(pH:9.6)] for an hour at room temperature. Following blocking with 5% powdered milk 
(diluted in PBS), plates were incubated with pure LT-B (John Clements) or CT-B (1 (xg/well; 
Sigma) at 37°C for one hour. Next, diluted serum samples and fecal extracts were added and 
the plates were incubated at 37°C for one hour. Plates were incubated with biotinylated anti-
mouse IgG obtained from rabbit sera (B-8520, Sigma, diluted 1:100,000 in PBS containing 
1% powdered milk) and anti-IgA from goat sera (B-2766, Sigma, diluted 1:20,000 in PBS 
containing 1% powdered milk) for one hour at 37°C to determine IgG and IgA levels, 
respectively. Next, the enzyme conjugate, streptavidin-horse radish peroxidase (554066, BD 
Biosciences, San Diego, CA, USA), was added to the wells (diluted 1:1000 in PBS 
containing 1% powdered milk) and the plates were incubated at room temperature for 30 
minutes. Finally, wells were coated with ABTS substrate (3-ethylbenzthiazoline-6-sulfbnic 
acid, A-1888, Sigma) in substrate buffer [1.37 M ABTS, 0.1 M citric acid (pH: 4.35)] and 
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incubated at room temperature for 30 minutes allowing color development. At the end of the 
incubation period end-point readings were performed using absorbance at 405 nm. Antibody 
concentrations were determined as pg/ml by using standard curves derived from pure mouse 
IgG (MOPC 21, M-9269, Sigma) and pure mouse IgA (MOPC315, M-2046, Sigma). 
Due to lack of commercially available LT-B, concentrations of anti-LT-B IgG and 
anti-LT-B IgA in serum were measured by a sandwich ELIS A that utilizes CT-B to capture 
antibodies induced in mice after LT-B corn administration. Fecal anti-LT-B IgA levels were 
measured by the same ELI S A protocol except bacterial LT-B was used to capture anti-LT-B 
IgA in fecal extracts. We measured specific IgG and specific IgA antibodies in sera of 4 mice 
from LT-B com group obtained on days 51, 62 and 94 of initial immunization by using both 
LT-B and CT-B in the ELISA protocol described above. We obtained the ratios indicated in 
Table 1. Our analysis indicated that anti-LT-B antibodies cross react with CT-B, although 
cross reactivity is not 100%. The results indicate that actual IgG anti-LT-B antibody 
concentrations will be higher than what we report in Figure 1, Figure 2 c and d, and Figure 3a 
and c due to the use of CT-B for antibody capture. 
Determination of total IgGl and IgG2a levels 
For determination of total IgGl and IgG2a, sera from days -1, 6, 13, 20 and 27 from 
the initial immunization part of the study and sera from days 6, 13, 20, 27 and 34 from aged 
mice study were analyzed. A total of 11 serum samples from mice fed with non-transgenic 
(NT) com and 15 serum samples from mice fed with LT-B com in initial immunization part 
of the study were analyzed along with serum samples from the aged mice study (3 mice in 
each group; NT com & LT-B corn). Purified IgGl (MI 10-102, Bethyl Laboratories, Inc.) and 
IgG2a (0103-01, Southern Biotechnology Associates, Inc) were used as standards. The same 
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standard range was used for both total IgGl and IgG2a assays (2.5-0.019 (J-g/ml). Standards 
and samples (diluted at 1:150) in sodium carbonate coating buffer (described in previous 
section) were directly coated on the 96 well high binding ELISA plates and were blocked 
with 150 jal of 5% milk. Total IgGl and IgG2a samples were probed with goat anti-mouse 
IgGl (M-8770, Sigma- dilution 1/3,000) and biotin conjugated goat anti-mouse IgG2a (1080-
08, Southern Biotechnology Associates, Inc - dilution 1/10,000), respectively. For IgGl 
assay a secondary antibody conjugated to biotin (A-5420, Sigma-dilution 1/40,000) was 
used. Incubations with enzyme and substrate and end-point readings were carried out as 
described in the previous section. 
A ratio of [IgG2a]/[IgGl] was used to estimate changes in TH1/TH2 responses. 
Although, IgG2a/IgGl ratio is only indicative of the T-helper balance, the isotypes have been 
correlated with the production of TH1 and TH2 cytokines, respectively [28]. Earlier 
experiments attempting to stimulate T-cell cytokine production in splenocytes from LT-B 
immunized mice using purified recombinant bacterial LT-B were inconclusive due to the 
abundance of endotoxin associated with the LT-B. Thus, we are unable to measure LT-B 
induced stimulation of antigen specific T-cells and their cytokines at this time, which would 
provide a direct measure of TH1 vs TH2 responses. 
Statistical analysis 
Anti-LT-B antibody kinetic data for serum IgG, serum IgA and fecal IgA were 
analyzed by ANOVA for estimation of mean differences and IgG2a/IgGl ratio were 
analyzed by ANOVA to determine main effects of age, pellet type, and the interaction of 
age*pellet using SAS® V8.2. 
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2.4 Results 
Antibody response in mice upon initial immunization and a booster LT-B administration: 
Twelve young mice (3-month-old) were initially fed four times with LT-B expressing 
transgenic corn pellets (LT-B Corn group) and six mice were initially fed four times with 
non-transgenic com pellets (Initial/Control group). When they reached 14 months of age, the 
twelve mice from the LT-B Com group were divided equally into three groups to test a 
booster response. The three groups included: 1) Recall/Control group (fed once with non-
transgenic com pellets), 2) LT-B Com group (fed with transgenic com pellets) and 3) LT-B 
Injection group [fed with non-transgenic com pellets but injected with purified bacterial LT-
B intraperitoneally (IP)]. Figure 2 shows antigen specific IgG concentrations over the 11-
month period following the initial immunization regime on days 0, 7, 21 and 35 and the 
secondary response after a single recall dose of LT-B administered when the mice were 14 
months old (day 337). On day 13, specific IgG antibody concentrations were detected at a 
level significantly higher than that of the control group (p=0.0034) and remained 
significantly higher throughout the remaining assay dates (p's < 0.005). Specific IgG 
concentrations steadily increased and reached a peak at day 27 with a mean concentration of 
226.21 ±26.71 ja-g/ml. Specific IgG concentrations decreased gradually after the last 
immunization (day 35), but did not significantly differ from day 27 until day 270 (p=0.0037). 
In the recall experiment, 14-month-old mice were given one single dose of LT-B 
orally (LT-B Com group) or intraperitoneally (LT-B Injection group) on day 336. We 
observed remarkably high levels of specific IgG in sera of both groups as early as 7 days 
(day 343) after the booster antigen administration, while the recall control group showed no 
change in levels of specific IgG. The recall responses on day 343, one week after a single 
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dose of LT-B by feeding and injection, were not significantly different from the specific IgG 
level on day 41. These two dates (day 41 and 343) both represent secondary responses one 
week after immunization and were significantly higher than specific antibody concentrations 
observed on days 6 and 13 in young mice (p's <0.0001). Two weeks after the day 336 
booster dose, specific IgG concentrations increased with a higher level of antibody in sera of 
the group that received LT-B by injection. The specific IgG levels in the LT-B Injection 
group on day 350 were significantly higher than that of the LT-B Corn fed group (p<0.0014). 
Figure 3 shows concentrations of anti-LT-B specific IgA measured in fecal material 
(Fig 3 A & B) and serum (Fig 3 C& D) of mice fed or injected with LT-B. As shown in 
Figure 3 A, concentration of LT-B specific secretory IgA in feces increased gradually 
following the first immunization on day 1. The highest concentration was recorded on days 
27 (1.07±0.07 (ig/g) and 41 (0.93±0.16 jag/g) one week post feedings. We observed a 
relatively lower concentration of specific fecal IgA on days 34 and 41 compared to peak 
level observed on day 27, approximately two weeks post feeding. However, antigen specific 
fecal IgA remained significantly higher than control through day 62, one month post feeding. 
Figure 3B shows the fecal anti-LT-B IgA response after booster antigen 
administration when the mice were 14 months old. Fecal anti-LT-B secretory IgA was not 
detectable before the administration of the booster dose. As in the case of antigen specific 
serum IgG response to recall, a significant increase is observed as early as 7 days following 
the administration of the antigen through either route (oral or injection). It is noteworthy that 
in 14-month old mice the specific fecal IgA response to the booster on day 343, 6 days after 
recall immunization, was more robust than that of specific IgG. The levels of specific IgA 
were 2.66 and 3.53 times higher (2.84=1=0.41 and 3.77±0.68 pg/g for recall feeding and recall 
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injection groups, respectively) than the peak level (1.07±0.07 jLig/g) of specific IgA during 
the initial immunization and represent a significant difference in response (pO.OOOl). 
Specific IgG concentrations of the recall response did not exceed responses seen in animals 
during the initial immunization period. In the recall experiment, the specific fecal IgA 
concentrations continued to increase for both groups through day 350 (2 weeks post recall 
exposure), but the LT-B injection group had significantly higher specific fecal IgA compared 
to the LT-B corn fed group (pO.OOOl). 
During the initial immunization phase, antigen specific serum IgA was first detected 
on day 13 and reached a peak on day 27 (Figure 3C). As with fecal IgA, we observed a 
significant decrease on day 34 compared to day 27 (pO.OOOl) two weeks after a feeding and 
a large increase on day 41 compared to day 34 (pO.OOOl) one week after a feeding. Specific 
serum IgA antibodies declined gradually, but were detectable over an 11 -month period. In 
the recall experiment, a robust specific serum IgA response was observed upon booster dose 
administration in 14 month old mice. The aged mice had a more rapid and stronger specific 
serum IgA response as compared to young mice (Figure 3D). In addition, the concentration 
of specific serum IgA in the LT-B Corn fed group remained constant from day 343 to day 
350, while the level of the LT-B Injection group decreased significantly (pO.OOOl) 
compared to day 343. This differs from the result seen with the antigen specific fecal IgA 
response in the recall mice (compare Figs 3B and 3D). 
Antibody response in naïve aged mice upon oral LT-B administration: 
Two groups (n=3/group) of aged mice (14-month-old), which were never exposed to 
LT-B when younger, were used in a separate feeding study to elucidate the immune response 
to corn derived LT-B in aged mice. One of the groups was fed with LT-B corn pellets, each 
45 
containing approximately 10 |a,g of LT-B on days 0,7,21 and 35, while the other group was 
given non-transgenic corn pellets on the same days. Figure 4 displays the results of feeding 
young and aged mice with LT-B containing com. We observed a significant effect of age on 
the antigen specific IgG concentrations (pO.OOOl). As indicated in Figure 4A, specific 
serum IgG antibodies were first observed on day 13, however the concentration of specific 
IgG antibodies in aged mice were significantly lower than in sera of young mice on day 13 
(pO.OOl) and remained significantly lower throughout days 20 to 41 (p's < 0.05). 
Contrary to the delayed antigen specific IgG response in the aged LT-B fed group; a 
very rapid antigen specific secretory IgA response was observed as early as day 6 in the fecal 
extracts of the aged mice in the LT-B treatment group (Figure 4B). The specific fecal IgA 
concentrations were significantly higher on days 13, 20, 27 and 41 in both young and aged 
mouse groups compared to pre-feeding (p'sO.OS). In the overall analysis, we observed no 
significant age effect for anti-LT-B fecal IgA levels in young vs aged mice. However, day 41 
anti-LT-B fecal IgA was significantly higher for young vs aged mice (pO.O4). 
Figure 4C shows the antigen specific serum IgA concentrations in young vs aged 
mice during an initial immunization regimen. Serum IgA was measurable in aged mice as 
early as day 6 following the first feeding and remained relatively constant over 42 days. Peak 
antigen specific IgA levels in sera of aged mice (4.1 ±0.02 |ag/ml) were comparable to the 
peak anti-LT-B concentration recorded on day 27 in young mice (4.63±1.76 (ig/ml). 
However, we observed a significant overall age effect for serum IgA levels in young vs aged 
mice (pO.OOl) as anti-LT-B IgA antibody concentrations in sera of aged mice were 
s ign i f ican t ly  h igher  than  tha t  measured  in  se ra  o f  young  mice  (p ' sO.OS)  on  days  6 ,  13 ,20  
and 34. 
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Both in fecal extracts and in sera collected from the mice in this part of the study, 
anti-LT-B IgA antibodies were observed as early as one week following the initial LT-B corn 
administration. This rapid specific IgA response led us to preliminarily investigate changes in 
Thl and Th2 responses in these mice as a possible explanation for these results. Using the 
serum samples collected in this experiment we measured total IgG2a (a Thl antibody) and 
IgGl (a Th2 antibody) concentrations. We were not able to measure antigen specific forms of 
the antibody, due to lack of sufficient serum. Figure 5 demonstrates the ratio of total IgG2a 
and IgGl in young and old mice. The IgG2a/IgGl ratio was significantly lower in sera of 
LT-B fed mice (p < 0.01). The main effect of LT-B feeding was due to the large decrease in 
IgG2a/IgGl ratio seen in the aged mice (p<0.05) after immunization. A comparison of young 
mice fed NT com and LT-B com did not demonstrate a significant shift in total IgG2a/IgGl 
ratio. 
2.5 Discussion 
In this study, we monitored antigen specific IgG and IgA concentrations in sera and 
fecal samples of mice immunized with corn-derived LT-B over 11 months. The peak 
antibody production was reached after a minimum of 3 feedings over 4 weeks in young mice. 
This is similar to data published previously by ourselves and others using either recombinant 
bacterial LT-B (Clements, 1990) or plant derived LT-B (Wang et al, 2004). We previously 
demonstrated that the specific antibodies can provide protection from challenge with whole 
E. coli heat labile toxin (Chikwamba et al, 2002). The present study expanded our previous 
research to show specific antibody remained elevated over background for an 11-month 
period following the initial immunization paradigm. 
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We observed a kinetic difference in the recall response for anti-LT-B IgG and IgA. A 
rapid and stronger antibody response is a characteristic of immune memory. Upon booster 
immunization in aged (14-month) mice, our results indicated a rapid recall response for both 
feeding and injection of LT-B in measurements of antigen specific serum IgG, serum IgA 
and fecal IgA. While the recall response of specific IgG levels (day 343 & 350) was not 
greater than that of initial peak response at week 4, the fecal and serum IgA responses were 
quite robust and 2-5 times higher than initial peak responses in young animals. This IgA 
response is important in protection against mucosal pathogens and toxins. It should be noted 
that our robust IgA response was seen subsequent to both recall immunization using feeding 
and injection of LT-B. 
Others have reported a shift in the type of immune response in aged animals 
(Wakikawa et al, 1997, Robinowich et al, 1985, Kurashima et al, 1995,). They have noted 
that aged animals respond with more of a Th2 type immune response and have a decreased 
Thl response in comparison to young mice. This shift may help explain our robust IgA (Th2 
type) response in aged mice. Thl cells support production of serum IgG2a while Th2 cells 
induce production of IgGl serum antibodies (Kaplan et al, 2002). We measured total IgG2a 
versus IgGl in the serum samples from immunized young and aged mice as an indicator of 
the Thl:Th2 balance. Immunization at the mucosal surface favors a Th2 type of response 
(Hiroi et al, 1995). Thus, it is not surprising that our analysis indicated that IgG2a/IgGl ratio 
of the LT-B com treatment group is significantly lower than that of non-transgenic control 
group. The suppression of the IgG2a/IgGl ratio was significant in the immunized aged mice, 
but not in the immunized young mice. This result is indicative of a shift towards a Th2 type 
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response in the aged mice which could account for the rapid production and high levels of 
antigen specific IgA antibodies. 
In addition to a shift from Thl to Th2 responsiveness, there have been reports of a 
general decline in immune responses to antigen in the elderly (Schmuker et al, 1997, Koha et 
al, 2000). In this study we also compared the initial immune response against corn-derived 
LT-B in young and aged naive mice. Aged mice immunized with LT-B for the first time 
demonstrated a delayed and lower peak anti-LT-B IgG production through 4 feedings and 7 
weeks of monitoring as compared to young mice. In contrast to the delayed IgG response, the 
aged mice demonstrated maximal specific IgA production by day 6 after the first feeding. 
This is much sooner than the IgA response detected in young mice fed LT-B. One other 
difference between the initial antigen specific IgA response of young and aged mice was that 
the response of young mice appears to increase one week after each feeding and decrease at 2 
weeks after each feeding. This corresponds well with the half life of IgA (6 days in serum). 
In aged mice there was no fluctuation of antigen specific IgA concentrations seen in serum or 
in fecal samples in relation to feeding. These differences may be due in part to age related 
changes in immune regulation. 
Although the concentrations of specific IgA in serum of young and elderly mice were 
comparable, the fecal IgA levels in aged mice did not reach the same concentration observed 
in young mice on day 41. This observation is not surprising as other researchers have noted 
increased serum IgA in elderly people (Arranz et al, 1992, Beharka et al, 2001). Schmuker et 
al. (1997) suggests that the detection of higher serum immunoglobulin levels in the elderly 
could be due to altered epithelial cell transport to mucosal surfaces. 
To date, a significant amount of evidence indicates that edible plant-made antigens 
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can be a part of clinical practices in the foreseeable future. Corn and its products are a major 
food source for humans and animals. Moreover, production of edible vaccines in com is 
highly desirable in terms of safety, cost efficiency and high yield of transgenic protein. This 
study demonstrates that com derived LT-B can elicit high levels of systemic and secretory 
antibody levels which persists for over 11 months. Re-administration of the antigen does not 
lead to immune tolerance, but instead boosts the immune response significantly indicating 
induction of a strong memory cell component. However, immunization of aged mice with 
LT-B for the first time does not result in a robust mucosal IgA or serum IgG response, 
indicating that use of LT-B as an adjuvant in aged animals may not be as beneficial as in 
young animals. These findings may be useful for determining edible vaccine strategies for 
both young and aged animals. 
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Bleed days Anti-LT-B IgG Anti-LT-B IgA /Anti-CT-B IgG /Anti-CT-B IgA 
Day 51 2.9 6.6 
Day 62 2.7 12.7 
Day 94 2.8 5.6 
Average 2.8±0.1 8.3±2.2 
Table 1. Specific antibody ratios. Sera from LT-B com group analyzed for anti-LT-B and 
anti-CT-B antibodies on the indicated days. 
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Aged mice study 
# of mice Group ID Feed type 
Young mice study 3 Negative Control NT corn 
# of mice Group ID Feed type y / 3 LT-B Corn LT-B corn 
6 Initial/Control NT corn ^ 
12 LT-B Corn LT-B corn \ Recall study 
\ # of mice Group ID Feed type V 4 Recall/Control NT corn 
* 4 Recall/Feeding LT-B corn 
4 Recall/Injection NT corn* 
' mice were fed with NT corn but injected with 
bacterial LT-B. 
Figure 1. Study design for mouse immunizations. 
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Figure 2. Antigen specific serum IgG concentrations in mice orally immunized with corn 
derived LT-B and recall to re-immunization through oral and IP administration of the toxin. 
The X axis are days of initial immunization and recall study. Initial immunization regime 
involved feeding on days 0, 7, 21 and 35. A booster dose was administrated once (day 337) 
and antibody response was monitored for two weeks. * indicates the blood collection day 
immediately prior to a feeding or injection. #Specific IgG measured with bacterial CT-B. 
Antibody concentrations are presented as mean+SE. 
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B) 
Fecal IgA-lnitial 
• NT Corn _ 
• LT-B Corn 
» 0.6 
« 0.2 
13 20* 27 34* 41 
Bleed Days 
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Fecal IgA-Recall 
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Bleed Days 
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C) D) 
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LT-B Corn 
-1* 6* 13 20* 27 34* 41 51 62 94 270 345 
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Serum IgA-Recall 
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350 
Figure 3. LT-B specific fecal IgA (A & B) and serum IgA (C& D) concentrations for initial 
immunization in young mice (A & C) and recall in aged mice to re-immunization (B & D). 
In initial immunization study, mice were fed with meal pellets from non-transgenic 
corn (NT Corn) and transgenic corn expressing LT-B (LT-B Corn) on days 0, 7, 21 and 
35 when mice were three-months old. Mice were given a booster dose of the toxin 
through oral route and through injection when they were 14 months old (day 337). * 
indicates sample collection day immediately prior to a feeding and injection. # Specific 
fecal IgA measured with bacterial LT-B (A&B), specific serum IgA measured 
with bacterial CT-B (C&D). Antibody concentrations are presented as mean+SE. 
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Figure 4. Antibody concentrations of initial oral immunization in aged mice and young mice. 
Young mice (LT-B corn-young) and aged mice (LT-B corn-aged) were fed with corn meal 
pellets from transgenic com on days 0, 7, 21 and 35. (A) Concentration of specific serum 
IgG, (B) concentration of specific fecal IgA and (C) concentration of specific serum IgA. 
#Specific serum IgG and serum IgA (A&C) measured with bacterial CT-B, specific fecal IgA 
(B) measured with bacterial LT-B. Antibody concentrations are presented as mean±SE. 
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Figure 5. Comparison of IgG2a/IgGl ratios in young and aged mice. 
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Chapter 3: Expression of B sub-unit of cholera toxin (CT-B) in corn seeds 
and evaluation of its immunogenicity in vivo 
Manuscript in preparation 
Sule Karaman, Joan Cunnick, Kan Wang 
3.1 Abstract 
The Non-toxic B subunit (CT-B) of cholera toxin from Vibrio cholerae is a strong 
immunogen and amplifies the immune reaction to co-administered or conjugated antigens. 
Plants are attractive vectors for recombinant protein production. In this work, a synthetic 
gene encoding for CT-B was expressed under control of a y-zein promoter in transgenic com 
seeds. Levels of CT-B in corn plants were determined via ganglioside dependent ELISA. The 
highest expression level recorded in R1 generation seeds was 0.0014% of total aqueous 
soluble protein (TASP). Expression level of the same event in the R2 generation was 
significantly increased to 0.0197% of TASP. Using Western analysis, we found that, unlike 
corn-derived LT-B (Chikwamba et al., 2003), the bacterial signal peptide of CT-B was not 
cleaved in corn seed tissue. Immunogenicity of com derived CT-B was evaluated by 
immunizing mice through feeding. Mice immunized with CT-B com (5 or 10 (ig/g per dose) 
have elevated anti-CT-B specific antibody levels in their sera on day 27 after three feedings. 
When mice were administrated with an equal amount (5 jj,g/g each) of mixed com-derived 
CT-B and LT-B (Chikwamba et al, 2002), the specific antibody levels were moderately 
enhanced compared to either the same or a higher amount of CT-B alone. The mice were 
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partially protected against holotoxin challenge with either CT or LT. These results suggest 
that a synergistic action may be achieved using a CT-B and LT-B mixture that may lead to a 
more efficacious combined vaccine against both cholera and diarrhea induced by 
enterotoxigenic strains of Escherichia coli. 
3.2 Introduction 
Expression of antigens in plant systems for oral vaccine production has been studied 
extensively. A number of antigens have been produced in plant systems and a few of them 
are in Phase I and Phase II clinical trials (Ma et al, 2005). Antigens produced in plants can be 
purified from plant tissue; however there are a number of advantages using plant tissue as 
delivery vehicle. Seeds for example provide a dry and stable environment for long term 
storage. As specialized organs for protein storage, seeds also provide increased capacity for 
producing high amounts of the antigen in a smal unit. Plants are innately free of animal 
pathogens. Therefore utilization of plants for sub-unit vaccine production is cost efficient and 
safer than conventional alternatives. 
In this work, we expressed the B subunit of cholera toxin (CT) from Vibrio cholerae 
in corn endosperm. CT is highly homologous to heat labile enterotoxin (LT) from 
Escherichia coli. Both of these toxins are composed of pentameric non-toxic B subunit and 
toxic A subunit. The action of toxic the A subunit leads to watery diarrhea via a mechanism 
as follows: the toxic A subunit is linked to the B subunits and is cleaved into A1 and A2 
fragments by exogenous proteases. The A2 fragment is linked to the B subunits whereas A1 
fragment possesses cytotoxic activity. The B subunits binds to Gmi (galactosyl-N-
acetylgalactosamyl-syalil-galactosylglucosyl ceramide) receptors on intestinal epithelial 
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cells. This binding aids the toxic A1 fragment to be internalized into the cytosol. In the 
cytosol A1 catalyzes ADP-ribosylation of GTP binding and hydrolyzing receptors (Gsa), 
activating adenylate cyclase which increases cyclic AMP (adenosine mono phosphate) levels. 
Elevated cyclic AMP levels leads to phosphorylation of protein kinase A which in turn leads 
to opening of CI" channels. Movement of CI" is followed by movement of water to lumen 
(Williams et al, 1999). 
The biologically active form of the B subunits of both CT (CT-B) and LT (LT-B) are 
pentameric. Although the B subunits are non-covalently linked, they are highly stable due to 
their structural properties. There is high number of salt bridges between adjacent monomers 
and two or three anti-parallel (3 sheet structures interacting with neighboring monomers. 
Therefore, B subunits are highly resistant to trypsin and proteinase K digestion and low pH 
(Ruddock et al, 1995). Hence, oral immunization with CT-B and LT-B results in strong 
humoral and mucosal immune response (Rigano et al, 2003). 
CT-B has been shown to be a mucosal adjuvant and a good carrier for targeting 
unrelated antigens to mucosal immune system (Luci et al, 2006). It has also been shown to be 
an effective carrier for the antigens that are chemically or genetically linked (Dertzbough and 
Elson, 1993). It was recently reported that intravaginal (ivag) administration of bacterial CT-
B chemically conjugated to ovalbumin (OVA) helps to induce OVA specific CD4+ T cells. In 
that study neither OVA alone nor OVA co-administered with CT-B resulted in OVA specific 
CD4+ cells (Luci et al, 2006). In fact, CT-B is used as an adjuvant in an oral cholera vaccine 
(Dukoral®, SBL Vaccin Sweden - used for human use), the basic component of which is 
attenuated cholera bacteria (Holmgren et al, 2003). Interestingly, some CT-B conjugates 
were reported to be highly tolerogenic (a substance which invokes immune non-
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responsiveness) when administered orally (Holmgren and Czerkinsky, 2005). This function 
of CT-B has been successfully exploited to carry out proof of concept studies for treatment of 
human autoimmune diseases. For example, oral administration of the B chain of insulin 
conjugated to CT-B led to oral tolerance to the B chain of insulin. This in turn resulted in a 
lower dose of antigen and administration rate in mice models of diabetes for suppression of 
the disease (Sadeghi et al, 2002). Similar success was attained against type II collagen-
induced arthritis (Tarkowski et al, 1999). 
The two internationally used oral cholera vaccines Mutacol® (Berna, Switzerland) 
and Dukarol® (SBL Vaccin, Sweden) are made of live attenuated cultures of V. cholerae and 
killed whole cell V. cholerae in combination with the CT-B subunit, respectively. The 
presence of CT-B in Dukarol® also provides some immunity to E. coli infections causing 
diarrhea. However, they pose a risk by using the whole cells and they only provide short term 
immunity (National Advisory committee on Immunization, 2005). They are also expensive. 
Dukarol® is licensed in Canada and a dose costs 75 Canadian dollars (78 US$). Therefore, 
there is still need for effective and cheap vaccine formulations for treating cholera. 
We have expressed a recombinant CT-B gene (optimized for com expression system) 
in endosperm of com kernels to provide a cheaper source for cholera vaccine formulations. 
We monitored the transgene expression level for two generations. We tested in vivo 
immunogenicity of corn derived CT-B in mice with an oral feeding trial. In addition to test 
anti-CT-B antibody levels of mice fed with com derived CT-B, we also evaluated the 
specific antibody levels of the mice that were fed with a mixed CT-B and LT-B. This is to 
investigate whether the combination of these two B-subunits can elicit higher levels of 
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specific antibodies than either B-subunit alone, thus providing a better protection against 
both cholera and traveler's diarrhea. 
3.3 Materials and Methods 
Plasmid Construction 
The gene segment encoding for CT-B (PubMed Accession #: U25679) optimized for 
corn expression system was synthesized and cloned into the plasmid pUC57 
(GenBank/EMBL Accession #: Y14837) at Xmal site by Genescript Corp. gene synthesis 
company (New Jersey, USA). The resultant plasmid was named as pUC57-CTB (Figure 1 A). 
CT-B gene was then cloned under 2x3 5 S CaMV promoter (Figure 1C) and an endosperm 
specific y-zein promoter (Figure IE). For constructing the 35S promoter construct, the CT-B 
gene was isolated from pUC57 with Ncol and Kpnl restriction digestions and inserted into 
the Ncol and Kpnl sites (replacing the sLT-B gene) in the plasmid pTH210 (Figure IB). The 
newly constructed plasmid was named as pCTB-BS (Figure 1C). For constructing the y-zein 
promoter construct, the Ncol and EcoRI fragment carrying the sCT-B and VSP terminator 
was inserted into the plasmid pRC4 (Figure ID) to replace the sLT-B and VSP fragment. 
This plasmid was given the name pCTB-BSG (Figure IE). Both pTH210 (Mason et al., 
1998) and pRC4 (Chikwamba et al, 2002) were previously used for production of transgenic 
LT-B corn plants (Chikwamba et al, 2002). 
Maize transformation 
Embryogénie maize Hi II callus was transformed using microprojectile bombardment 
as described by Frame et al. (2000). The plasmids pCTB-BS and pCTB-BSG were each co-
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transformed with the selectable marker gene construct, pBARl 84 (Frame et al, 2000). 
pBAR184 confers resistance to the herbicide bialaphos by expression of the bar gene. 
Transgenic calli and plants obtained via transformation with pCTB-BS and pCTB-BSG were 
designated as P247 and P248, respectively. Bialaphos resistant calli obtained from pCTB-BS 
transformations (P247 lines) were analyzed by ELIS A for CT-B expression and Southern 
blot for integration of the CT-B gene. Clones obtained from pCTB-BSG transformations 
(P248 lines) were analyzed by polymerase chain reaction. CT-B expressing P247 lines and 
PCR positive P248 lines were regenerated and raised to maturity in the greenhouse. B73 
and/or Hi II inbred lines were used as pollen donor for obtaining R1 generation seeds. DMA 
obtained from leaves of P248 plants were analyzed by Southern blot. Seeds obtained from 
this line were analyzed by ELIS A and Western blot for expression of CT-B gene in corn 
endosperm. 
PCR analysis 
The presence of the cassette including the CT-B gene segment in corn genome was 
verified with PCR analysis conducted on a 100 ng of total genomic DNA obtained from 
transgenic callus (P248). DNA isolation from calli was performed as following: 0.1 to 0.25 g 
of bialaphos resistant callus was transferred to 1.5 ml sterile micro-centrifuge tubes. The calli 
were homogenized by autoclaved pestles (Kontes Pellet Pestle, K749520-0000, Fisher 
Scientific, PA, USA) until juice exudes. Four hundreds micro liters of extraction buffer [200 
mM Tris-Cl (pH 7.5), 250 mM NaCl, 25 mM EDTA] was added to the tube. The tissue and 
buffer were mixed gently by inverting the tube a few times. An equal amount of saturated 
phenol was added to each sample and mixed gently in a similar fashion. The mixtures were 
centrifuged for 10 minutes at 12,000 rpm at room temperature. The aqueous phase was 
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transferred to new micro-centrifuge tubes and 350 jal of chloroform: iso-amyl alcohol mix 
(24:1 v:v) was added to each tube and mixed gently. This was followed by centrifugation for 
10 minutes at 12,000 rpm at room temperature. The aqueous phase was transferred to a new 
tube and 300 pi of isopropanol was added. DNA was allowed to precipitate for 30 minutes. 
Next, DNA was pelleted by centrifugation for 10 minutes at 12,000 rpm at room temperature. 
Isopropanol was discarded and pellets were washed with 500 pi of 70% ethanol by 
centrifuging at the same speed for 5 minutes. The pellets were air dried for 15-30 minutes 
and re-suspended in autoclaved water. Three sets of primers were used to verify the presence 
of promoter-leader-CT-B-terminator region in genomic DNA. The primer sets used are as 
follows: 1) Fl: 5'-gct-atg-acc-atg-att-acg-cca-agc-3' and Rl: 5'-cat-tct-gta-ctt-ctg-cgt-ggc-
tca-3', 2) F2: 5 ' -tga-gcc-acg-cag-aag-tac-aga-atg-3 ' and R2: 5 ' -ggg-tct-tat-tgt-tcc-aca-cgc-
ag-3', 3) F3: 5'-aag-acc-cca-cac-gct-att-gct-g-3' and R3: 5'-gaa-ttc-gct-tca-aga-cgt-gct-ca-3'. 
These primers amplify 925 bp, 738 bp and 629 bp fragments respectively. The relative 
positions of sequences on pCTB-BSG aligning to these primers are indicated in Figure IE. 
The reaction mixtures and conditions were as follows: Total volume of 25 pi containing 100 
ng of maize callus genomic DNA, 1 pi of dNTP mix (containing 10 mM of each dNTP), 1 pi 
of each primer (2.5 pM stock), 1 pi of MgCl% (50 mM), 2.5 pi of 10X Taq polymerase PCR 
buffer and 0.2 pi of Taq polymerase (Biolase USA Inc., City, NJ, USA). PCR was initiated at 
95°C for 4 minutes. This was followed by 30 cycles of amplification steps of which are; 
denaturation at 95°C for 1 minute; annealing at 62°C for 40 seconds, and extension at 72°C 
for 1 minute. 
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Southern blot analysis 
Sothern blot analysis to estimate copy numbers of the CT-B gene in P247 and P248 
events was carried out on DNA extracted from leaf tissue of R1 young plants. Approximately 
0.2 g of leaf tissue was ground in liquid nitrogen with mortars and pestles. The powder was 
transferred into a 15 ml test tube (Fisher Scientific Cat # 232917028) and re-suspended in 2.5 
ml of 2x cetyltrimethylammonium bromide (CTAB) buffer [100 mM Tris-HCL, pH 8.00, 1.4 
M NaCl, 20 mM EDTA pH 8.00, 2% w/v CTAB]. Following incubation at 65°C for 30 
minutes, an equal amount of chloroform was added into tubes and mixed well for 5 minutes 
at room temperature. The samples were centrifuged at 8,000 rpm in a Beckman J-12 rotor at 
room temperature for 20 minutes. The aqueous phase was transferred to new 15 ml tube and 
5 ml of 100% ethanol was added. Samples were mixed gently to allow genomic DNA to 
precipitate. The precipitate was hooked out with pipette tips and transferred to 1.5 ml micro­
centrifuge tubes which containing 1 ml of wash buffer [76% ethanol, 0.2 M sodium acetate 
pH 5.2]. Pellets were spun down at 14,000 rpm for 10 minutes at room temperature. The 
supernatant was discarded and pellets were washed with 70% ethanol and spun for 5 minutes 
at the same speed. The pellets were then air dried for 7 minutes and re-dissolved in 50 pi of 
TE 10/0.1 buffer containing 2 pi of 10mg/ml RNase A (R-4642, Sigma, St Louis, MO, USA) 
at 56°C for 10 minutes. Re-dissolved DNA samples were kept in 4°C overnight to ensure 
complete re-suspension. Ten micrograms of genomic DNA obtained from selected P247 and 
P248 events was digested with the restriction enzyme Ncol at 37°C overnight and resolved 
on 0.8% agarose gel. The 950 bp fragment containing synthetic CT-B gene and VSP 
terminator was excised from pCTB-BS plasmid with Ncol and EcoRI restriction enzymes and 
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used as probe following labeling with 32P (Figure 1C). DNA blot was carried out following 
standard procedures (Sambrook et al, 1989). 
Protein Extraction from corn seeds 
For CT-B expression analysis of RI P248 seeds, 15-20 mg of endosperm tissue from 
20 seeds of each event was collected with a drill (DREMEL, Mutipro-225 T2) as described 
by Sangtong et al (2001). The powder was transferred to a 1.5 ml tube. For ELISA extraction 
buffer [25 mM sodium phosphate, pH:6.6, 100 mM sodium chloride, 1 mM EDTA, 0.1% 
Triton X-100, Leupeptin (10p.g/ml), 0.25 mM Pefabloc SC] was added at a ratio of lOpl/mg 
of powder. The samples were incubated at 37°C on a shaker incubator for two hours. Highest 
expressers among R1 seeds were planted to obtain high expressing R2 seeds. For Western 
analysis, ground whole seeds from R2 p248 plants were used. Ground seed mixtures were 
suspended in extraction buffer [200 mM Tris-HCl, (pH 8.0), 100 mM NaCl, 400 mM 
sucrose, 10 mM EDTA, 14 mM 2-Mercaptoethanol, 0.05% Tween-20] at the rate of 10 jal 
buffer per milligram of powder. The powder was shaken for one hour on a vortex shaker at 
room temperature and further soaked in refrigerator overnight. Before loading to protein gels, 
samples were centrifuged on a bench-top micro-centrifuge at maximum speed for 15 minutes 
to remove cellular debris. The amount of total soluble proteins (TASP) were determined by 
the Bradford Assay (Bradford, 1976) with the BioRad (Hercules, CA, USA) protein dye 
concentrate using a standard curve derived from bovine serum albumin (BSA). 
Quantification of CT-B expression in corn calli and seeds 
CT-B expression in corn calli, endosperm and ground whole kernels were determined 
by ganglioside dependent ELISA (Mason et al, 1998, Chikwamba et al, 2002). Anti-sera and 
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CT-B standard were obtained from Sigma chemical company. Each of the ELISA steps were 
carried out at 37°C and 50 jj.1 volumes were used unless otherwise specified. Wells were 
washed three times between steps with 400 pi of phosphate buffered saline Tween-20 
[PBST; 0.01 M Na2HP04, 0.003 M KH2P04, (pH 7.2), 0.1 M NaCl, 0.05% Tween-20 (v/v)]. 
High binding microtiter plates (Costar 3590, Fisher Scientific, PA, USA) were coated 
with Type III mixed bovine gangliosides (G2375, Sigma, St Louis, MO, USA), dissolved in 
sodium carbonate coating buffer [15 mM NazCOg, 35 mM NaHCOg, 3 mM NaNg, (pH9.6)] 
at room temperature for one hour. The wells were blocked with 150 gl of 5% dry milk (w/v, 
DM, DIFCO, Becton Dickinson, MD, USA) dissolved in phosphate buffered saline to 
prevent nonspecific binding to the plate. Next protein extracts and CT-B standards were 
loaded to the wells and incubated for 1 hour. Anti-CT antibodies raised in rabbit (C-3062, 
Sigma, St Louis, MO, USA) and biotinylated anti-rabbit goat IgG was used as primary and 
detection antibodies, respectively. Both antibodies were diluted 1/20,000 in phosphate 
buffered saline. After detection antibody, wells were loaded with streptavidin horse radish 
peroxidase diluted 1/1,000 (BD Biosciences, 554066, MD, USA). The color development 
was obtained by addition of ABTS substrate (3-ethylbenzthiazoline-6-sulfonic acid, Sigma 
A-1888, MO, USA) prepared according to manufacturer's instructions. End point readings 
were measured spectrophotometrically at 405 nm in a PowerWave XS plate reader (BT-
MQX200R, Bio-Tek). All samples were measured in duplicates and non-transgenic maize 
protein extracts were used as negative controls. Calculations of CT-B concentrations were 
carried out using a standard curve of purified bacterial CT-B (C-9903, Sigma, St Louis, MO, 
USA). 
Western Blot 
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Ground whole seeds from selected P248 ears (R2 generation) and the meal that was 
used for making CT-B corn containing pellets were analyzed by Western blot for detection of 
CT-B pentamers and monomers. Approximately 70 mg of total protein extracted from 
ground material were separated by SDS-PAGE (Laemmli, 1970). The resolved proteins were 
transferred to 0.45 pm nitrocellulose blotting membrane (BioRad) using a BioRad Transblot 
apparatus following manufacturer's instructions. After blocking with 5% milk, membranes 
were incubated at room temperature on a shaker for 1 h in primary antibody raised against 
CT (rabbit-anti-CT, Sigma C-3062) diluted 1/3,000 in 1% milk. This was followed by 
incubation in alkaline phosphatase conjugated secondary antibody diluted at the ratio of 
1/5,000 in 1% milk (Sigma A-9919) in a similar manner for 1 h. Detection was performed 
following procedures of Blake et al, (1984). 
Preparation of feeding pellets and immunizations 
Among the R2 generation plants, P248 event number 4 was found to be expressing 
CT-B at high levels. Seeds obtained from four individual P248 R2 ears (P248-4-8-4, P248-4-
8-5, P248-4-8-8 and P248-4-8-18) were ground in a coffee grinder (Braun, Type 4041: 
Model KSM2) and a homogenous mix was prepared. The CT-B concentration in the mixed 
mill was 8.2 |j,g/g of ground powder. 
Five feed categories were used in this feeding trial. The feeding groups used were 
referred to as CTB-5, CTB-10, LTB-5, CTB5-LTB5 and WT. Mice in CTB-5 and CTB-10 
groups received feed pellets containing 5p.g and 10|_ig of corn derived CT-B, respectively. 
Mice in LTB-5 group were fed with feed pellets containing 5 jag of corn derived LT-B 
(Chikwamba et al, 2002). Mice in CTB5-LTB5 group received feed pellets containing 5 ng 
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of corn derived CT-B and 5|a,g of com derived LT-B. Mice in WT group were fed with feed 
pellets made of non-transformed corn and served as a negative control group. A fixed amount 
of powder (Table 1) was weighed for obtaining the required amounts of CT-B and LT-B for 
feeding groups and mixed with ground non-transformed corn kernel when necessary to have 
the same size of pellet for each treatment (1.22 g). The powder was then mixed with sterile 
distilled water and the dough was shaped into a cylinder by passing it through a 3 ml 
disposable syringe barrel with the Leur tip cut off. Non-transformed corn powder was used 
for feeding pellets to be fed to mice in the negative control group. 
Four-week-old female BALB/c mice were obtained from Harlan (Indianapolis, IN, 
USA). Prior to start of the experiment, mice were allowed a two-week adjustment period 
with a reverse light-dark cycle (lights-off at 9AM) in the ISU animal facility where they were 
housed throughout the experiment. All animal procedures were approved through the Iowa 
State University (ISU) Committee on Animal Care. Eight mice were randomly assigned to 
each treatment group. Mice were fed a basic diet of mouse chow with water ad libitum. Mice 
were fasted overnight (during the light phase) prior to feeding corn pellets on days 0, 7, 21 
and 49 of the study. Throughout the study two mice were housed in each cage. However, 
during feeding of the corn pellet they were caged individually and one maize pellet was 
placed on the lid of each cage (without bedding) 30 min before lights off. Mice were allowed 
to eat the maize pellet in the dark cycle for 5 hours until the pellet was completely consumed 
and then returned to their home cage with their normal mouse chow. 
Preparation of serum samples 
Approximately 100 pi of blood was collected weekly starting the day before first 
immunization over 8 weeks. Blood samples were collected from sephanous vein except for 
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the day of necropsy. On day 55 mice were euthanized blood was collected from their hearts 
via cardiac puncture. Sera were isolated from blood samples immediately after collection by 
centrifugation at 14,000 for 15 minutes and kept at -20°C until analyzed. Anti-LT-B and anti-
CT-B antibodies were measured with ELISA as described below. Dilutions ranged from 1/60 
to 1/400. 
Quantification of anti-CT-B and anti-LT-B antibodies 
Quantification of anti-CT-B and anti-LT-B was conducted as described in Chapter 2 
with a minor modification. Twenty five ng of pure LT-B (John Clements) and CT-B (Sigma) 
was loaded in each well instead of 1 pg. This modification was determined based on 
comparison of different amounts of LT-B and CT-B with sera of known antibody levels (data 
not shown). 
Patent Mouse Assay 
To assess protection from toxin challenge a patent mouse assay was undertaken 
(Guidry et al, 1997). Mice in each group were divided into three groups and subjects were 
randomly assigned to toxin challenge treatments. Three of them were challenged with 30 |ag 
of LT (John Clements), 3 of them were challenged with 30 pg of CT (Sigma, C3012) and 2 
of them were gavaged with an equal volume of (200 |Lil) water. Toxins were administered in 
200 pi of phosphate buffered saline via gavaging. The mice were fasted overnight ad libitum 
prior to gavage administration of toxin. Three and half hours after toxin administration mice 
were euthanized and their carcasses were weighed. Following dissection, guts were removed 
from duedonum to anus and weighed separately. The gut/carcass ratios (Richardson et al., 
1984) were calculated to determine the amount of water influx into the gut. 
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Statistical Analysis 
Data were analyzed by Analytical Software Statistix® 8 (Tallahassee, FL). ANOVA 
and repeated measures analysis of variance tests were used for analysis of gut:carcass ratios 
and IgG levels, respectively. 
3.4 Results 
Analysis of transgenic corn lines carrying CT-B gene under a constitutive promoter 
The CT-B coding sequence was synthesized by GenScript DNA Synthesis Company 
with a codon bias for optimizing expression in corn and cloned under enhanced CaMV35S 
promoter and a TEV leader sequence (Figure 1C). This construct was co-transformed into 
maize embryogenic callus along with plasmid pBAR184 carrying the bar gene. Transgenic 
events obtained were designated as P247 (Figure 1). Twenty one out of 75 putative 
transformants analyzed were expressing CT-B at varying levels (0.00092-0.009% of total 
aqueous soluble proteins). CT-B levels were determined by ganglioside dependent ELISA 
(Haq et al., 1995; Chikwamba et al., 2002). Because only the pentameric form of CT-B can 
bind to gangliosides, the ganglioside dependent ELISA values are reflective of their 
biological active quantities. The level of CT-B expression was also analyzed in young leaf 
tissues of putative P247 transformant lines (R0). As can be seen in Table 2, five of eleven 
lines showed enhanced CT-B expression (16.6 - 57.5 fold increase) in leaf materials 
compared to calli tissues. Three of eleven had marginal increase (1.2-3.6 fold increase) and 
another three lines showed no or decreased expression in leaves. These results indicate that 
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the transgenic CT-B protein was assembled into a pentameric and potentially biological 
active conformation in both corn callus and leaf tissues. 
Southern blot analysis was used to characterize 13 P247 lines. Genomic DNA was 
extracted from leaves of RO plants and digested with restriction enzyme Ncol that cuts at 5' 
end of CT-B gene. 32P-labeled 950 bp fragment carrying CT-B and VSP terminator (Figure 
1C) was used as probe. Our results indicated integration of CT-B into the corn genome 
(Figure 2). Event specific integration was observed. Copy numbers ranged from 1 to 7, which 
is typical with biolistic gun-mediated transformation (Christou, 1996). 
Analysis of transgenic corn lines carrying CT-B gene under a seed specific promoter 
After validating functionality of synthetic CT-B gene by constitutive expression in 
com calli and leaf tissue, a plasmid (pCTB-BSG) was constructed by cloning CT-B gene 
under endosperm specific y-zein promoter (Figure IE). Transgenic events transformed with 
pCTB-BSG along with pBAR184 (carrying a selectable marker gene) were referred as P248. 
The putative transformant (herbicide resistant) calli were screened with PCR for the presence 
of CT-B gene. Seven out of nine bialaphos resistant events were shown to carry the intact 
CT-B gene. RO plants were regenerated from these events and Southern analysis was carried 
out on DNA obtained from young leaves of six lines in a similar fashion to P247 RO plants. 
The Southern results are shown in Figure 3. Event specific integration of the CT-B gene was 
observed. Half of the events had high copy number insertion (>10 copies). 
RO young plants were grown to maturity to obtain R1 seeds. Event P248-3 failed to 
produce any seeds. A total of 25 ears representing 6 events were obtained. Selected ears from 
each event were analyzed for expression of CT-B in endosperms of R1 seeds. Endosperm 
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tissue was obtained from 20 seeds for each ear by drilling as described Sangtong et al. 
(2001). 
Expression levels of CT-B were determined by ganglioside dependent ELISA. As 
summarized in Table 3, four out of six lines were expressing CT-B at varying levels. Among 
4 plants generated from line 2, only one ear was shown to be expressing CT-B at low levels. 
The drilled seeds from ears P248-1-1, P248-1-7 and P248-4-8 were germinated and grown to 
maturity to obtain R2 seeds. The choice of specific lines for further analysis was based on 
their CT-B expression levels and seed quantity at the time of analysis. A total of 28 R2 ears 
representing two independent events were obtained. Forty seeds from each R2 ear were 
ground to obtain a homogenous mix and analyzed by ganglioside dependent ELISA. One of 
two lines (P248-1) has stable transgene expression and the other line (P248-2) has 14 folds 
increase of CT-B in R2 generation (Table 3). The enhanced transgene expression in some 
events in advanced generations was observed previously with LT-B expression levels in corn 
seeds (Chikwamba et al, 2002). 
Western analysis was also performed in protein extracts obtained from R2 seeds of 
two events (P248-1 and P248-4). Figure 4A shows the results with non-boiled protein 
samples while 4B shows the boiled sample results. The bacterial pentameric CT-B has an 
approximate size of 55 kDa while monomers have approximate size of 11.6 kDa (Zhang et 
al, 1995). Non-boiled bacterial CT-B used as control (Lane bCTB, Figure 4A) showed 
multiple bands, suggesting that the commercial bacterial CT-B may contain a mixture of CT-
B multimer conformations. This phenomenon was observed by other groups (Arakawa et al, 
1997, Jani et al, 2002, Jani et al, 2004). The second strongest band closest to 56.7 kDa 
marker was considered as the pentamer (indicated by an open arrow). As shown in Figure 
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4A, three ears of P248-4 and R2-Mix have a band (indicated by a black arrow) cross reacted 
to CT-B antibody. This is due to lower level of expression in this event. The Lane "R2-Mix" 
represents the ground com meal mixture of P248-4 used for mice feeding. No bands were 
observed in lanes loaded with extracts from P248-1 ears. Interestingly, this band is 
approximately 20 kDa heavier than that of the bacterial CT-B standard. This result was also 
reported in recombinant CT-B produced in potatoes (Arakawa et al. 1997), tobacco (Jani et 
al, 2004) and tomato (Jani et al, 2002). It was suggested that plant tissues were unable to 
cleave the bacterial signal peptide of CT-B. This was also confirmed by a parallel experiment 
using the boiled protein samples (Figure 4B). Corn-derived monomeric CT-B moves with an 
apparent size of 15 kDa while its bacterial counterpart moves with 11 kDa apparent size. 
In addition to non cleaved CT-B protein in non-boiled samples, we also observe 
bands representing CT-B monomers (Figure 4A, Lane R2mix), suggesting instability of CT-
B in com tissues. 
Evaluation of immune response of mice fed with corn-derived CT-B and LT-B 
It has previously been shown that corn-derived LT-B can elicit anti-LT-B specific 
antibody in mice orally administered 10 pg/g of com pellets (Chikwamba et al., 2002). It has 
also been shown that CT-B produced in potato (Arakawa et al, 1998) and tobacco (Jani et al, 
2004) can elicit anti-CT-B specific antibody in animals. Therefore, it is expected that corn-
derived CT-B should be able to stimulate anti-CT-B antibody in mice fed with CT-B com. In 
addition to evaluating the immunogenecity of CT-B corn in mice, we are also interested in 
investigating the potential adjuvencity or synergistic effects when CT-B and LT-B are 
combined. 
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Mice were assigned to five treatment groups and were administered feed pellets either 
made of transgenic corn or non-transformed corn (Table 1). There were eight mice in each 
treatment group. Treatment groups were as follows: The CTB-5 and CTB-10 groups were fed 
with pellets containing 5 or 10 pg of corn-derived CT-B, the LTB-5 group was given pellets 
containing 5 pg of corn-derived LT-B, and the CTB5-LTB5 group was administered pellets 
containing 5 pg of corn-derived CT-B and 5 pg of corn-derived LT-B. The NT group was 
administered pellets made of non-transformed corn and served as negative control. The data 
are presented as mean±SE (standard error) in (ig/ml (Figure 5). 
As shown in Figure 5, anti-CT-B and anti-LT-B antibodies in sera of all groups were 
measured. For both analyses there was significant feed effect (p values < 0.05). Anti-CT-B 
antibody levels observed in sera of all treatment groups were lower than anti-LT-B levels 
observed in sera of LTB-5 and CTB5-LTB5 groups (Figure 5). While anti-LT-B antibodies 
cross react with CT-B (Figure 5 A), anti-CT-B antibodies were found to not cross-react with 
LT-B (Figure 5B). Starting from day 13, anti-CT-B levels in sera of LTB-5 group 
(111.58±6.6 |ig/ml, Figure 5A) were significantly different than that of WT group 
(37.29±3.13 pg/ml ) throughout the study (p's <0.05). However, as it can be seen in Figure 
5B, anti-LT-B antibody levels measured in sera of mice received 5 and 10 pg of corn-derived 
CT-B were not different than that of WT group at any bleed day (p values for these 
comparisons >0.05). 
Anti-CT-B antibodies in sera of mice in CTB-5 and CTB-10 groups (Figure 5 A) were 
moderately different than that of WT group starting from day 27 (p=0.0241) until day 55 
(p=0.02). Anti-CT-B antibody levels induced by 5 and 10 |_ig of corn-derived CT-B were not 
different until day 55. On day 55 anti-CT-B antibodies detected in sera of CTB-10 group 
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(179.73±25.75) was marginally higher than that of CTB-5 group (110.08±22.26, p=0.04). 
Anti-CT-B antibody levels in sera of LTB-5 group were found to be significantly higher than 
that of CTB-10 group on days 13 (p=0.0001) and 20 (p=0.0001). However, on days 27 and 
34 the differences were not significant (p=0.84, p=0.6, respectively). Interestingly, anti-CT-B 
antibody levels in sera of the LTB-5 group exceeded that of CTB-10 group and were 
moderately larger on days 41 and 55 (p=0.07, p=0.04, respectively). On days 34, 41 and 55 
anti-CT-B antibody levels in sera of CTB5-LTB5 group were significantly higher than that of 
LTB-5 group (p's=0.0061, 0.0008, and 0.001, respectively). On days 34 and 41, anti-CT-B 
antibody levels in sera of CTB5-LTB5 group were moderately higher than that of CTB-10 
group (p=0.02 significant and p=0.076 marginal, respectively). 
Analysis of anti-LT-B IgG levels indicated significant treatment effect throughout the 
study. However, anti-LT-B antibody levels in sera of CTB-5 and CTB-10 groups were not 
significantly different than that of WT group on any bleed day (p values > 0.05). On the other 
hand, anti-LT-B levels in sera of LTB-5 and CTB5-LTB5 groups were significantly higher 
than that of other three groups (p values >0.05) starting from day 13 until the day of necropsy 
(day 55). Anti-LT-B antibody levels in sera of LTB-5 and CTB5-LTB5 were not 
significantly different on any bleed days (p values>0.05). 
Responses of immunized mice to CT and LT toxin challenges 
In order to evaluate whether immunization with com derived CT-B (at two different 
doses) and combined treatment (along with com derived LT-B) provides protection against 
challenge with CT or LT we conducted the patent mouse assay (Guidry et al, 1997). These 
toxins cause fluid flow from the body to the lumen of the bowel (Williams et al, 1999). The 
secreted fluid can not be re-absorbed (Mason et al, 1998) thus accumulates in the gut. This 
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results in the weight of gut to increase relative to the weight of the body. Therefore the gut: 
carcass ratios serve as a measure of response toward toxin challenge. If immunizations 
provide protection we would expect similar gutxarcass ratios with unchallenged control mice 
that were given water in place of toxin. Larger gutxarcass ratios indicate diarrhea therefore 
no protection of the treatments. 
On day 55 we divided the feeding groups into three sub-groups. Three mice in each 
feeding group received 30 pg of CT while three different mice received 30 pg of LT. Two 
mice in each group received water as a negative control. Three and half hours after toxin 
challenge, mice were euthenized, weighed and dissected. The guts were removed and the 
gutxarcass ratios were calculated. The results are displayed in Figure 6. Analysis of variance 
indicated significant toxin effect (p=0.0001). However, the feed x toxin interaction for 
overall data set was not significant (p=0.28). 
Toxin challenge of the group which received non-transformed corn (WT) throughout 
the study indicated significant effect of toxins (p values of CT-30 versus water and LT-30 
versus water were 0.0322 and 0.0175, respectively). Significant protection against CT was 
observed in the group which was immunized with 5 pg of corn derived CT-B (group CTB-5, 
p value for comparison of CT in this group versus CT in WT group is 0.0009). When LT 
challenge in CTB-5 group is compared to all water treatments a moderate protection was 
recorded (p=0.0584). Interestingly when mice in CTB-10 group were challenged with CT 
and LT there was no protection (p values for comparisons with water treatment are 0.0006 
and 0.0035, respectively). Similarly mice challenged with CT and LT in LTB-5 group were 
also not protected when compared to water treatment (p values for these comparisons are 
0.0004 and 0.0044, respectively). Mice in CTB5-LTB5 group, when challenged with CT 
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(compared to water treatment p value is 0.005) were not protected however mice challenged 
with LT in this group were moderately protected (compared to water treatment p value is 
0.532). 
3.5 Discussion 
We have expressed a synthetic gene encoding for B subunit of cholera toxin (CT-B) 
from Vibrio cholerae in com seeds. We have also showed its Gmi binding capacity via 
ganglioside dependent ELISA and its immunogenicity through a feeding trial using mice. We 
have detected significant levels of anti-CT-B IgG antibodies in sera of the feeding groups 
that we utilized. Moreover, we have challenged mice which were fed with transgenic corn 
with CT and LT toxins and observed moderate protection from toxin challenge in some of 
the treatment groups. 
We have targeted the expression of CT-B to seed endosperms because seeds are 
tissues which are naturally designated for protein accumulation and storage making them 
attractive for vaccine expression (Ma et al, 2003). In addition seeds provide a dry stable 
environment for storing proteins at ambient temperatures. Seeds can also serve as ideal 
delivery vehicles for plant derived vaccines since they are edible. This would eliminate 
purification and downstream processing expenses. Expression of CT-B in corn endosperms 
was achieved by cloning the CT-B gene under control of the seed specific y-zein promoter 
which is a strong endogenous com promoter (Marks et al, 1985). In addition to utilization of 
a strong promoter, the synthetic CT-B gene used in this study was optimized for com 
expression system codon preference (Genescript Corp) to ensure high expression levels. 
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Seeds obtained from six transgenic lines were analyzed using ganglioside dependent 
ELISA to determine CT-B expression levels. This analysis has also indicated Gmi binding 
capacity of corn derived CT-B suggesting successful assembly of pentamers. Four out of six 
lines were found to be expressing CT-B at varying levels. Expression levels in R1 generation 
ranged from 0.0002 to 0.00128% of total soluble protein. The expression levels within 
transgenic lines obtained from the same events also varied. The variance among different 
events might be due to differences in copy numbers of the gene integrated and the position on 
the genome where the integration occurred. Therefore, integration of the synthetic CT-B gene 
into the corn genome and copy numbers were also determined by Southern blot analysis. As 
expected, we observed varying copy numbers in different events. However, the number of 
events was not enough to make correlations or conclusions regarding copy number and 
expression level. For example, P248-4 and P248-7 express similar amounts of CT-B in R1 
endosperms (pg CTB/g of corn), and their transgene copy numbers were quite different with 
>10 and 3 copies of CT-B gene, respectively (Figure 3 and Table 3). 
Expression level analysis in R2 generation displayed an interesting outcome. R2 
seeds obtained from one event contained much higher levels of CT-B compared to their R1 
counterparts. A similar trend of increased levels of transgene expression in corn was 
observed by others. Chikwamba et al (2002) reported increased levels of LT-B expression 
and Hood et al (1997) reported increased levels of avidin expression in corn seeds in 
following generations compared to the R1 generation. The reason for this outcome is not 
known. However, lower performance in R1 generation might be explained by the stress that 
R0 plants undergo during tissue culture and regeneration. 
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We had shown via ganglioside dependent ELISA that corn-derived CT-B binds to 
Gmi gangliosides indicating correct folding and pentamer assembly. This suggests that corn 
derived CT-B is similar to bacterial CT-B in terms of forming pentamers. However our 
Western blot analysis performed on protein extracts obtained from R2 seeds suggested that 
bacterial signal peptide may not be cleaved (Figure 4). Our corn-derived CT-B result is in 
agreement with other plant-derived CT-B work (Arakawa et al, 1997, Jani et al, 2002, Jani et 
al, 2004) in which uncleaved CT-B products were found. However, this is different from the 
results obtained with LT-B com (Chikwamba et al, 2002). Although LT-B and CT-B are 
highly homologous and the bacterial signal peptide was also used in the case of LT-B com, 
bacterial signal was found to be cleaved of the mature LT-B protein in com tissue. In 
addition, LT-B com was found to be localized in starch granules (Chikwamba et al, 2003). 
We have also detected CT-B in starch isolates (data not shown). It is not clear if the bacterial 
signal peptide plays a role in localizing LT-B or CT-B in com tissue. Further experiments are 
needed to address specific roles of signal peptides of LT-B and CT-B in targeting to sub­
cellular organelles in maize endosperm. 
We have conducted a feeding experiment with mice to evaluate immunogenicity of 
com derived CT-B. In this experiment we also included groups fed with com-derived LT-B 
(Chikwamba et al, 2002) to assess potential of mixed administration to lead to enhanced 
antibody response. We were interested in answering the following questions: 1) are specific 
antibody levels in CTB5-LTB5 group significantly higher than that of CTB-10 group, 2) are 
there differences in terms of specific antibody levels in sera of CTB-5 and CTB-10 groups, 3) 
are anti-LT-B antibody levels in sera of CTB5-LTB5 group different than that of LTB-5 
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group? All sera obtained from all groups on each bleed day were analyzed for detection of 
anti-CT-B and anti-LT-B IgG antibodies (Figure 5). 
The results were analyzed with repeated measures analysis of variance. Overall 
analysis of anti-CT-B antibody IgG levels indicated that the treatment effect of CTB5-LTB5 
group was different than other treatments. This suggests that in combination corn derived 
CT-B and corn derived LT-B would work better. We have included two doses of corn-
derived CT-B (5 and 10 |_ig). On none of the bleed days the difference between anti-CT-B 
IgG antibody levels detected in sera of these two groups were significantly different (p values 
>0.05). However, on day 55 anti-CT-B IgG levels in sera of the group received 10 pg of corn 
derived CT-B (179.73±25.8 |ig/ml) was moderately higher (p=0.04) than that of the group 
received 5 pg of corn derived CT-B (110.08±22.3 pg/ml). This suggests that level of anti-
CT-B IgG antibodies induced by higher dose (10 pg) of CT-B are primed better although the 
difference between these two treatments (5 pg vs 10 jug) were not significant in previous 
bleed days. 
Cross reacting anti-CT-B IgG antibodies in sera of LTB-5 and CTB5-LTB5 groups 
were detectable earlier (day 13) than that of CTB-5 and CTB-10 groups (anti-CT-B IgG 
antibodies were different than that of wild type as late as day 27). As early as day 13 anti-
CT-B IgG levels in sera of CTB5-LTB5 group was higher than that of CTB-5 and LTB-5 
alone. On day 27 the antibody levels in all feed groups were similar. However on days 34 
and 41 anti-CT-B levels in sera of CTB5-LTB5 were marginally higher than that of CTB-5 
and LTB-5. This outcome might suggest that for vaccine formulations which aim prevention 
of both cholera and ETEC, presence of LT-B in the mix may be of benefit because the 
induction is faster and anti-LT-B antibodies cross react with CT-B. 
85 
Overall analysis of anti-LT-B IgG levels also indicated a significant feed effect. Anti-
LT-B antibodies were detectable at high levels as early as day 13 in sera of LTB-5 and 
CTB5-LTB5 groups. Starting from day 34 anti-LT-B antibody levels in sera of CTB5-LTB5 
group appeared to be higher although the differences were not significant. Only on day 34 the 
difference was marginally significant (p=0.0854). Comparison of anti-CT-B IgG antibody 
and anti-LT-B IgG antibody levels induced by 5 pg of com derived CT-B and LT-B 
indicated that antibody induction by CT-B occurs later and the levels are lower. The highest 
anti-CT-B IgG antibody levels in sera of CTB-5 group was recorded on day 41 with 
129.58+22.7 pg/ml whereas the highest anti-LT-B antibody levels in sera of LTB-5 group 
was observed on day 27 with 640.91±75.1 pg/ml. 
Our analysis also indicated that anti-LT-B antibody levels in sera of CTB-5 and CTB-
10 groups were not different than that of the WT group throughout the study (Figure 5B). 
This outcome indicates that anti-CT-B antibodies induced by corn derived CT-B are not 
cross reacting with LT-B. This finding is different compared to previous reports in which the 
bacterial CT-B was found to cross react with anti-LT-B antibodies Svennerholm et al, 1983, 
Lebens et al, 1996). This result also different compared with the observation that protection 
against ETEC could be achieved when individual was immunized with cholera vaccine 
Dukarol®. The poor antibody induction and absence of cross reactivity might be explained by 
signal peptide still being attached to CT-B. Therefore corn-derived CT-B might be behaving 
differently than bacterial CT-B. Arakawa et al, (1997) indicated that potato derived CT-B 
might posses signal peptide. When mice were orally immunized with potato derived CT-B, 
anti-CT-B antibody levels were shown to be significantly lower than these immunized with 
equal amount of bacterial CT-B (Arakawa et al, 1998). Arakawa et al, (1998) also reported 
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that 30 pg and 90 pg of potato derived CT-B induced similar levels of anti-CT-B antibodies. 
These findings may suggest that the presence of a signal peptide might reduce 
immunogenicity of the CT-B molecule. 
We observed mixed results regarding protection from challenge. Mice immunized 
with 5 pg of corn derived CT-B were moderately protected against both CT and LT 
challenge. However, we did not record protection against challenge in groups which received 
10 pg of corn derived CT-B or 5 fig of corn derived LT-B. Chikwamba et al, (2002) reported 
protection against challenge when mice were immunized with 10 pg of corn derived LT-B. It 
is possible that 5 pg of corn derived LT-B is not sufficient to provide protection even though 
elevated anti-LT-B and anti-CT-B antibodies were observed in these mice. Our observation 
regarding unexpected responses in CTB-5 and CTB-10 groups might be due to small sample 
size. 
Mice of the CTB-5 and the LTB-5 group were protected against LT however not 
against CT. Protection against LT was stronger than that observed in CTB-5 group. This 
suggests that these two subunits work better for providing protection against LT when 
combined. However the same outcome was not observed with CT. 
Enteric diseases cause 1.7-2.5 million deaths each year (Girard et al, 2006). 
Prevention of enteric diseases is challenging because immunity should be induced at mucosal 
sites for effective protection (Dougan et al, 2002). Cholera and ETEC are two enteric 
diseases responsible for high mortality especially in young children in developing countries 
(Girard et al, 2006) and there is still need for effective vaccines for these diseases. Due to 
shared mechanism of toxin action, it is desirable and possible to develop combined vaccines 
which would be effective against both ETEC and cholera. Non-toxic subunits CT-B from 
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Vibrio cholerae and LT-B from ETEC are strong immunogens and mucosal adjuvants. 
Therefore their potential as vaccine antigens against cholera and ETEC have been 
extensively exploited (Lebens et al, 1996, Mason et al, 1998, Chikwamba et al, 2002, Tacket 
et al, 1998, Tacket et al, 2004). Current ETEC vaccines in development include CT-B in 
combination with ETEC colonization factors to provide anti-toxic immunity along with 
antibacterial immunity (Qadri et al, 2003, Savarino et al, 2002). Although CT-B and LT-B 
share 85% homology (at the amino acid sequence level) in their mature proteins, some 
neutralizing epitopes in LT-B are missing in CT-B (Lebens et al, 1996). Therefore, utilization 
of both sub-units in vaccine preparations against both diseases might induce a mixture of 
antibodies which could neutralize both toxins more effectively. 
In addition to being investigated as mucosal adjuvants (Dertzbough and Elson, de 
Haan et al, 1998, 1993, Bowman and Clements, 2001, Sadeghi et al, 2002, Boyaka et al, 
2003, Holmgren et al, 2003), the ability of CT-B and LT-B to bind to intestinal receptors and 
the carrier function for the A subunit inspired research to utilize them as carriers for 
unrelated antigens (Kim et al, 2004a, 2004b, 2004c, Kang et al, 2006). Therefore 
recombinant production of CT-B and LT-B will be important for vaccine and pharmaceutical 
production in general. Due to high costs involved in current recombinant protein production 
systems plants are considered to be less expensive and safer alternatives. The subunits could 
be co-expressed with unrelated antigens in edible parts of plants or as fusion proteins 
genetically linking them to unrelated antigens could be expressed in plants. 
Corn is a major staple feed and food. Recombinant proteins produced in corn have 
already reached the market. Therefore com is one of the best crops to be utilized as plant 
factories for recombinant protein production. Corn can be fed raw. Feed pellets made of 
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ground raw corn were easily consumed by mice in our feeding experiment. Corn seeds allow 
high levels of transgene expression which reduces the amount required to be administered 
through feeding. In our study 1.22 grams of CT-B com (about 5 com seeds) provided 10 pg 
of CT-B. 
Our results indicated that recombinant CT-B can be successfully expressed in com 
seeds at high levels. We identified in vivo immunogenicity of com derived CT-B with a mice 
feeding experiment. We also wanted to address whether com derived CT-B and com derived 
LT-B would induce higher levels on antibodies when given together. Our results were 
suggestive of this interaction on certain days of sample collection. The bacterial signal for 
CT-B seemed not being processed in com tissue according to Western analysis. This suggests 
that anti-CT-B antibodies induced by com derived CT-B may be different than that induced 
by bacterial CT-B. This may also explain lack of cross reactivity between antibodies induced 
by corn-derived CT-B and LT-B. A new mice feeding experiment including a group with 
non-transformed corn spiked with bacterial CT-B would help to address this concern. 
Repeating combined treatments with bacterial CT-B spiked into LT-B corn would also help 
to deduce more sound results for adjuvant/synergistic actions of CT-B and LT-B*. 
3.6 Acknowledgments 
We are thankful to John Clements of the Tulane University Medical Center for 
providing LT-B subunit and LT. We are also grateful to Bronwyn Frame and Lise Marcell 
* During mice feeding experiment we have collected fecal samples on each bleed days. On the day of necropsy 
we collected lung lavages. We are currently analyzing these samples to quantify anti-CT-B and anti-LT-B IgA 
antibodies. IgA is usually considered to play a major role in protection of mucosa against invading pathogens 
(Corbeil et al, 2003). Therefore IgA levels would give insight to interpret outcomes observed in response to 
toxin challenges. When IgA analysis is completed, this chapter will be revised as a manuscript and be submitted 
for publication. 
89 
for conducting corn transformations and to Jennifer McMurray and Chad Niederhuth for their 
assistance for sample collection and analysis of sera. 
3.7 References 
Arakawa T, Chong DKX, Merrit JL, Langridge WHR. Expression of cholera toxin B subunit 
oligomers in transgenic potato plants. Transgenic research 1997; 6: 403-413. 
Arakawa T, Chong DK, Langridge WH. Efficacy of a food plant-based oral cholera toxin B 
subunit vaccine. Nature Biotech. 1998; 16: 292-7 
Bâkstrom M, Holmgren J, Schôdel F, Lebens M. characterization of an internal permissive 
site in the cholera toxin B-subunit and insertion of epitopes from human 
immunodeficiency virus-1, hepatitis B virus and enterotoxigenic Eschericia coli. 
Gene 1995; 165: 163-171. 
Blake MS, Johnston KH, Russell-Jones GJ, Gotschlich EC. A rapid sensitive method for 
detection of alkaline phosphatase conjugated antibody on Western blots. Annals of 
Biochemistry 1984; 136: 175-179. 
Bradford MM: A rapid and sensitive method for the quantification of microgram quantities 
of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254 
(1976). 
Brousseau R, Scarpulla R, Sung W, Hsiung HM, Narang SA, Wu R. Synthesis of a human 
insulin gene. V. Enzymatic assembly, cloning and characterization of the human 
proinsulin DNA. 1982; 17: 279-289. 
90 
Chen Y, Kuchroo VK, Inobe J-I, Hafler DA, Weiner HL. Regulatory T cell clones induced 
by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994; 265: 
1237-1240. 
Chikwamba RK, Cunnick J, Hathaway D, McMurray J, Mason H, Wang K: A functional 
antigen in a practical crop: LT-B producing maize protects mice against Escherichia 
coli heat labile enterotoxin (LT) and Cholera toxin (CT). Transgenic Res. 2002; 11: 
479-493. 
Chikwamba RK, Scott MP, Mejia LB, Mason HS, Wang K. Localization of a bacterial 
p r o t e i n  i n  s t a r c h  g r a n u l e s  o f  t r a n s g e n i c  m a i z e  k e r n e l s .  P r o c  N a t l  A c a d  S c i  U S A .  
2003; 100:11127-32. 
Daniell H, Lee SB, Panchal T, Wiebe PO. Expression of the native cholera toxin B subunit 
gene and assembly as functional oligomers in transgenic tobacco chloroplasts. J. Mol 
Biol. 2001; 311: 1001-1009. 
de Haan L, Fel IK, Verwej WR, Holtrop M, Hoi WG, Agsteribbe E et al. Role of GMI 
binding in mucosal immunogenicity and adjuvant activity of the Eschericia coli heat 
labile enterotoxin and its B subunit. Immunology 1998; 94: 424-430. 
Dertzbough, MT and Elson, CO. Comparative effectiveness of the cholera toxin B subunit 
and alkaline phosphatase as carriers for oral vaccines. Infect. Immun. 1993; 61: 48-
55. 
Frame BR, Zhang H, Cocciolone SM, Sidorenko LV, Dietrich CR, Pegg SE, Zhen S, 
Schnable PS, Wang K: Production of transgenic maize from bombarded type II 
91 
callus: Effect of gold particle size and callus morphology on transformation 
efficiency. In Vitro Cell Dev Biol-Plant 2000; 36: 21-29. 
Friedman A, Weiner HL. Induction of anergy or active suppression following oral tolerance 
is determined by antigen dosage. Proc. Nat. Acad. Sci. USA 1994; 91: 6688-6692. 
Gallic DR, Tanguay RL, Leathers V: The tobacco etch viral 5' leader and poly(A) tail are 
functionally synergistic regulators of translation. Gene 1995; 165: 233-238. 
Girard MP, Steele D, Chaignat CL, Kieny MP. A review of vaccine research and 
development: human enteric infections. Vaccine. 2006; 24: 2732-50. 
Guidry, JJ, Cardenas, L, Cheng, E, Clements, JD. Role of receptor binding in toxicity, 
immunogenicity and adjuvanticity of Escherichia coli heat labile enterotoxin. 
Infection and Immunity 1997; 65: 4943-4950. 
Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nature Medicine. 2005; 11: 
S45-S53. 
Holmgren J, Harandi AM, Czerkinsky C. Mucosal adjuvants and anti-infection and anti-
immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG 
DNA. Expert Rev. Vaccines. 2003; 2: 205-217. 
Hood EE, Witcher DR, Maddock S, Meyer T, Baszczynski C, Bailey M, Flynn P, Register J, 
Marshall L, Bond D, Kulisek E, Kusnadi A, Evangelista R, Nikolov Z, Wooge C, 
Mehigh RJ, Heman R, Kappel WK, Ritland D, Li CP, Howard JA. Commercial 
production of avidin from transgenic maize: characterization of transformant, 
production, processing, extraction and purification. Molecular Breeding 1997; 3: 291-
306. 
92 
Janeway CA, Travers P, Walport M, Sholmchik M. Immunobiology, 5th edition. Garland 
Publishing, New York, 2001. 
Jani D, Meena LS, Rizwan-ul-Haq QM, Singh Y, Sharma AK, Tyagi AK. Expression of 
cholera toxin B subunit in transgenic tomato plants. Transgenic Res. 2002; 11: 447-
54. 
Jani D, Singh NK, Chattacharya S, Meena LS, Singh Y, Upadhyay SN, Sharma AK, Tyagi 
AK. Studies on the immunogenic potential of plant-expressed cholera toxin B 
subunit. Plant Cell Rep. 2004; 22: 471-477. 
Laemmli UK. Cleavage of structural proteins during the assembly of the head of 
bacteriophage T4. Nature 1970; 227: 680-685. 
Lebens M, Shahabi V, Backstrom M, Houze T, Lindblad N, Holmgren J. Synthesis of hybrid 
molecules between heat-labile enterotoxin and cholera toxin B subunits: potential for 
use in a broad-spectrum vaccine. Infect Immun. 1996; 64: 2144-50. 
Li D, O'Leary J, Huang Y, Huner NPA, Jevnikar AM, Ma S. Expression of cholera toxin B 
subunit and the B chain of human insulin as a fusion protein in transgenic tobacco 
plants. Plant Cell Rep. 2005; 2: 1-8. 
Luci C, Hervouet C, Rousseau D, Holmgren J, Czerkinsky C, Anjuère F. Dendritic cell-
mediated induction of mucosal cytotoxic responses following intravaginal 
immunization with the nontoxic B subunit of cholera toxin. The Journal of 
Immunology 2006; 176: 2749-2757. 
Kang TJ, Han SC, Yang MS, Jang YS. Expression of synthetic neutralizing epitope of 
porcine epidemic diarrhea virus fused with synthetic B subunit of Escherichia coli 
heat-labile enterotoxin in tobacco plants. Protein Expr Purif. 2006; 46: 16-22. 
93 
Kim(a) TG, Galloway DR, Langridge WH. Synthesis and assembly of anthrax lethal factor-
cholera toxin B-subunit fusion protein in transgenic potato. Mol. Biotechnol. 2004; 
28: 175-83. 
Kim(b) TG, Ruprecht R, Langridge WH. Synthesis and assembly of a cholera toxin B 
subunit S HIV 89.6p Tat fusion protein in transgenic potato. Protein Expr. Purif. 2004; 
35: 313-9. 
Kim(c) TG, Gruber A, Ruprecht RM, Langridge WH. Synthesis and assembly of SIV mac 
Gag p27 capsid protein cholera toxin B subunit fusion protein in transgenic potato. 
Mol. Biotehnol. 2004; 28: 33-40. 
Ma JK(a), Drake PMW, Christou P. The production of recombinant pharmaceutical proteins 
in plants. Nature. 2003: 4; 794-805. 
Ma JK(b), Barros E, Bock R, Christou P, Dale PJ, Dix PJ, Fischer R, Irwin J, Mahoney R, 
Pezzotti M, Schillberg S, Sparrow P, Stoger E, Twyman RM; European Union 
Framework 6 Pharma-Planta Consortium. Molecular farming for new drugs and 
vaccines. Current perspectives on the production of pharmaceuticals in transgenic 
plants. EMBO Rep. 2005; 6(7): 593-9. 
Marks, MD, Lindell, JS, Larkins, BA. Quantitative analysis of the accumulation of zein 
mRNA during endosperm development. Journal of Biological Chemistry 1985; 260: 
16445-16450. 
Mason HS, Haq TA, Clements JD, Arntzen CJ: Edible vaccine protects mice against 
Escherichia coli heat labile enterotoxin (LT): Potatoes expressing a synthetic LT-B 
gene. Vaccine 1998; 16: 1336-1343. 
94 
National Advisory committee on Immunization. Statement on new oral cholera and 
traveller's diarrhea vaccination. Canada Communicable Disease Report, 2005; 31:1-
10. 
Qadri F, Ahmed T, Ahmed F, Bradley Sack R, Sack DA, Svennerholm AM. Safety and 
immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera 
toxin B subunit vaccine in Bangladeshi children 18-36 months of age. Vaccine. 2003: 
2; 2394-403. 
Richardson, SH, Giles, JC, Kriger, KS. Sealed adult mice: a new model for enterotoxin 
evaluation. Infection and Immunity 1984; 43: 482-486. 
Rhee Y, Staswick PE: Nucleotide sequence for the soybean vegetative storage protein vspB 
gene. Plant Physiol 1992; 98: 794-5. 
Sadeghi H, Bregenholt S, Wegmann D, Peterson JS, Holmgren J, Lebens M. Genetic fusion 
of human insulin B-chain to the B subunit of cholera toxin enhances in vitro antigen 
presentation and induction of bystander suppression in vivo. Immunology 2002; 106: 
237-245. 
Sambrook J, Frittsch EF, Maniatis TH (eds): Molecular Cloning, A Laboratory Manual (2nd 
ed) Chapters 9-31 to 9-62, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 
NY (1989). 
Sangtong V, Mottl EC, Long M J, Lee M, Scott MP: Serial extraction of endosperm drillings 
(SEED)-A method for detecting transgenes and proteins in single viable maize 
kernels. {Protocols) Plant Mol Biol Rep 2001 ; 19: 151-158. 
95 
Savarino SJ, Hall ER, Bassily S, Wierzba TF, Youssef FG, Peruski LF Jr, Abu-Elyazeed R, 
Rao M, Francis WM, El Mohamady H, Safwat M, Naficy AB, Svennerholm AM, 
Jertborn M, Lee Y J, Clemens JD; Pride Study Group. Introductory evaluation of an 
oral, killed whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit 
vaccine in Egyptian infants. Pediatr Infect Dis J. 2002;21(4): 322-30. 
Svennerholm AM, Holmgren J, Black R, Levine M, Merson M. Serologic differentiation 
between antitoxin responses to infection with Vibrio cholerae and enterotoxin-
producing Escherichia coli. J Infect Dis. 1983; 147: 514-22. 
Tacket CO, Mason HS, Losonsky G, Clements JD, Levine MM, Amtzen CJ. 
Immunogenicity in humans of a recombinant bacterial antigen delivered in a 
transgenic potato. Nat Med. 1998; 4: 607-9. 
Tacket CO, Pasetti MF, Edelman R, Howard JA, Streatfield S. Immunogenicity of 
recombinant LT-B delivered orally to humans in transgenic corn. Vaccine. 2004; 22: 
4385-9. 
Tarkowski A, Sun JB, Holmdahl R, Holmgren J, Czerkinsky C. Treatment of experimental 
autoimmune arthritis by nasal administration of a type II collagen-cholera toxoid 
conjugate vaccine. Arthritis Rheum. 1999; 42: 1628-1634. 
Williams NA, Hirst TR, Nashar TO. Immune modulation by the cholera-like enterotoxins: 
from adjuvant to therapeutic. Immunol Today. 1999; 20(2): 95-101. 
Zhang RG, Scott DL, Westbrook ML, Nance S, Spangler BD, Shipley GG, Westbrook EM. 
The 2.4 A crystal structure of cholera toxin B subunit pentamer: choleragenoid. J Mol 
Biol. 1995; 25: 550-62. 
96 
Corn line used CTB-5 CTB-10 CTB-LTB-5 LTB-5 WT 
CT-B-corn (P248) 0.61 g 1.22 g 0.61g 0g 0g 
WT-corn (B73) 0.61 g Og 0.47 g 1.08 g 1.22 g 
LT-B-corn (P77) 0 0g 0.14 g 0.14 g 0g 
Total (weight of pellet) 1.22 g 1.22 g 1.22 g 1.22 g 1.22 g 
Table 1. Amounts of transgenic and non-transgenic (WT) corn used to make feeding pellets 
for mice feeding experiment. 
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Event ID %CTB of TASP in callus 
%CTB of TASP in 
leaves of R0 plants 
Fold 
increase 
P247-2 0.0005 0.0266±0.026 51.5 
P247-10 0.0107 0.202±0 18.8 
P247-11 0.0089 0.0109±0.0009 1.2 
P247-12 0.0019 0±0 0.0 
P247-13 0.0005 0.0018±0.00045 3.6 
P247-25 0.0003 0.0162±0.01 57.5 
P247-35 0.0006 0.0311±0.013 52.3 
P247-48 0.0033 0.0093±0.00045 2.8 
P247-50 0.0021 0.0344±0 16.6 
P247-53 0.0012 0±0 0.0 
P247-72 0.0009 0±0 0.0 
Table 2. Comparison of expression levels of CT-B in calli and young leaves of selected P247 
events. Calli expressing CT-B at varying levels were regenerated to obtain RO plants. CT-B 
expression levels in leaves of two to four RO plants for each event were analyzed by 
ganglioside dependent ELISA. Results are presented as mean+SE. TASP; total aqueous 
soluble protein. 
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R1 generation R2 generation 
Event ID 
%CTB of TASP jig CTB/g of corn %CTB of TASP jig CTB/g of corn 
P248-1 0.0007+0.0003 0.02+0.008 0.0002+0.00007 0.04+0.02 
P248-2 0.0002+0.00006 0.009+0.003 not followed not followed 
P248-4 0.0014+0.00012 0.05+0.00012 0.0197+0.01 1.56+0.44 
P248-5 0 0 not followed not followed 
P248-6 0 0 not followed not followed 
P248-7 0.0007+0.00012 0.045+0.01 not followed not followed 
Table 3. Summary of expression level analysis in R1 and R2 generations. Four out of six 
transgenic lines producing seeds expressed CT-B in their kernels at varying levels. 
Expression levels in R1 seeds were determined by quantifying CT-B expression in 
endosperms of 20 seeds from each ear analyzed. Different number of ears/event was 
analyzed. Results are presented as mean+SE. CT-B positive seeds from two high expresser 
lines (1 and 4) were grown to maturity and R2 seeds were obtained from these seeds. R2 
expression levels were measured in extracts obtained from whole ground kernel mixes. 
Averages of CT-B expression levels measured in 9 ears obtained from line 4 and in 11 ears 
obtained from line 1 are presented as mean+SE. TASP; total aqueous soluble protein. 
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A) Nco I Kpn I 
pUC57 0.4 kb 
B) 
Hind III Xhol Nco I 
pUC57 
Kpn I 
Construct Name T-corn ID 
pUC57-CTB 
EcoRI 
I  I I I  1  
r2x CaMV 35 promoter VSP 
pUC19 
pTH210 
0.69 kb 0.15 kb 0.4 kb 
-* 4 • < • 0.6 kb 
pUC19 
C) 
Hind III Xho I NcoI Kpn I EcoRI 
pUC19 
2x CaMV 35 promoter | VSP 
0.69 kb 0.15 kb 
4 • 4 • 
0.4 kb 
4 
0.6 kb 
-» -4 
pUC19 
D) 
Hind III Xho I Nco 1 
I kb Probe 
Kpn I EcoRI 
pUC19 
Y-zein promoter VSP 1 
i 
1.16 kb 0.15 kb 0.4 kb 0.6 kb 
pUC19 
4 • 4 • •* • •*-
pRC4 
E) 
Hind III XhoI NcoI Kpn I EcoRI 
FI F2 I 1 F3 I I 
y-zein promoter | VSP 
pUC19 
1.16 kb RI 0.15 kb 0.4 kb R2 0.6 kb R3 
• < • 4 • 4 » 
pUC19 
P51 
pCTB-BS P247 
P77 
pCTB-BSG P248 
Figure 1. Schematic representation of constructs, their IDs and PTF nominations. Primers 
used for PCR analysis of P248 events (E) and probe used in Southern analysis (C). 
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Figure 2. Southern blot analysis of selected P247 transgenic events (2, 10, 12, 11, 13, 25, 35, 
40, 42, 48, 50, 53 and 71). Approximately ten micrograms of total leaf genomic DNA 
obtained from young R0 plants was digested with Ncol, a restriction enzyme with a single 
cut within at 5' end of the sCT-B gene (Figure 1). DNA samples were resolved in a 0.8% 
agarose gel overnight at 23 V and blotted onto a Zeta-probe nitrocellulose membrane 
(BioRad). 32P-labeled 1 kb fragment containing CT-B gene and VSP fragment was used as 
probe. M indicates molecular weight marker (in kilobases). lx and 5x indicates 1 and 5 
copies of the plasmid pCTB-BS which was used as positive control. Lanes 4 through 16 were 
loaded with genomic DNA obtained from respective transgenic events. 
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M B73 lx 3x 1 1 2 3 4 6 7 
23.13 
4.36 
2.32 
2.03 r 
Figure 3. Southern blot analysis of selected P248 transgenic events (1, 2, 3, 4, 6 and 7). 
Approximately ten micrograms of total leaf genomic DNA obtained from young RO plants 
was digested with Ncol, a restriction enzyme with a single cut within at 5' end of the sCT-B 
gene (Figure 1). DNA samples were resolved in a 0.8% agarose gel overnight at 23 V and 
blotted onto a Zeta-probe nitrocellulose membrane (BioRad). 32P-labeled 1 kb fragment 
containing CT-B gene and VSP fragment was used as probe. M indicates molecular weight 
marker (in kilobases). Non-transgenic B73 corn DNA was used as negative control, lx and 
3x indicates 1 and 3 copies of the plasmid pCTB-BS which was used as positive control. 
Lanes 5 through 11 were loaded with genomic DNA obtained from respective transgenic 
events. 
102 
M B73 R2-Mix M-1-13 1-1-2 1-7-4 bCTB 4-8-4 4-8-5 4-8-8 
Figure 4. Western blot analysis of P248-1 and P248-4 R2 seeds. Protein extracts were 
separated in a 12% denaturing acrylamide gel and transferred to 0.45jj. nitrocellulose 
membrane (BioRad). Following blocking in 5% skim milk for one hour at room temperature, 
the membranes were incubated in rabbit anti-CT- antibody (Sigma) diluted 1/3,000 in 1% 
skim milk for 1 hour at room temperature. Next, membranes were incubated in alkaline 
phosphatase conjugated detection antibody goat anti-rabbit IgG (Sigma) diluted 1/5,000. The 
color development was generated by Alkaline phosphatase substrate kit (BioRad) following 
manufacturer's instructions. M indicates molecular weight marker (in kilodaltons). Protein 
extract of non-transgenic corn was used as negative control. Bacterial CT-B (Sigma) was 
used as positive control and indicated as bCTB. R2-M refers to mill made of R2 seeds which 
was used in feeding experiment. Black and red arrows indicate bacterial CT-B and corn 
derived CT-B, respectively. CT-B pentamers (A) and monomers (B) were detected in 
extracts of event P248-4 unlike that of P248-1. 
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A) 
Anti-CT-B antibodies 
B) 
Anti-LT-B antibodies 
1200 -p CTB-5 
I CTB-10 
3 LTB-5 
3 CTB5-LTB5 
• WT 
f 
13 20* 27 
Bleed Days 
& 600 
CTB-5 
CTB-10 
• LTB-5 
B CTB5-LTB5 
I 
20* 27 34 
Bleed Days 
Figure 5. Anti-CT-B (A) and anti-LT-B IgG antibodies (B) measured in sera of all feeding 
groups over 55 days. Eight mice in each feed group were fed four times with transgenic and 
non-transgenic (WT) corn on days 0, 7, 21 and 49. Mice in CTB-5 and CTB-10 groups 
received 5 and 10 jag of corn derived CT-B, respectively. Mice in LTB-5 group received 5 \xg 
of corn derived LT-B. Subjects in CTB5-LTB5 group received feeding pellets containing 5 
pg of corn derived CT-B and (xg of com derived LT-B. * indicates the day before feedings. 
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CT-30 
LT-30 
• Water 
n 0.10 
$ 
g 0.09 
a 0.08 -
0.07 -
CTB-5 CTB-10 LTB-5 CTB5-LTB5 
Treatment Groups 
WT 
Figure 6. Gut:carcass ratios of immunized mice following toxin challenge. On day 55 three 
mice from each feed group were gavaged with 30 |ag of CT or LT. Two mice from each 
group were gavaged with water and served as negative control. Gutxarcass ratios were 
obtained 3.5 hours post-necropsy. 
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Chapter 4: Attempts for the production of corn derived oral vaccine 
against Alzheimer's disease 
Sule Karaman, Joan Cunnick, Kan Wang 
4.1 Abstract 
Carrier activity of non-toxic B subunits of E. coli heat labile toxin (LT-B) and cholera 
toxin (CT-B) for targeting unrelated antigens to mucosal immune system has been well 
established. In an effort to generate corn-derived orally administered vaccine against 
Alzheimer's disease we fused amyloid beta gene to 3' end of LT-B and we introduced two 
major epitopes of amyloid beta into internal permissive site of CT-B in three different 
constructs. The constructs were expressed in transgenic maize callus under the regulation of 
the CaMV 35S promoter. Analysis of calli transformed with LT-B-A^ indicated LT-B 
pentamer formation. We observed mRNA formation for the whole fusion gene however we 
failed to detect amyloid beta protein in com calli. Transformation with the latter two 
constructs harboring CT-B-epitope fusions did not yield any detectable pentameric CT-B 
expression. 
4.2 Introduction 
ADP-ribosylating enterotoxins LT from enterotoxigenic strains of E. coli and CT 
from Vibrio cholerae have been shown to be strong immunogens and mucosal adjuvants. 
Non-toxic subunits of these toxins LT-B and CT-B retain most of these functions 
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(Czerkinsky et al, 1999). The adjuvant effect of LT-B has been well established, however 
there have been conflicting reports regarding adjuvant effect of CT-B (Freytag and Clements, 
2005). Recently it was shown that CT-B chemically conjugated to ovalbumin (OVA), when 
administered through vagina (ivag), helps to induce OVA specific CD4+ T cells. In this 
study, neither OVA alone nor OVA co-administered with CT-B resulted in OVA specific 
CD4+ cells indicating antigen specific response (Luci et al, 2006). It has been also shown that 
CT-B induces oral tolerance to linked antigens (Li et al, 2005) suggesting usefulness of CT-B 
as a carrier to treat human autoimmune diseases. Promising results have been obtained with 
oral administration of B chain of insulin conjugated to CT-B. Oral tolerance to B chain of 
insulin was induced, using a lower dose of antigen and administration rate in NOD mice for 
suppression of diabetes (Sadeghi et al, 2002). Similar success was attained against type II 
collagen-induced arthritis (Tarkowski et al, 1999). 
A number of studies were carried out involving expression of LT-B and CT-B fusions 
with unrelated antigens in plants (Kim et al, 2004a, Kim et al 2004b, Kim et al, 2004c, Choi 
et al, 2005, Kang et al, 2006, Walmsley et al, 2003, Rigano et al, 2004) The present work 
aimed at utilizing LT-B and CT-B as carriers for a human protein 'amyloid beta' and its 
epitopes to generate an orally administered plant-derived vaccine against Alzheimer's disease 
(AD). Alzheimer's disease is a neurodegenerative disorder characterized by cognitive 
decline, memory loss, language deficits and personality changes. Physiological hallmarks of 
AD are senile plaques made of 40-43 amino acid long amyloid beta protein (Gelinas et al, 
2004) and neurofibrillary tangles (NFT) made of hyper-phosphorylated tau proteins (Walker 
et al, 2005). Amyloid beta protein produced at varying length (40-43 amino acids long) 
derives from proteolytic cleavage of a membrane spanning amyloid precursor protein (APP). 
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In healthy individuals, the most abundant form of amyloid beta is AP40 (Gelinas et al, 2004). 
A042 is more fibrillogenic (Selkoe 2001) and aggregates into a neurotoxic form rich in p 
sheet structure forming the senile plaques (McLaurin et al, 2000). Figure 1 indicates the 
sequence of AP42 and its epitopes. 
Given the critical role of amyloid beta deposition in AD pathology, modification of 
amyloid beta aggregation became the target of a number of therapy approaches. Both active 
immunization with amyloid beta and passive immunization with anti-amyloid beta antibodies 
have resulted in prevention of Ap deposition, clearance of deposits if immunization was done 
after the onset of the disease, and improvement of cognitive abilities in several transgenic 
mice models of AD (Schenk et al, 1999, Sigurdson et al, 2002, McLaurin et al, 2002, Lemere 
et al, 2002, Bard et al, 2000, Pfeifer et al, 2002, Janus et al, 2000, Kotilinek et al, 2002). 
However, active immunization with AP42 during Phase II clinical trials resulted in brain 
inflammation (encephalitis) in 6% of patients which required termination of the study 
(Weksler 2004). Inflammation has been indicated to be part of the disease process by varied 
groups (Eikenbloom & Veerhius 1996, Maccioni et al, 2001). The relationship with 
immunization and enhanced local inflammation in affected patients in the trial still remains 
to be explained. Most parenteral vaccines induce both T-helper 1 lymphocytes (Thl) and T-
helper 2 lymhocytes (Th2) (Friedman and Weiner, 1994). Thl lymphocytes activate 
macrophages and macroglial cells which trigger inflammation, while Th2 lymphocytes 
activate B-cell antibody responses which down regulates the Thl response (Janeway et al, 
2001). Mucosally administered antigens induce anti-inflammatory IL-4/IL-10 (Th2 response) 
and tumor growth factor (TGF-P) (Th3 response) (Chen et al, 1994). This suggests that 
mucosal administration of antigens can prevent inflammation. 
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In this study, we aimed at producing a corn-derived vaccine which would be orally 
administered, against Alzheimer's disease. We attempted to create fusion proteins with AP42 
to use LT-B and CT-B as carriers. To use LT-B as a carrier, we fused the coding sequence of 
AP42 to 3' end of the gene encoding for the LT-B subunit. To use CT-B as a carrier, we 
inserted two epitopes of AP42 (in two different constructs) to a surface exposed region of CT-
B subunit (Bakstrôm et al, 1995). Although we detected LT-B pentamers in transformed corn 
calli, we failed to detect AP42. Analysis of transgenic corn calli transformed with CT-B- AP42 
fusions did not result in production of either CT-B pentamers or expression of epitopes. 
4.3 Materials and Methods 
Plasmid Construction: LT-B-Afi42fusion 
A gene fragment encoding for AP42 (optimized for com codon preference) was 
generated by annealing four synthetic oligomers synthesized in DNA Synthesis and 
Sequencing Facility at Iowa State University. The following oligomers were used: 1; 5'-ccg-
ggt-cca-gac-gcc-gag-ttc-cgc-cac-gac-agc-ggc-tac-gag-gtg-cac-cac-cag-aag-ctg-gtg-ttc-ttc-
gcc-ga-3', 2; 5'-g-gac-gtg-ggt-tcc-aac-aag-ggc-gcc-atc-atc-ggc-ctg-atg-gtg-ggc-ggc-gtg-gtg-
atc-gcc-taa-gtc-ttc-ggt-ac-3 ', 3; 5 ' -ggt-gca-cct-cgt-agc-cgc-tgt-cgt-ggc-gga-act-cgg-cgt-ctg-
gac-3 ', 4; 5'-cga-aga-ctt-agg-cga-tca-cca-cgc-cgc-cca-cca-tca-ggc-cga-tga-tgg-cgc-cct-tgt-
tgg-aac-cca-cgt-cct-cgg-cga-aga-aca-cca-gct-tct-ggt-3 '. Annealing and ligation was carried 
out as described by Brousseau et al, (1982). Figure 2 indicates the positions and orientations 
of each oligomer used to form double stranded DNA coding for AP42 with modified ends. 
Briefly, 500 pmols of each of four oligos were mixed in a test tube and the total volume was 
brought up to 50 |ol with sterile distilled water. The tubes were then wrapped with teflon 
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sealing tape and immersed in a boiling water bath for five minutes. The mixture of oligos 
was then cooled down to room temperature overnight. Annealed fragments were ligated by 
using 0.5 units of T4 DNA ligase (15224, Invitrogen CA, USA). The final gene fragment 
contained a partial Xmal site in 5' end and Kpnl site at the 3' end ready for ligation. Xmal 
site was generated in a way that half of the hinge (GPGP) was introduced in 5' end of A|342 
gene fragment. Amyloid beta coding sequence was first cloned into pBlueKSP(+) at Xmal 
site. The DNA of pBlueKSP(+) (8.5 |_il) was cut with Xmal and Kpnl yielding sticky ends. 
Since the gene was designed in such a way that it posses the ends in cut form, it did not 
require digestion. The gene was cloned into pBlueKSP(+) following Xmal and Kpnl 
digestion of the vector. The newly constructed plasmid was called as pSK2. In order to fuse 
the gene that encodes for amyloid beta protein and half of the hinge to C-terminal end of LT-
B, the ends of the LTB gene had to be modified in a way to carry other half of the hinge and 
an Xmal restriction site at 3' end and a NotI restriction site in its 5'end. This modified LT-B 
was produced by PGR amplification on pTH210 (Figure 3a) by using the following primers: 
1; LTBNotIF2: 5 '-attacgagcggccgcccatggt-3', 2; SK-LTBR-1: 5'-ctactacccgggccgttctccatg-
3'. Modified LTB, following NotI and Xmal digestion, was inserted into pSK2 at the N 
terminal of modified A|342. This construct containing the fusion gene from start to stop 
codon was named as pSK3. The fusion gene was cut from pSK3 (Figure 3b) with Ncol and 
Kpnl and cloned under enhanced 35SCauMV promoter by replacing LT-B in pTH210. The 
final construct to be used for maize transformation was named as pSK4 (Figure 3c). 
Plasmid Construction: Insertion ofAft42 epitopes into an internal permissive site of CT-B 
pCTB-BS (see Chapter 3) which has synthetic CT-B gene (optimized for corn expression 
system) under enhanced CaMV 35S promoter was altered via site directed mutagenesis by GenScript 
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Corp. gene synthesis company (New Jersey, USA) to introduce the N-terminal or middle epitopes of 
Ap42 into an internal permissive site of CT-B. The constructs carrying N-terminal epitope and 
middle epitope of AP42 were named as pCTB-ABl and pCTB-AB2, respectively (Figure 3d). 
Amino acid sequences of synthetic CTB and modified CTB genes are given in Figure 4. 
Maize transformation 
For expressing LT-B-AP42 embryogénie maize Hill callus and for expression of CT-
B-A(3 epitopes embryogénie maize Hill calli was transformed using microprojectile 
bombardment as described by Frame et al. (2000). The plasmids pSK4, pCTB-ABl and 
pCTB-AB2 were each co-bombarded with the selectable marker gene construct, P2. P2 
plasmid confers resistance to the herbicide bialaphos by expression of bar gene (Frame et al., 
2000). Transgenic calli transformed with pSK4, pCTB-ABl and pCTB-AB2 were designated 
as PC214, PHC268 and PHC269, respectively. PC214 clones were analyzed using the 
polymerase chain reaction (PGR) for presence of the LT-B-AP42 fusion gene, reverse 
transcriptase polymerase chain reaction (RT-PCR) for presence of messenger RNA, enzyme 
linked immunoabsorbtion assay (ELISA) for detection of LT-B pentamers and AP42 and 
Western blot. PHC268 and PHC269 calli were tested with ELISA. 
PCR analysis 
One hundred ng of total genomic DNA obtained from transgenic callus (for DNA 
isolation from corn calli see Chapter 3 in this dissertation) PC214 were used to amplify 
transgenes in each construct. For amplification of LT-B-AP42 fusion gene, following primers 
were used: PSK4-F2: 5'-cga-acg-ata-gcc-cat-ggt-gaa-gg-3" and PSK4-R2: 5x-cgg-cca-gtg-
aat-tcg-ctt-caa-ag-3 '. These primers amplify 813 bp from 5' end of TEV leader to 3' end of 
VSP terminator spanning whole fusion gene (Figure 3c). The reaction mixture and conditions 
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were as follows: Total volume of 25 pi containing 100 ng of maize callus genomic DNA, 1 
(al of dNTP mix (containing 10 mM of each dNTP), 1 pi of each primer (2.5 pM stock), 1 jj.1 
of MgCla (50 mM), 2.5 pi of 10X Taq polymerase PCR buffer and 0.2 pi of Taq polymerase 
(Biolase USA Inc., City, NJ, USA). PCR was initiated at 95°C for 4 minutes. This was 
followed by 30 cycles of amplification steps of which are; denaturation at 95°C for 1 minute; 
annealing at 58°C for 40 seconds, and extension at 72°C for 1 minute. 
Detection of Expression of LT-B and CT-B pentamers with ELISA 
Expression of LT-B and CT-B pentamers in transformed corn calli were detected by 
ganglioside dependent ELISA previously described in Chapter 3. Protein extracts obtained 
from calli were diluted 10, 20 or 40X for different clones assayed. For monomeric CTB 
detection, the assay was modified such that the protein extracts were coated on to the plate 
instead of gangliosides capture. 
Detection of Expression of A [i42 and its epitopes with ELISA 
To detect expression of AP42 96 well microliter plates (Costar 3590, Fisher Scientific, 
PA, USA) were coated with mixed gangliosides (100pg/ml) (Type III from bovine, Sigma G-
2375, MO, USA) in coating buffer [15 mM Na^CO^, 35 mM NaHCOs, 3 mM NaNg, (pH: 
9.6)]. After blocking with 5% milk, calli extracts were loaded to the wells. Gangliosides bind 
to LTB pentamers in the extracts. To capture amyloid beta protein, a biotinylated monoclonal 
anti-amyloid beta antibody (Mouse monoclonal against human amyloid beta protein, Clone 
4G8, Signet Laboratories Inc.9220-02, MA, USA) was used at 1/1,000 dilution. For 
standards; 31.25, 16.1, 8.625, 4.3 and 2.15 ng/ml of amyloid beta protein (Beta-Amyloid (1-
42) human, American Peptide Co. Inc. CA, 62-0-80, USA) were sandwiched in duplicates in 
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between two mouse monoclonal anti-amyloid beta antibodies raised against different 
epitopes of AP42. Mouse monoclonal antibody which is raised against the N-terminal epitope 
of AP42 (Mouse monoclonal against human amyloid beta protein, Clone 6E10, Signet 
Laboratories Inc.9320-02, MA, USA) was used at 1/100 dilution to coat the plate and clone 
4G8 which is raised against middle epitope of AP42 was used as detection antibody at 1/1,000 
dilution. Antibodies were diluted in 1% milk in PBS. Calli extracts were diluted 1, 10, 20 and 
40X. In all ELISA analysis that is described above, the wells to be used for samples were 
coated with gangliosides based on the assumption that amyloid beta should be linked to LT-
B. In case the fusion protein was broken, calli extracts were also analyzed as standards were 
developed (with 6E10-4G8 sandwich) without ganglioside coating. After detection antibody, 
wells were loaded with streptavidin horse radish peroxidase diluted 1/1,000 (BD Biosciences, 
554066, MD, USA). The color development was obtained by addition of ABTS substrate (3-
ethylbenzthiazoline-6-sulfonic acid, Sigma A-1888, MO, USA) prepared according to 
manufacturer's instructions. Fifty pi of reaction volume was used except for blocking step. 
One hundred fifty pi of 5% milk diluted in PBS was used for blocking. Coating and blocking 
steps were done at room temperature for one hour. Sample, standard, and antibody 
incubations were done at 37°C for one hour. Plates were incubated for 30 minutes at room 
temperature for enzyme and substrate steps. Absorbance at 405 nm was read, a standard 
curve was generated and sample calculations were carried out. 
For detection of N-terminal and C-terminal epitopes of amyloid beta inserted into the 
permissive site of CTB, protein extracts from calli were directly coated on the plate wells. 
For detecting epitopes 6E10 and 4G8 were used at dilutions indicated above for pHC268 and 
pHC269 respectively. 
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RT-PCR Analysis 
RNA extraction from transgenic calli was carried out as follows. Approximately 100 
mg of callus tissue was transferred to a 1.5 ml RNase-free test tube and ground with a 
peroxide treated (pestles were placed in a 50 ml falcon tube and incubated in 30%H20z for 
10 min at room temperature and then washed with DEPC treated water several times) sterile 
Kimble pestle. One ml of Trizol (GIBCO BRL, Life Technologies, Inc.) reagent was added 
and samples were incubated for 5 minutes at room temperature. Next, 0.2 ml of chloroform 
was added and tubes were capped securely. Tubes were shaken vigorously by hand for 15 
seconds and then incubated at room temperature for 2 minutes. After centrifuging at 12,000 
rpm at 4°C for 15 minutes, supernatant was transferred into a fresh tube. Isopropanol (0.5 ml) 
was added to each tube and incubated at room temperature for 10 minutes. Tubes were 
centrifuged at 12,000 rpm at 4°C for 10 minutes to precipitate RNA. Supernatant was 
removed and RNA pellets were washed with 1 ml of 75% ethanol. Pellets were re-suspended 
in ethanol and centrifuged at 9,000 rpm for 5 minutes at 4°C. Ethanol was removed and 
pellets were air-dried. RNA pellets were dissolved in 30 pi of DEPC (diethylpyrocarbonate) 
treated, RNase free water. In order to eliminate false positive results in RT-PCR analysis due 
to DNA contamination, RNA samples from clones #7, 12, 16, 17 and 18 were treated with 
Deoxyribonuclease I (DNasel, 18068-015, Invitrogen, CA, USA). In a total of 10 pi, 1 p,g of 
RNA, 1 pi of lOx DNasel reaction buffer and 1 p,l of DNasel (lu/pl) were mixed well and 
samples were incubated at room temperature for 15 minutes. Dnasel was inactivated by 
addition of 25mM EDTA solution and heating at 65°C for 10 minutes. Samples were kept at 
-20°C until analyzed. 
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RT-PCR was carried out using the Qiagen OneStep RT-PCR kit (210210, Qiagen 
Sciences Inc. MD, UA). 3 sets of primers were used for this analysis. The first set of primers 
was designed using the 5X and 3" regions of promoter. This served as a DNA contamination 
control since this part of the cassette is not transcribed. The second set of primers was 
designed using the sequences that reside only in the LT-B gene. Since some of the clones 
were positive for LT-B ELISA analysis, this set served as internal control. The third set was 
designed using the sequences residing within the amyloid beta and LTB gene segments so 
that the PCR product would contain hinge region. The following primers were used for 
testing DNA contamination: 1; RT-PR-F1: 5x-gcc tgc-agg-tca-aca-tgg-tgg-3x and 2; RT-PR-
Rl: 5x-gga-tag-tgg-gat-tgt-gcg-tca-tcc-3x. Primers used as internal control were: 1) RT-LTB-
Fl: 5x-gcc-cat-ggt-gaa-ggt-gaa-gtg- c-3x and 2; RT-LTB-R1: 5x-tgg-cag-caa-tgg-agt-ttg-gag-
tc-3\ These primers amplify 362 nucleotides from the 3' end of the TEV leader to middle of 
the LTB gene. Primers used for amplifying a 128 base pair long fragment from the 3' end of 
the LTB gene to the 3' end of the AP42 coding sequence spanning the hinge region were: RT-
AB-F1: 5'-tcc-aga-cgc-cga-gtt-ccg-cc-3x and RT-AB-R1: 5x-cga-tca-cca-cgc-cgc-cca-3x. 
The RT-PCR reaction mixture contained the following in total volume of 50 pi: 100 
ng of total RNA (in 1 pi), 10 pi of 5x Qiagen OneStep RT-PCR buffer, 1.5 pi of dNTP mix 
(10 mM of each dNTP), 12 pi of each primer (2.5 pM), 1.5 pi of Qiagen OneStep RT-PCR 
enzyme mix and 12 pi of RNase free water. The reaction was initiated with reverse 
transcription at 50°C for 30 minutes which generated a cDNA copy of the relevant RNA 
fragments. This was followed by initial denaturation at 95°C for 15 minutes. Next, 30 cycles 
of amplification (denaturation at 94°C for 45 seconds; annealing at 60°C for 45 seconds, and 
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extension at 72°C for 1 minute) followed. After 30 cycles were completed, fragments were 
allowed to be fully extended at 72°C for 10 minute. 
Western Blot 
Approximately 200 mg of calli transformed with pSK4 were sampled into 1.5 ml 
eppendorf tubes for the events 9, 10, 11, 12, 14, 16 and 18. Calli were ground with 
autoclaved pestles (Kontes Pellet Pestle, K749520-0000, Fisher Scientific, PA, USA) until 
juice exudes. A 25-35 |ul aliquot of extract was analyzed by SDS-PAGE (Laemmli, 1970). 
Two sets of proteins were prepared for each sample analyzed; samples in one of the sets were 
boiled for 5 minutes at 95°C. Proteins were run at 100V for 1 hour and transferred to a 0.45 
fjrn nitrocellulose membrane using the BioRad Transblot apparatus following manufacturer's 
instructions. Rabbit anti-CT IgG (Sigma, C-3062, MO, USA) diluted 1.5/20,000 in 1% milk 
was used as the primary antibody and goat anti-rabbit AP-conjugate anti-IgG diluted 1/5000 
in 1% milk (KPL, 475-1506, MD< USA) was used as secondary antibody. Proteins were 
evaluated with the expectation of shift to higher molecular weight because of the presence of 
amyloid beta. Non-transformed callus was used as negative control while p77 seed extract 
was used as positive control. 
4.4 Results and Discussion 
Construction of LT-B fusion genes 
In this study we attempted to generate a corn-derived vaccine against Alzheimer's 
disease by fusing amyloid beta protein (42 amino acid long version) to the C-terminal end of 
LT-B subunit. To give flexibility to the fusion protein we utilized a hinge made of four 
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amino acids (Glycine-Proline-Glycine-Proline) in between LT-B and AP42. This hinge was 
previously used in tobacco and potato for fusion protein expression (Smerdou et al, 1996, 
Arakawa et al, 1998, Yu and Langridge, 2001). 
Analysis of transgenic calli transformed with LT-B-Aj542 
The plasmid carrying the synthetic LT-B-AP42 fusion gene and a plasmid carrying 
herbicide resistance gene were introduced to maize hybrid Hi II through biolistic 
transformation (Frame et al, 2000). Eighteen herbicide resistant calli clones were obtained. 
Fifteen of those clones were shown to carry LT-B-AP42 fusion gene via PCR analysis. All 
PCR+ clones expressed pentameric LT-B at varying levels as indicated in Figure 5. 
However, we failed to detect amyloid beta with ELISA. Our ELISA system for detection of 
amyloid beta included human amyloid beta (1-42) as standard. 
In order to detect mRNA of the fusion gene, RT-PCR analysis was performed. For 
this analysis, clones numbered 7, 12, 16, 17 and 18 which were among the highest expressers 
of pentameric LT-B were selected. For amplification of the RNA product of the LT-B gene 
and amplification of the amyloid beta coding sequence which also spans the hinge region two 
sets of primers were used. The former primer set amplifies a 362 bp region from 3' end of 
TEV leader to middle of LT-B. The later primer set amplifies a 128 bp region from 3'end of 
LT-B gene to 3' end of amyloid beta gene. A third set of primers which amplifies a region in 
the promoter was used as DNA contamination control. (Figure 7B) 
Figure 7A shows fragments obtained by amplification of RNA fragments, obtained 
from selected LT-B positive calli, with primers that detect hinge and amyloid beta and LT-B 
gene. Figure 7B indicates amplification products of DNA contamination control from the 
same LT-B positive clones. RNA obtained from clone 16 was amplified with the primer set 
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that amplifies LT-B gene as an integral control for validity of the PCR run. Our results 
showed expected fragments with the right size for both LT-B (lane 9 and 10 in figure 7A) 
and for hinge and amyloid beta region (lanes 3, 4, 5, 6, 7 in figure 7A). Contrary to our 
expectations due to negative ELISA result, RT-PCR analysis indicated presence of full 
length RNA for the whole fusion gene. 
Next, to verify pentameric assembly which was shown with ganglioside binding 
ELISA and to analyze presence of amyloid fusion, western blot was performed. Pentameric 
LT-B is 55 kDa made of 11.6 kDa monomers. LT-B can only bind to GM1 gangliosides on 
the intestinal surfaces when it is pentameric. Immunogenicity of the molecule also depends 
on pentameric native conformation (de Haan et al, 1998). Extracts of LT-B positive calli 
lines 7, 9, 10, 11, 16, 18 were used for this analysis. We observed a major band between 35.8 
and 56.2 kDa standards (figure 6). A second nonspecific band was observed slightly above 
56.2 kDa standard in all samples. As also seen in the lane loaded with Hi II non-transgenic 
negative control, this band was coming from the negative control background. Presence of 
amyloid beta on each monomer of pentameric LT-B would have caused approximately 20 
kDa up-shift in immunoblot assay. In consensus with ELISA results, LTB pentamers were 
detectable without amyloid beta. 
Although mRNA was detectable for the whole fusion gene, we failed to detect 
amyloid beta protein via ELISA and western blot. Possible reasons for this outcome could be 
as follows: 1) mRNA would be unstable. 2) An unknown proteolytic cleavage site might 
have been introduced at the site where hinge links LT-B and amyloid beta. The sequence of 
the fusion gene was screened for known trouble causing sequences with GCG program 
(Appendix II). However, it is unlikely that all proteolytic cleavage sites or mRNA 
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destabilizing sequences in corn have been identified. Once cleaved, the small protein would 
possibly get degraded in the cell. 
Construction of CT-B fusion genes 
To utilize CT-B as carrier we applied a different approach. An internal site in the 
cholera toxin B subunit previously has been shown to allow expression of short epitopes 
(Bâkstrôm et al., 1995) without affecting pentamer formation of CT-B. In that study epitopes 
from human immunodeficiency virus-1, hepatitis B virus and enterotoxigenic E. coli with 
varying amino acid length (10-19 aa) were tested. These epitopes were introduced within a 
surface exposed region of CT-B by performing deletions at that site. Different combinations 
of deletions/insertions tested. The conclusion from this study was that Pro53, Gly54, S55 and 
Ala64 are critical for stable expression of epitopes and the CT-B pentamer. . Authors called 
the site from S55 to Ala64 as 'internal permissive site'. Moreover, 10 aa epitopes were found 
to be more successful in terms of expression of the epitope. 
It has been shown that among three epitopes of A042, monoclonal antibodies raised 
against the first one residing in N-terminal had a high solubilization effect (80 to 98%) on 
preformed fibrillar p-amyloid. It was also shown that anti-aggregating ability of middle 
epitope was considerably smaller while monoclonal antibodies raised against the C-terminal 
epitope did not have detectable solubilization effect on the aggregates (Solomon et al., 1997, 
Frenkel et al., 2004). Therefore, we inserted N-terminal epitope and middle epitope to 
internal permissive site of CT-B. We created two versions of CT-B A(3 epitope fusion 
versions. We chose the first 10 amino acids from N-terminal and amino acids from 16-25 to 
be inserted into the permissive site. Plasmids harboring these genes under 35S cauliflower 
mosaic virus constitutive promoter were transformed to immature zygotic corn embryos. 
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Analysis of transgenic calli transformed with CT-B-Ab42 fusions 
Plasmids pCTB-ABl and pCTB-AB2 containing N-terminal and middle epitope of 
amyloid beta in the internal permissive site of synthetic CT-B gene were introduced to maize 
calli (Hi II) in a similar fashion as described in previous section. Total of 101 and 54 calli 
clones were obtained for PHC268 and PHC269, respectively. Pentameric and monomeric 
CT-B expression was analyzed by ELIS A. None of the clones expressed either pentameric or 
monomeric CT-B. Epitope insertions at the permissive site disrupted native conformation of 
the CT-B. ELISA results with antibodies raised against the relevant amyloid beta epitopes 
did not yield significantly positive results, either. 
In the original study, Bâkstrôm et al, (1995) reported 13 CT-B hybrid proteins created 
with the envelope glycoprotein gpl20 from human immunodeficiency virus type 1 (HIV-1), 
11 amino acid epitope from hepatitis B virus (HBV) and short peptides related to the heat-
stable toxin (STa) of enterotoxigenic E. coli. The size of the oligos inserted ranged from 10 
amino acids to 19 amino acids while deletions occurred at varying lengths between 53rd aa 
and 64th aa of CTB. It was postulated that both size of the insertion and amino acid 
composition play role in ensuring proper folding of recombinant CTB proteins. Ten amino 
acid lengths was found to be a working length while presence of cysteine residues was found 
to have stabilizing effect on the recombinant protein. It was also concluded that Proline at 
53rd position and Alanine at 64th are essential for correct folding of CTB. It was also shown 
that Glycine at 54th position along with Alanine at 64th position is required for stable 
expression of the hybrids suggested by the varying expression levels of the constructs 
studied. Moreover, Serine at 55th position along with Alanine at 64th position was found to be 
allowing expression independent of the amino acid composition. Taking these into account 
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we deleted eight amino acids in between Ser55 and Ala64 and replaced them with 10 amino 
acid lengths for each epitope. Since there was not a Cys residue in the epitopes or in their 
neighboring amino acids and since there is no technical tool which would predict precisely 
three dimensional structures of amino acid deletions or insertions into a larger protein we did 
not add cysteine but kept the original sequences. 
4.5 Concluding remarks 
We attempted to produce a corn-derived vaccine against Alzheimer's disease using 
two different protein fusion strategies, 1) fusion of A^ to C-terminal of LT-B and 2) 
insertion of amyloid beta epitopes to an internal permissive site of CT-B. Analysis of calli 
transformed with LT-B-AP42 indicated correct folding of LT-B pentamers however we failed 
to detect amyloid beta proteins. Our second approach did not yield any detectable CT-B 
pentamers or detectable amyloid beta epitopes. Bâkstrôm et al (1995) also reported failure 
with three of the constructs out of thirteen analyzed. With these constructs, they failed to 
detect pentameric CT-B or the epitopes of interest. 
With the current technology and tools of protein biochemistry it is impossible to 
predict the fate of fusion proteins or modified proteins with replaced amino acids. Varying 
lengths of proteins have been fused to LT-B and CT-B with or without a hinge and expressed 
in both bacteria and plant systems (Lipscombe et al, 1991, Arakawa et al, 1998, Smerdou et 
al, 1996, Luci et al, 2006, Li et al, 2005, Walmsley et al, 2003, Rigano et al, 2004). However, 
success of the fusion protein approach has to be evaluated on a case-by-case basis (Rigano et 
al, 2003). The only way of getting positive results from such projects will be testing a 
number of versions (different amino acid composition and number) of the epitopes and also 
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border regions. Therefore new versions of these fusions and epitopes should be tested. 
Assaying such constructs in a transient expression system is desirable. This will allow testing 
of a number of constructs in a shorter time. 
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Amyloid beta precursor protein (APP) 
Transmembrane region 
N terminal C terminal 
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGWIAT 
Figure 1. Schematic representation of amyloid beta precursor protein, sequence of amyloid 
beta (1-42) and epitopes residing on amyloid beta. Bold sequences indicate epitopes. 
Underlined sequences show fragments inserted into internal permissive sites of CT-B. 
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mLT-B-3' Xmal Oligomer 1 (74 bp) Oligomer 2 (75 bp) Kpnl 5'-pSK4. 
aac-ggç 
ca-tgg g-ggc-cc 
.gcc-ga g-gac. 
V 
Oligomer 3 (45 bp) Oligomer 4 (96 bp) 
Figure 2. Four synthetic oligomers were used to create synthetic AP42 which was optimized 
for corn expression system. 5' and 3' ends of annealed fragments contained portions of Xmal 
and Kpnl restriction sites, respectively. In the final construct (pSK4) an annealed fragment 
was linked to 3' end of modified LT-B which has the other portion of Xmal restriction site. 
Underlined sequences indicate restriction enzyme sites. At the 3'end, annealed fragments 
were inserted to psK4 at Kpnl site. 
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Figure 3. Schematic representation of constructs, their IDs and PTF nominations. 
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A) 
1  M V K L K F G V F F T V L L S S A Y A H G T P Q N I T D L C A E Y H N T Q I H T L N D K I F S Y T E  
5 0  S L A G K R E M A I I T F K N G A T F Q V E V P G S Q H I D S Q K K A I E R M K D T L R I A Y L T E  
100 AKVEKLCVWNNKTPHAIAAISMAN 
B) 
1  M V K L K F G V F F T V L L S S A Y A H G T P Q N I T D L C A E Y H N T Q I H T L N D K I F S Y T E  
5 0  S L A G K R E M A I I T F K N G A T F Q V E V P G S  D A E F R H D S G Y  A I E R M K D T L R I A Y L  
100 TEAKVEKLCVWNNKTPHAIAAISMAN 
C) 
1  M V K L K F G V F F T V L L S S A Y A H G T P Q N I T D L C A E Y H N T Q I H T L N D K I F S Y T E  
5 0  S L A G K R E M A I I T F K N G A T F Q V E V P G S  K L V F F A E D V G  A I E R M K D T L R I A Y L  
1 0 0  T E A K V E K L C V W N N K T P H A I A A I S M A N  
Figure 4. Amino acid sequences of A) CT-B, B) modified CT-B with its internal permissive 
site replaced by N-terminal epitope of amyloid beta and C) modified CT-B with its internal 
permissive site replaced by middle epitope of amyloid beta. Sequences in red indicate 
bacterial signal peptide. Sequences in blue indicate internal permissive site in A) and 
epitopes from amyloid beta with neighboring amino acids. 
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Figure 5. Amount of pentameric LT-B (jug/g) expressed in pC214 calli. 
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Figure 6. Western analysis of selected transgenic calli; pC214 -9, 10, 11, 12, 14, 16, 18. 30 
(ig of total protein from calli extracts were separated on 12% SDS PAGE. Rabbit anti-CT 
IgG and goat anti-rabbit IgG (alkaline phosphatase conjugate) were used as primary and 
secondary antibodies. The same amount of Hill calli extract and p77 ground whole kernel 
extract were used as negative and positive controls, respectively. M indicates molecular 
weight marker. 
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M Hill 7 12 16 17 18 Water 7 16 
Figure 7. RT-PCR analysis of pC214 calli. ELISA+ selected calli (pC214-7, 12, 16, 17, 18) 
were analyzed for expression of mRNA for the fusion gene. Panel A indicates amplification 
of hinge+amyloid beta fragment (pC214-7, 12, 16, 17, 18) and that of LT-B gene (pC214-7 
and 16). Panel B indicates amplification results of promoter region from indicated calli. RNA 
obtained from pC214-16 was amplified with primer sets spanning LTB gene as an internal 
control for this run. 
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Chapter 5: Assessment of allergenic potential of corn derived LT-B and C-
TB in comparison to Cry lAb and cp4 epsps based on their primary 
sequences 
Sule Karaman, Kan Wang 
5.1 Abstract 
In spite of the great promise it holds for increasing nutritional quality, yield and 
production of value added crops, genetic modification of food crops has raised safety 
concerns. One of the human health concerns regarding biotech crops is the risk of 
allergenicity. Not all the characteristics that make a protein allergenic are known yet. 
Therefore, there is no straightforward strategy to evaluate the allergenic potential of a given 
protein. International Food Biotechnology Counsel and the International Life Sciences 
Allergy and Immunology Institute, Food and Agriculture Organization (FAO), World Health 
Organization (WHO) and Food and Drug Administration (FDA) all separately initiated 
studies to develop a system to assess the allergenic potential of biotech food crops by 
integrating currently available data regarding what constitutes an allergen. These efforts 
resulted in a decision tree approach. The initial step in decision tree approach is the 
homology analysis of amino acid sequence of the protein of interest in regard to that of 
known allergens. Currently, a number of public allergen databases are available. Among 
those, the Food Allergy Research and Resource Program (FARRP) and Structural Database 
of Allergenic Proteins (SDAP) provide F AO/WHO allergenicity testing. Using these two 
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databases we performed potential allergenicity test of B subunits of E. coli heat labile 
enterotoxin and Cholera toxin, LT-B and CT-B, which were used to generate transgenic corn 
for production of edible vaccines described in this dissertation. We also performed the same 
test on the sequences of insecticidal protein CrylAb and herbicide tolerant enzyme cp4 epsps 
which are expressed in Bt corn and Roundup ready soybean, respectively. From this analysis 
we determine future studies are needed to complete the investigation of potential 
allergenicity of recombinant proteins produced in corn. 
5.2 Introduction 
Allergies in general are a major public health concern. It is estimated that up to 40% 
of the population in industrialized countries are affected by allergies towards various 
environmental or food sources (Hoffmann-Sommergruber and the SAFE consortium, 2005). 
Specifically, food allergies have been on rise in developed countries within the last 20 years 
(Sampson, 2005). 
Allergy is defined as hypersensitivity of the immune system to a natural substance 
(certain kinds of food, pollen, animal dander and dust) that does not cause symptoms in non-
allergic people. People who show symptoms of allergy to any given allergen develop 
immune response against only a few proteins in the given allergenic substance. Allergic 
symptoms are mainly mediated through production of IgE antibodies, although other forms 
of immune reaction that lead to allergic response exist. Following initial exposure 
(sensitization) to a particular allergen, specific IgE molecules are fixed on basophil and mast 
cells. Re-exposure to the same allergen activates basophils and mast cells by cross-linking 
specific IgEs. Activation of these cells results in a set of reactions including histamine 
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release, production of arachidonic metabolites and immunomodulatory molecules. These 
molecules interact with target tissues bringing about symptoms of allergies. In the case of 
food allergies, classical symptoms include itchy mouth, fullness in the throat, shortness in 
breath, red, itchy rash on skin, difficulty in breathing and vomiting. Some severe allergic 
reactions might even result in death. 
Although no evidence regarding increased allergenicity of genetically modified food 
crops have been shown, the use of biotechnology in food crops raised health concerns. First, 
the gene introduced into the crop might be encoding a known allergen or a protein that cross 
reacts with an allergen. Second, existence of a novel protein in the crop might change the 
behavior of other proteins in the cell rendering them allergenic or enhancing endogenous 
allergenicity. Third, novel proteins that we are exposed rarely or none in our daily lives, 
when introduced to our environment through transgenic crops might cause allergenicity. And 
fourth, post-translational modifications, such as N-glycosylation, might raise allergenicity 
concern by altering solubility, stability, size and susceptibility of recombinant proteins to 
proteases (Lesher and Bannon, 2005, Aalberse, 2000). N-glycosylation occurs on asparagine 
residues separated by one amino acid from serine or threonine. For example, in a sequence of 
Asparagine-X-Serine/Threonine), Asparagine usually is N-glycosylated. However, if the 
amino acid in between is proline or aspartic acid, asparagine residue does not get 
glycosylated (Lerouge et al, 1998). Glycosylation at this site in plants is critical because a(l-
3)-fucosyl and P(l,2)-xylose that are glycosyl groups unique to plants might be included in 
the final structure creating potential for allergenicity (Goodman et al, 2005). As a matter of 
fact, bean a-amylase inhibitor, when expressed in peas was reported to be structurally altered 
and immunogenic (Prescott et al, 2005), while it was not immunogenic in bean. 
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Elimination of transferring potentially allergenic proteins to food crops is highly 
desirable. However due to lack of complete information regarding the structural and 
functional parameters that make a protein allergen, currently there is no straightforward 
strategy to achieve this goal (Metcalfe, 2003). In spite of the accumulating knowledge 
regarding allergens and allergenic immune mechanisms, the concepts underlying allergy and 
allergens are still not very clear. For example, it is well established that allergens must cross­
link IgEs. Interestingly, IgE binding to food allergens are observed in persons who are 
tolerant to the given food allergen (Poulsen, 2004). Therefore a decision tree approach which 
integrates testing for all known parameters of allergenicity sequentially is applied to evaluate 
potential risks of recombinant proteins. 
The first step of the decision tree approach adopted by F AO/WHO (Metcalfe, 2003) 
is to perform homology search between amino acid sequence of the protein to be transferred 
with protein sequences of known allergens. There are a number of publicly available allergen 
databases (described below). Following that in vitro IgE binding assays are performed. Since 
most allergens are known to be resistant to proteolytic digestion, the next step of the analysis 
involves pepsin digestion resistance. The analysis would be completed with information 
obtained through animal model testing where applicable (Metcalfe, 2003). 
In order to assess potential allergenicity of proteins LT-B and CT-B, that are used in 
the projects described in this dissertation, at the sequence level, FASTA search have been 
performed by using SDAP and FARRP allergen databases. As control comparison, we also 
choose two known transgenic proteins CrylAb (NCBI Accession #: PA0370) expressed in 
Bt corn and cp4 epsps (NCBI accession #: Q9R4E4) expressed in Roundup Ready soybean. 
These two transgenic crops have been studies extensively and deregulated in the United 
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States. A synopsis of currently available public allergen databases which explains the reason 
for choosing these two databases for our search is given below. 
Allergen Databases: 
Rapid increase in number of characterized protein allergens made advanced 
bioinformatics search tools a necessity. A number of public databases have been generated in 
US and Europe. These databases typically provide the name, nomenclature and source of the 
allergen, structural and clinical features and links to references. Two of these databases 
provide sequence homology search to predict cross-reactivity and potential allergenicity of a 
given protein. The features of these databases are briefly given below and Table 1 indicates 
institutes created and maintaining the databases and their URL addresses. 
Allergome.org: The list of allergens found in this website is based on selected papers 
since 1960s. The list is continuously updated. Information provided through this search tool 
includes source of the allergen, tissue in which the protein is found and the route of exposure 
(physical contact, inhalation, ingestion, etc). Protein sequence, isoforms, allergenicity of the 
allergen in its natural conformation and plasmid information in cases where the creation of 
the allergen occurs through gene recombination are also included (Mari et al, 2004). The 
allergens included in this database are determined following criteria which are recognized by 
WHO. Even though it includes all the characterized allergenic molecules, this database 
however does not provide blast search to determine potential allergenicity of a given protein. 
IUIS (International Union of Immunological Societies): The site has been created and 
maintained by the Allergen Nomenclature sub-committee of IUIS. Two major criteria of the 
site to include proteins as allergens is more than 5% IgE reactivity and occurrence of IgE in 
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at least five patients. It merely lists allergens from different organisms and gives references 
and accession numbers regarding the sequences. 
Swiss-PROT index of allergen sequences: This site also contains allergen sequences 
designated by IUIS. Currently the list of allergens on this site contains 1263 sequences from 
different organisms. 
IFBC-ILSI: This database was formed by the International Food Biotechnology 
Council (IFBC) and ILSI Allergy and Immunology Institute during joint study that resulted 
in development of 'decision tree ' approach for assessment of potential allergenicity of GM 
crops (Metcalfe et al, 1996). This list has not been updated since publication. 
CSL Allergen Database: This database was released by the Food Safety and Quality 
Directorate of The Central Science Laboratory at Sand Hutton York, United Kingdom. The 
list provides links to sequence and reference information as well as PDF structural data. 
PROTALL: The Institute of Food Research of the United Kingdom compiled this 
database to study issues regarding food allergy. The database contains physical features of 
allergens such as molecular weight, epitopes, stability and cross-reactivity. This is a 
searchable database where the query term would either be free text or a specific plant. 
ALLALLERGY: This database contains chemical allergens in addition to proteins. It 
includes more than 4500 entries. The database is currently updated and can be searched using 
the name or allergen category (grains, fish, pollen etc.). 
BIFS Tables: The Biotechnology Information for Food Safety web site lists food 
allergens, non-food allergens and wheat-gluten proteins. It provides links to sequence 
information, species name, allergen nomenclature and references. The goal of the project was 
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facilitating sequence comparisons for potential allergenicity of proteins produced in GM food 
crops (Gendel, 1998), however it does not provide this function. 
Asthma and allergy gene database: This database contains sequence information 
about linkage and mutation studies regarding asthma and allergy related traits. It was 
generated by the National Research Center for Environment and Health, Munich, Germany. 
SDAP-Structural Database of Allergenic Proteins: SDAP web server was established 
and is maintained by The University of Texas Medical Branch. This server contains 737 
allergens and isoallergens, 829 protein sequences and 22 IgE and IgG epitopes. Allergen list 
of this server is updated every three months and majority of the allergen sequences are 
obtained from International Union of Immunological Societies (IUIS). SDAP server 
provides PASTA search (Pearson and Lipman, 1998) for testing potential allergenicity of 
new proteins based on F AO/WHO criteria. According to F AO/WHO allergenicity rules 
addressed in 2001 in a joint report entitled as 'Evaluation of Allergenicity of Genetically 
Modified Foods ' 
(http://www.fao.org/documents/show cdr.asp7url file=/docrep/OO7/yO82Oe/yO82OeOO.htm), 
there would be cross-reactivity with a given allergen if there is identity of six adjacent amino 
acids and over 35% cross-reactivity along 80 amino acid length on the given protein with a 
known allergen. It is also possible to change these cut-off values if the user desires. 
FARRP Allergen Database: Food Allergy Research and Resource Program allergen 
database contains 1537 entries of all kinds (food, contact, etc.) of allergens and putative 
allergens and gliadins that cause celiac disease. This database was created and maintained by 
a group at Monsanto Company. The sequences are obtained from public protein databases 
(SwissProt, PIR, PRF, PDB, and translations from annotated coding regions in GenBank and 
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RefSeq) by using 'allergen' and 'celiac' words as keywords. A minor portion of the entries 
were identified from Medline which were not entered into any database yet. This database 
also provides similar FASTA search as SADP does. All the sequences in FARRP are claimed 
to be unique because duplicate entries and irrelevant sequences are removed from the 
database. This database has been updated in January 2006. 
5.3 Materials and Methods 
FARRP and SDAP allergen databases were searched to assess potential allergenicity 
of LT-B, CT-B, CrylAb and cp4 epsps proteins. Both FARRP and SDAP provide 'full 
FASTA alignment and 80-mer sliding window search '. Full FASTA alignment considers that 
two proteins are homologues if e-value is less than 0.01. The alignment of the 80-mer sliding 
windows in both servers considers cross-reactivity between the query sequence and aligned 
sequences if there is 35% identity within 80 amino acid portion of the aligned proteins. In 
addition, SDAP also provides an additional feature which meets the second requirement for 
fulfilling F AO/WHO allergenicity rules. This server provides 'exact match for contiguous 
amino acids' search where the cut-off value is 6 amino acids. We also analyzed the 
sequences of CT-B, LT-B, CrylAb and cp4 epsps for presence of Asparagine-X-
Threonine/Serine (where X is not proline:P). 
5.4 Results and Discussion 
We have analyzed amino acid sequences of antigens; CT-B and LT-B which were 
used in this dissertation for generation of corn-derived vaccines, to assess their allergenic 
potential at the sequence level. We also wanted to analyze sequences of proteins which are 
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expressed in commercial crop varieties and therefore which are already in food supply. We 
chose insecticidal protein Cry lAb expressed in Bt corn and herbicide tolerant enzyme cp4 
epsps (5-enolpyruvylshikimate-3-phosphate synthase from Agrobacterium tumefaciens, 
involved in aromatic amino acid biosynthesis) which is expressed in roundup ready soybean 
(Fischhoff et al, 1987, Harison et al, 1996). 
CT-B & LT-B 
FASTA search for finding homologous sequences by using cut off value of e<0.01 
did not yield any LT-B or CT-B homologous among allergenic proteins listed in either 
FARRP or SDAP. The 80-mer sliding window search did not yield any hits in the 
aforementioned databases either. However, as it can be seen from Figure la and b, exact 
match search for contiguous amino acids by using 6 amino acids as cut off value, we found 2 
matches for CT-B and 1 match for LT-B, respectively. Figure 1 also indicates relevant 
potential N-glycosylation sites. 
The two allergens that have 6 amino acids exact match to CT-B are Can f 3 (Genbank 
accession number: AAB30434) which is dog serum albumin allergenic to human and Die v a 
(Genbank accession number: 76352) which is a lipid binding polyprotein from lungworm 
(Dictiocaulus viviparous) causing hypersensitivity in cattle. The allergen with a 6 amino acid 
exact match to LT-B is a wheat protein Tri a TAI. This short segment resides in signal 
peptide of LT-B. It was shown that the bacterial signal is cleaved in LT-B com (Chikwamba 
et al, 2002). However if the signal peptide is not degraded in com seed after cleavage it 
might still posses allergenic potential. Assessment of these matches and their possible 
significance are given in below. 
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FAO/WHO rules (2001) states that a protein might be an allergen if it shares 35% 
identity over 80 amino acid window and 6 contiguous amino acids with an allergen. Since 
these rules were published there have been criticisms over them by the scientific community. 
Only a small fraction of IgE epitopes have been identified. Given the fact that this 
characterization is done through in vitro mapping assays by using only small number of sera 
obtained from allergic individuals, what is known about allergic epitopes is far from being 
complete. It has been indicated by different groups that most known IgE epitopes are at least 
eight-amino acid long (Chatchatee et al, 2001). It was also shown that high affinity binding 
which is more relevant to in vivo allergenicity also requires at least eight amino acids 
(Banarjee et al, 1999, Rabjohn et al, 1999). Most striking evidence regarding six-amino acid 
window search size was shown by Stadler and Stadler in 2003. They indicated that whatever 
the source of the protein is, 60-80% of all protein sequences have six-amino acid matches to 
known allergens. 
Based on these findings we also searched for presence of eight contiguous amino 
acids in CT-B and LT-B with known allergens using SDAP and FARRP databases. We did 
not find any matches for these queries. However as Banerjee et al, also reported in 1999, 
some epitopes could be as short as five amino acids. Therefore these three matches would 
still have potential to cause allergy. In addition, presence of two potential N-glycosylation 
sites in CT-B, and one N-glycosylation site in LT-B (Figure 1) requires thorough assessment 
of potential allergenicity of recombinant products in com. 
CrylAb and cp4 epsps 
The same analyses were carried out for these two sequences; FASTA search, 80-mer 
sliding window search, 6 contiguous amino acid homology and also 8 contiguous amino acid 
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search with the above mentioned allergen databases. We also analyzed the sequences for 
presence of potential N-glycosylation sites. 
The FASTA search, 80-mer alignment and 8 contigous amino acid searches did not 
yield any hits. When we used 6 contiguous amino acid search we found nine homologous 
regions to known allergens in sequences of CrylAb and 4 regions for cp4 epsps (Fig 2). 
Information regarding these allergens (source organism, function of the allergenic proteins if 
known, etc.) is given in Tables 2 and 3. In addition to these homologous regions, there are 
also eight and two potential N-glycosylation sites in CrylAb and cp4 epsps, respectively. 
5.6 Concluding remarks 
We analyzed primary sequences of CT-B, LT-B, CrylAb and cp4 epsps following 
FAO/WHO guidelines. Our analysis indicated presence of varying numbers of 6 contiguous 
amino acids to known allergens and potential N-glycosylation sites. Analysis of extracts 
obtained from Bt com and roundup ready soybean with sera of individuals known to have 
food allergies indicated that these commercial transgenic crops are not allergenic (Batista et 
al, 2005). As it was mentioned earlier there has been growing doubts regarding value of short 
amino acid sequence homologies in assessment of allergenic potential of proteins (Stadler 
and Stadler, 2003, Silvanovich, 2006). Therefore presence of 6 contiguous amino acids and 
potential N-glycosylation sites in CT-B and LT-B might not render them allergenic. 
Moreover LT-B is highly resistant to low pH and heat. These findings raise concerns and 
these transgenic lines should be studied thoroughly. We suggest the following approach. 
Following the decision tree approach of FAO/WHO (see Chapter 1, Section 3.8), 
protein extracts obtained from com seeds transformed with either CT-B or LT-B should be 
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evaluated by specific (against sera of individuals and animals known to be allergenic to dog 
serum albumin, lung worm and wheat) and targeted serum tests. If negative result is obtained 
from serum screening, pepsin resistance and animal models should be utilized. 
For determining whether potential N-glycosylation sites were glycosylated and if they 
did whether they possess a(l-3)-fucosyl and P(l,2)-xylose groups, extracts should be 
analyzed by MALDI-TOF-MS analysis. The above mentioned studies are essential for 
complete characterization of corn-derived CT-B and LT-B to be able to assess safety of the 
product. 
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Database Institute URL 
Allergome.org Multiple partners http://www.allergome.org 
IUIS International Union of Immunological Societies http://www.allergen.org 
SWISS-PROT Swiss Institute for Bioinformatics http://www.expasy.org/cgi-bin/sport-search-de7allergen 
CSL The Central Science Laboratory at Sand Button York, United Kingdom http://csl.gov.uk/allergen 
PROTALL The Institute of Food Research of the United Kingdom http://www.ifr.bbsrc.ac.uk/Protall 
ALLALLERGY German National Research Center for Environment and Health http://www.allergy.net 
BIFS Biotechnology Information for Food Safety http://www.iit.edu/~sgendel/fa.htm 
Asthma and Allergy German National Research Center for Environment and Health http://cooke.gsf.de/asthmagen/main.cfln 
SDAP The University of Texas Medical Branch http://www.fermi.utmb.edu/SDAP/sdap_ovw.html 
FARRP Monsanto Company http://www.allergenonline.com 
Table 1. Currently available public allergen databases, institutes created and maintaining 
them and their URL addresses. 
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Allergen 6 aa match Organism Common name Source or function 
Gal d vitellogenin EFVPGA Gallus domesticus chiken Egg yolk 
Pha a 1 GSAQGI Phalaris aquatica grass Pollen 
Cup a 1 GNAAPQ Cupressus arizonica cedar Pollen 
Jun v 1 GNAAPQ Juniperus virginiana eastern red cedar Pollen 
Jun a 1 GNAAPQ Juniperus ashei mountain cedar Pollen 
Jun o 1 GNAAPQ Juniperus oxycedrus prickly juniper Pollen 
Tria 1 glutenin QLGQGV Triticum aestvum wheat Glutenin 
Horns 1 LPSAVY Homo sapiens human Autoantigen 
Chit 9 YVTLIXj Chironomus thummi thummi midge Hemglobin component 
Asp o 21 TLLGTF Aspergillus oryzae a kind of fungus Amylase A 
Phlp 11 ESKLKA Phleum pretense grass (timothy) Trypsin inhibitor homologue 
Eur m 14 VKRAEK Euroglyphus maynei mites Apolipophorin 
Table 2. List of allergenic proteins with 6 contiguous amino acid homologies to insecticidal 
protein CrylAb expressed in Bt corn (aa stands for amino acids). 
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Allergen 6 aa match Organism Common name Source or function 
Mala s 1 SHGASS Malassezia sympodialis fungi (molds) Unknown 
iDerp 7 VKSEDG Dermatophagoides pteronyssinus mites Unknown 
Oyj2 LLVPGS Cryptomeria japonica Japanese cedar Pollen 
Horv 1 LAVAAA Hordeum vulgare barley Trypsin/alpha-amylase inhibitor 
Table 3. List of allergenic proteins with 6 contiguous amino acid homologies to herbicide 
tolerant enzyme cp4 epsps expressed in roundup ready soybean (aa stands for amino acids). 
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A) Signal Peptide 
1 MVKLKFGVFFTVLLSSAYAHGTPQA//TDLCAEYHNTQ1HTLNDKIFSYTE 50 
51 SLAGKREMAIITFKNGATFQVEVPGSQHIDSQKKAIERMKDTLRIAYLTE 100 
101 AKVE KLC VWN NKTP H Al AAIS MAN 124 
Signal Peptide 
1 MVKVKCYVLFTALLSSLCAYGAPQSITELCSEYRNTQIYTINDKILSYTES 50 
51 MAGKREMVIITFKSGATFQVEVPGSQHIDSQKKAIERMKDTLRITYLTET 100 
101 KIDKLCVWN/VK7PNSIAAISMEN 124 
Figure 1. Amino acid sequences of CT-B (A) and LT-B (B). Underlined sequences indicate 6 
contiguous amino acid matches to known allergens. Italicized and bold characters indicate 
potential N-glycosylation sites. 
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A) 
1 MDNNPNINECIPYNCLSNPEVEVLGGERIETGYTPIDISLSLTQFLLSEFVPGAGFVLGL 60 
61 VDIIWGIFGPSQWDAFLVQIEQLINQRIEEFARNQAISRLEGLSNLYQIYAESFREWEAD 120 
121 PTNPALREEMRIQFNDMNSALTTAIPLFAVQNYQVPLLSVYVQAANLHLSVLRDVSVFGQ 180 
181 RWGFDAATINSRYNDLTRLIGNYTDHAVRWYNTGLERVWGPDSRDWIRYNQFRRELTLTV 240 
241 LDIVSLFPNYDSRTYPIRTVSQLTREIYTNPVLENFDGSFRGSAQGIEGSIRSPHLMDIL 300 
301 NSITIYTDAHRGEYYWSGHQIMASPVGFSGPEFTFPLYGTMGNAA.PQQRIVAQLGQGVYR 360 
361 TLSSTLYRRPFNIGINNQQLSVLDGTEFAYGTSSNLPSAVYRKSGTVDSLDEIPPQNNNV 420 
421 PPRQGFSHRLSHVSMFRSGFSNSSVSIIRAPMFSWIHRSAEFNNIIPSSQITQIPLTKST 480 
481 NLGSGTSWKGPGFTGGDILRRTSPGQISTLRVNJIAPLSQRYRVRIRYASTTNLQFHTS 540 
541 IDGRPINQGNFSATMSSGSNLQSGSFRTVGFTTPFMFSNGSSVFTLSAHVFNSGNEVYID 600 
601 RIEFVPAEVTFEAEYDLERAQKAVNELFTSSNQIGLKTDVTDYHIDQVSNLVECLSDEFC 660 
661 LDEKKELSEKVKHAKRLSDERNLLQDPNFRGINRQLDRGWRGSTDITIQGGDDVFKENYV 720 
721 TLLGTFDECYPTYLYQKIDESKLKAYTRYQLRGYIEDSQDLEIYLIRYNAKHETVNVPGT 780 
781 GSLWPLSAPSPIGKCAHHSHHFSLDIDVGCTDLNEDLGVWVIFKIKTQDGHARLGNLEFL 840 
841 EEKPLVGEALARVKRAEKKWRDKREKLEWETNIVYKEAKESVDALFVNSQYDRLQADTNI 900 
901 AMIHAADKRVHSIREAYLPEL SVIPGVNAAIFEELEGRIFTAFSLYDARNVIKNGDFNNG 960 
961 LSCWNVKGHVDVEEQNNHRSVLWPEWEAEVSQEVRVCPGRGYILRVTAYKEGYGEGCVT 1020 
1021 IHEIENNTDELKFSNCVEEEVYPNNTVTCNDYTATQEEYEGTYTSRNRGYDGAYESNSSV 1080 
1081 PADYASAYEEKAYTDGRRDNPCESNRGYGDYTPLPAGYVTKELEYFPETDKVWIEIGETE 1140 
1141 GTFIVDSVELLLMEE 1155 
B) 
1 MSHGASSRPATARKSSGLSGTVRIPGDKSISHRSFMFGGLASGETRITGLLEGEDVINTG 60 
61 KAMQAMGARIRKEGDTWIIDGVGNGGLLAPEAPLDFGNAATGCRLTMGLVGVYDFDSTFI 120 
121 GDASLTKRPMGRVLNPLREMGVQVKSEDGDRLPVTLRGPKTPTPITYRVPMASAQVKSAV 180 
181 LLAGLNTPGITTVIEPIMTRDHTEKMLQGFGANLTVETDADGVRTIRLEGRGKLTGQVID 240 
241 VPGDPSSTAFPLVAALLVPGSDVTILNVLMNPTRTGLILTLQEMGADIEVINPRLAGGED 300 
301 VADLRVRSSTLKGVTVPEDRAPSMIDEYPILA.VAAAFAEGATVMNGLEELRVKESDRLSA 360 
361 VANGLKLNGVDCDEGETSLWRGRPDGKGLGMASGAAVATHLDHRIAMSFLVMGLVSENP 420 
421 VTVDDATMIATSFPEFMDLMAGLGAKIELSDTKAA 455 
Figure 2. Amino acid sequences of CrylAb (A-NCBI accession #: PQA370) and cp4 epsps 
(B-NCBI accession #: Q9R4E4). Underlined sequences indicate 6 contiguous amino acid 
matches to known allergens. Italicized and bold characters indicate potential N-glycosylation 
sites. 
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Chapter 6: Preliminary analysis of sera specific anti-LT-B antibodies in 
pigs administrated orally with corn-derived LT-B 
Sule Karaman , Mathew Erdmann, Kan Wang 
6.1 Abstract 
An oral immunization trial was conducted to test the antigen specific antibody 
production in pigs against B subunit (LT-B) of E. coli heat labile enterotoxin. Transgenic 
corn producing recombinant LT-B was used as a delivery agent. Pigs were fed with one of 
two doses of transgenic com on days 0, 7, 21 and 34. Sera were collected weekly over a 41 
day period starting the day before the initial feeding and analyzed for presence of anti-LT-B 
IgG and serum IgA. Our preliminary results indicated that 50% of subjects in the treatment 
groups had elevated levels of anti-LT-B IgG in their sera. Also, sera of 50% and 75% of the 
pigs in lxLT-B and 2xLT-B groups, respectively, were anti-LT-B IgA positive. This 
preliminary work investigating dosage requirements for antibody induction against corn-
derived LT-B formed a reference for future studies which will evaluate potential of corn-
derived LT-B as an adjuvant in pigs. 
6.2 Introduction 
Infectious diseases cause high mortality and morbidity in livestock including pigs. 
Porcine reproductive and respiratory syndrome virus (PRRSV), foot and mouth disease virus 
(TMDV), classical swine fever virus (CSFV) and enterotoxigenic E. coli are among the 
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pathogens that have had important economic impact on the swine industry (Nilubol et al. 
2004, Song et al 2005, Maurer et al. 2005, Verdonck et al. 2005, Joensuu et al. 2004). In 
addition to the economic loss that they cause, the prevalence of these infectious diseases 
raises concerns about pork safety. Therefore, development of effective, safe and cost-
efficient vaccines is essential. 
Recently, a significant amount of work has been done on the development of mucosal 
vaccines for prevention of a number of diseases that affect pigs. Oral immunization of newly 
weaned pigs with FaeG and that of suckling pigs with F4 fimbriae against E. coli (Verdonck 
et al. 2005, Snoeck et al.2003), oronasal administration of CSFV replicon particles (Maurer 
et a. 2005), administration of a DNA vaccine against PRRSV to the tongue of pigs via gene 
delivery gun (Barfoed et al. 2004), oral delivery of recombinant corn-derived spike (S) 
protein of transmissible gastroenteritis virus (TGEV) in a pre-immunize-oral boosting study 
(Lamphear et al. 2004) and intranasal and oral vaccination against foot-and-mouth disease 
(Song et al. 2005) have indicated promising results for success of mucosal vaccination in 
pigs. 
Mucosal vaccination is particularly important and essential for prevention of enteric 
infections. Antigen-specific antibody induction at intestinal mucosa is required to defeat 
pathogens that enter the intestine (Porter et al. 1974, Bloom and Boedeker, 1996). The best 
level of response at intestinal mucosa can be obtained by oral immunization however; most 
of the protein antigens are not stable in gastrointestinal (GI) tract. Another challenge 
regarding oral immunization is oral tolerance. There are a few proteins which are stable in 
the GI tract. These include bacterial toxins such as cholera toxin (CT) from Vibrio cholera 
and its homologue heat labile toxin (LT) from enterotoxigenic strains of E. coli. CT and LT 
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are multimeric proteins made of a pentameric non-toxic subunit B and the toxic subunit A 
(Freytag and Clements, 2005). B subunits bind to receptors on intestinal epithelial cells and 
aid in internalization of the toxic A subunit which leads to a sequence of intracellular events 
resulting in ion and water loss. CT, LT and LT-B are strong immunogens and mucosal 
adjuvants (Freytag and Clements, 2005). CT-B alone is weakly immunogenic (Hyland et al. 
2004). Due to toxicity of the holotoxins CT and LT, which results in severe diarrhea, much 
of the interest has focused on CT-B and LT-B. 
The purpose of this work was to investigate antibody response against corn-derived 
LT-B in post-weaning pigs. This preliminary work tested dosage requirements for elicitation 
of LT-B specific antibodies in pigs that were orally administered corn-derived LT-B. The 
long term goal of this project is to investigate whether corn-derived LT-B can be used as oral 
adjuvant for pigs. The results presented here form a basis for further studies. 
6.3 Materials and Methods 
Immunization of pigs with LT-B-corn 
All animal procedures were approved through the Iowa State University (ISU) 
Committee on Animal Care. Naturally farrrowed, cross-bred, weaned pigs were obtained at 
three weeks of age from a high health status herd located in Iowa. Prior to starting of the 
experiment, pigs were allowed a one week adjustment period with a light-bulb above their 
tub to keep the room warm in ISU animal facility where they were housed throughout the 
experiment with 15/7 light-dark cycle. Pigs were fasted 12 hours prior to syringe feeding. 
Table 1 indicates the design of the overall study. Pigs were fed with regular pig feed, 
starter ration throughout the study. Initial LT-B immunization was done when the pigs were 
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four weeks old. Feedings were carried out on days 0, 7, 20 and 34. Twelve pigs were divided 
into three groups of four: 1) wild type (WT) group. Pigs in this group were fed with non-
transgenic com powder suspension. 2) lxLT-B and 3) 2xLT-B groups. Pigs in these groups 
were fed with two different doses of LT-B com suspensions. The lxLT-B dose corresponds 
to amount used in a human Phase I clinical trial testing antibody response against potato 
derived-LTB (Tacket et al, 1998). In that study, the average dose of LT-B used was 750 pg 
per subject. We generated a dose/kg ratio by considering average weight of a human as 80 
kg. We obtained a dose/kg of body weight ratio and used it as lxLT-B dose in this study 
(9.38 ng/kg). We included a group receiving double dose to increase the chances of 
responders due to likely differences in processes in human and swine gastrointestinal 
systems. On day 0, lxLTB and 2xLTB doses corresponded to body weight ratios of 9.38 and 
18.76|a,g of LTB/kg, respectively. Due to limited amount of LT-B com we had, for the last 
three feedings the doses were 8.83 and 17.76pg of LTB/kg. In order to feed pigs with a 
constant ratio of LTB, we increased the amount of transgenic com powder for both group 2 
and 3 following initial immunization, based on the expected weights of the pigs (see Table 
1). Throughout the study, pigs within a group were all held in a single enclosure. 
Both non-transgenic and LT-B-com powders were re-suspended in Esbilac milk 
replacer (PetAg, Hampshire, USA) to desired concentration. The suspensions were then 
delivered to pigs' mouths with 60 ml syringes. Some volume of leakage occurred during each 
feeding. Therefore the fed volume was always close but approximate. 
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Collection of blood samples and analysis of sera for quantification of anti-LTB IgG and anti-
LTB IgA antibodies 
Approximately 3 ml of blood were obtained from the anterior vena cava via 
disposable syringe and 20 gauge needle on days -1, 6, 13, 20, 27, 34, and 40. Blood samples 
were collected directly into serum separator tubes which were centrifuged in a large, floor 
model centrifuge at 3500 rpm for 25 minutes at 5°C. Sera were then aliquoted into 1.5 ml test 
tubes and frozen at -20°C. 
For anti-LTB IgG and anti-LTB IgA analysis, high binding microtiter plates (Costar 
3590, Fisher Scientific, PA, USA) were coated with mixed type gangliosides (Type III from 
bovine, Sigma G-2375, MO, USA), 1.5 gg/well diluted in sodium carbonate coating buffer 
[3.75 mM NaaCOg, 8.75 mM NaHCOg, 0.75 mM NaNg, pH:9.6]. Following incubation at 
room temperature for 1 h, 25 ng/well pure bacterial LTB (John Clements, Tulane University, 
LA, USA), diluted in lxPBS (phosphate buffer saline) were loaded into wells and incubated 
at 37°C for 1 h. Following this, wells were blocked with 5% dry milk (Difco 232100, MD, 
USA) for 1 h at room temperature. Serum samples diluted in lxPBS were loaded and 
incubated at 37°C for 1 h. Next, plates were incubated at 37°C for 1 h with biotinylated anti-
pig-IgG (Bethyl Laboratories Inc. A100-104P TX, USA) and anti-pig-IgA (Serotec Ltd. 
AAI40P Oxford, UK) diluted in 1% dry milk at 1/20,000 for IgG and 1/10,000 ratios, 
respectively. Enzyme streptavidin-horse radish peroxidase (554066, BD Biosciences, X, 
USA) was added to the plates at 1/20,000 ratio diluted in 1% milk and incubated at room 
temperature for 30 minutes. Color development was obtained by incubating the plates at 
room temperature for 30 minutes with ABTS (3-ethylbenzthiazoline-6-sulfonic acid, Sigma 
A-1888, MO, USA) substrate. Incubations with enzyme and substrate and end-point readings 
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were carried out as recommended by the manufacturer (BD Biosciences). A total volume of 
200 juil per well was used at each step except for blocking. Milk 250|j.l (5%) was loaded into 
each well for blocking. Anti-LTB antibody levels were calculated as pg/ml by using standard 
curves developed from pig reference serum (Bethyl Laboratories Inc. A100-104P TX, USA). 
The standard ranges used were 0.65, 0.325, 0.161, 0.08, 0.04, 0.02 and 0.0 pg/ml and 4, 2, 1, 
0.5, 0.25, 0.125, 0.063 and 0.031 pg/ml for IgA and IgG, respectively. 
Statistical analysis 
Anti-LT-B antibody kinetic data for serum IgG and serum IgA were analyzed with 
ANOVA for estimation of mean differences in SAS® V8.2. 
6.4 Results and Discussion 
We investigated the ability of corn-derived LT-B to induce LT-B specific antibody 
production in pigs. The sequence of the synthetic LT-B gene used to generate a transgenic 
corn line used in this study came from E. coli strain that infects human (NCBI #: JO 1646). 
LT-B subunits of heat labile holotoxins obtained from E. coli strains infecting pigs (NCBI #: 
Ml 7873) and human are highly homologous. As indicated in figure 4, these two subunits are 
99.97% homologues at amino acid sequence level and three dimensional structures of both 
versions are considered the same (Spangler 1992). Therefore antibodies raised against 
different versions cross react (Kazemi and Finkelstein, 1990). 
Pigs were orally immunized with ground LT-B com in a liquid suspension. In this pig 
feeding trial, two different doses of LT-B com were used. A dose/body weight ratio based on 
a human trial carried out with LTB-potato (Tacket et al., 1998) was taken as reference. The 
ratio used in the trial carried out by Tacket et al., 9.38 ng/kg body weight, formed lxLTB 
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group in this study. Since human and pig gastrointestinal tract and immune systems are likely 
to function differently, a 2xLTB dose group was included in this study to avoid possibility of 
non-induction of the specific antibodies with lx dose. LT-B com was given to pigs on days 
0, 7, 21, and 35. Blood samples were collected on days -1, 6, 13, 20, 27, 34 and on day 41. 
Here we report induction of LT-B specific serum IgG and serum IgA antibodies in pig sera 
upon oral administration of corn-derived LT-B. 
Induction of LT-B specific IgG and IgA in sera of each individual subject: 
LT-B specific antibodies were quantified with ganglioside dependent ELISA. Figure 
1A shows anti LT-B specific IgG in four pigs of group that were administrated with wild 
type non-transgenic com. One of the subjects (pig-3), showed a higher level of specific IgG 
compared to the other three pigs even before the experiment started (day -1). While it was 
not clear whether this high level was due to LT-B contamination in the sample or possible 
passive immunity through maternal pass over, this pig seemed to have higher specific 
antibody throughout the experiment. Interestingly, when IgA responses were analyzed in this 
group, pig-3 did not seem to be an outlier (figure l.D). Instead, in sera of all subjects in WT 
group a comparable low level of background IgA levels were detected throughout the study. 
When IgG levels of individual subjects in lxLTB group were analyzed, it was 
observed that, pig-7 showed a slight response on bleed days 27 and 34 (Figure l.B). Very 
high levels of anti-LT-B IgA was detected in serum of pig-7 on day 27 following similar 
pattern that was observed for IgG level of this particular subject. Serum IgA level of pig-5 
was also elevated on day 27 even though anti-LT-B IgG was detectable on day 34 for this 
subject (Figure l.E&B). Anti-LT-B IgG and IgA levels peaked at different days in sera of the 
responders in this group. Peak values for both kinds of antibodies were observed on day 27 in 
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serum of pig-7 and on day 41 in serum of pig-5. The IgA level in serum of pig-7 dropped 
largely on day 34 and slightly increased after last feeding on day 35. On the other hand, IgA 
level in serum of pig-5 continued increasing gradually until the end of the study. On day 41, 
IgA levels of both pig-7 and pig-5 seemed comparable. 
As shown in figure l.Ca, much rapid induction of anti-LT-B IgG were observed in 
serum of responder pigs in 2xLTB group (pig-10 and pig-12). On day 13, the specific IgG 
levels in serum of pig-10 was approximately 5.5 times higher than the average of pre-feeding 
values of this group. Similarly, on day 13, the specific IgG level in serum of pig-12 was also 
higher (3.4x) than average of pre-bleeding antibody levels in this group. A second peak value 
was recorded IgG levels in serum of pig-10 on day 34 following administration of corn 
derived LT-B on day 21. 
When serum IgA levels were analyzed in sera of 2xLTB group (Figure 1 ,F), three of 
the subjects seem to have increased levels of LT-B specific IgA. These were pig-9, pig-10 
and pig-11. Although anti-LT-B IgGs were recorded in serum of pig-12, anti-LT-B IgA 
levels in serum of this subject were not different than background. The level of IgA in serum 
of pig-9 began increasing on day 20, continued to increase until day 34, however dropped 
after day 34 even though the pigs were fed one more time with LT-B corn on day 35. Anti-
LT-B IgA levels in serum of pig-10 peaked twice as it was the case for IgG levels in serum 
of this particular pig. However peaks were observed on days 27 and 41 for IgA levels. Anti-
LT-B IgA levels in serum of pig-11 started increasing on day 27 and kept increasing until 
day 34 which was followed by drop on day 41. It should be noted that even though pig-11 is 
the subject with the highest level of serum IgA, anti-LT-B IgG level in serum of this subject 
did not increase compared to the level recorded before the first feeding. 
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As a result, 2 out of 4 of the subjects in each transgenic corn treatment groups (lx 
LTB and 2xLTB) showed induction of anti-LT-B IgG antibodies upon oral administration of 
LT-B corn, with higher levels in 2xLTB group compared to that observed in lxLTB group. 
While anti-LT-B serum IgA levels were elevated in 50% of the subjects in lxLTB group, 
anti-LT-B antibody levels were detectable in sera of 75% of the subjects in 2xLTB group. 
Overall serum IgG analysis: 
As it can be seen in Figure 2, anti-LT-B IgG levels in sera of the 2x LTB group began 
to increase on day 6 upon initial sensitization performed on day -1. The IgG level in 2x group 
reached a peak on day 13 after first two feedings and began to decline gradually. IgG levels 
in lx LTB group and WT group followed a similar pattern and antibody levels until day 34. 
On day 41 IgG levels in lxLTB group seemed increasing compared to WT group. If antibody 
levels were screened during a longer period, an increase in IgG levels in lx LTB group might 
have been observed. This delayed response is likely due to the low amount of LTB given 
with lx dose, because the increase in IgG levels was observed 7 days after the first feeding 
for 2xLTB group. 
A high background for the level of LT-B specific IgG was observed in wild type 
group and in sera of treatment groups (lxLTB and 2xLTB) on day -1 prior to initial 
sensitization with corn-derived LT-B. This might be due to: 1) cross-reactivity of other 
proteins in sera of pig with secondary antibody used in our ELISA procedure to detect anti-
LTB IgGs, 2) the presence of a base level of anti-LTB antibodies in sera of piglets in all 
groups which might have been acquired through passive transfer of antibodies in maternal 
colostomas. 
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While increased anti-LTB antibody levels are seen in 2xLTB group (Figure 2), due to 
small sample size and large differences between individual subjects, the comparisons among 
all three groups at any sample collection day did not yield statistically significant results (p's 
for all pair wise comparisons >0.05). 
Overall serum IgA analysis: 
In the case of serum IgA overall analysis, a different pattern was observed such that, 
the highest anti-LT-B serum IgA level was observed on day 27 in lxLT-B group. As 
indicated in figure 3, the IgA levels began to rise on day 20 for both treatment groups. The 
third feeding performed on day 20 boosted IgA levels in both lxLTB and 2xLTB groups. 
Unlike lxLTB group, the highest level of 2xLTB group was observed on day 34. On day 34, 
anti-LT-B IgA levels of lxLTB group declined sharply, followed by an increase upon last 
feeding administered on day 35. Interestingly, the last feeding did not further increase the 
levels of IgA in sera of 2xLTB group. As in the case of overall IgG analysis (Figure 2), a 
high level of background was observed. However the level of background was much lower 
than that of IgGs. This might be due to nature of anti-LT-B antibody-secondary antibody 
interaction which leads to cross reactivity. Or as stated before in previous section, maternal 
IgG antibodies might have passed to pigs through breast feeding yielding a baseline of 
specific IgG antibodies at the start of the feeding trial. It should also be noted that, as in the 
case of comparison of averages of anti-LT-B IgG levels in all groups, comparisons between 
treatment groups versus wild type group or comparisons between treatment groups did not 
yield any significant difference on any given sample collection day. 
These preliminary results indicated that two out of four subjects (50%) in treatment 
groups showed elevated serum IgG levels. Two out of four subjects (50%) of the lxLTB 
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group produced detectable levels of serum IgA with respect to WT group. Anti-LTB IgA 
antibodies were detectable in three out of four subjects (75%) in 2xLTB group. 
This trial forms a basis and preliminary data to design a second trial with a larger 
sample size to obtain more sound results. Several parameters should be considered in the 
next study: 1) Using pigs from mothers with no anti-LT-B antibodies could decrease the 
background antibody readings. 2) Adding a higher dose to the study might eliminate 
occurrence of non-responders because certain individuals might react to higher doses. 3) 
Monitoring the antibody levels for longer periods could give a better idea to determine the 
number and timing of antigen administration. 4) Functionality of antibodies should be tested 
with challenge with enterotoxigenic strain of E. coli which causes diarrhea in pigs. 
This study suggests that corn-derived LTB can induce serum specific IgG and IgA in 
pigs. More experiments are needed to confirm whether LTB-corn has potential to serve as a 
vaccine against diarrhea and it might also be utilized as carrier or adjuvant for antigens to 
treat other pig diseases. 
6.5 Further experiments 
Fecal samples, saliva and tears are going to be analyzed by our collaborators Dr. Joan 
Cunnick and her student April Beyer. In this chapter we report LT-B specific serum IgG and 
serum IgA responses. 
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Table 1. Design of the study. 
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Figure 1. Anti-LT-B IgG and anti-LT-B IgA levels in sera of 12 pigs studied. * indicates the day before administration of LT-B corn. 
The results are presented as (xg/ml. A), B), C) indicate anti-LT-B IgG levels in sera of pigs in WT, lx LTB and 2x LTB groups, respectively. 
D), E), F) indicate anti-LT-B IgA levels in sera of pigs in WT, lx LTB and 2x LTB groups, respectively. 
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Figure 2. Anti-LT-B IgG levels in sera of subjects in WT, lxLTB and 2xLTB groups. 
Four pigs were used in each group as subjects. * indicates the day before administration of 
LT-B corn. The results are presented as mean±SE in (j,g/ml. 
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Figure 3. Anti-LT-B IgA levels in sera of subjects in WT, IxLTB and 2xLTB groups. 
Four pigs were used in each group as subjects. * indicates the day before administration of 
LT-B corn. The results are presented as mean+SE in jig/ml. 
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Figure 4. Amino acid sequences of LT-B subunits from enterotoxigenic strains infecting 
human (h) and pigs (p). Two versions are 99.97% homologous. 
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Chapter 7: General conclusions 
In this work we examined the potential of corn to be utilized as a vehicle for 
production of vaccines and vaccine components which would be used in oral immunization 
regimens for both human and livestock. We used nontoxic, highly homologous B-subunits of 
heat labile toxin from enterotoxigenic strains of E. coli (LT-B) and cholera toxin from Vibrio 
cholerae (CT-B) as model antigens. The following aspects of plant-derived vaccines were 
explored in this dissertation; 1) investigation of long term antibody and immune memory 
responses to a booster administration following initial oral immunization with LT-B corn 
(Chikwamba et al, 2002), 2) generation of transgenic corn producing CT-B in their seeds and 
structural and immunogenic characterization of corn derived CT-B, 3) using LT-B and CT-B 
as carriers to produce a corn derived oral vaccine against Alzheimer's disease, 4) evaluation 
of the allergenic potential of LT-B and CT-B at amino acid sequence level to determine a 
strategy for complete analysis of these two transgenic corn lines, 5) analysis of immunogenic 
potential of corn derived LT-B in pigs. 
Chapter 2 indicates that plant derived vaccines can induce immune memory 
formation. Mice were immunized with LT-B corn when they were young and a booster 
administration was given eleven months after initial immunization. LT-B specific IgG and 
IgA antibody concentrations were monitored during 11 months. When mice were 14-mo-old, 
booster immunization through feeding of corn derived LT-B and injection of bacterial LT-B 
was carried out. A rapid and strong anti-LT-B IgG and IgA response was observed. An 
accelerated immune response in this case shows that antigens delivered in edible tissues of 
plants through feeding can elicit immune memory. This finding provides a new evidence for 
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potential of vaccination with plant derived antigens through feeding. This work also 
examined responses of aged mice against corn derived LT-B. A lower level of IgG antibodies 
in sera and lower levels of fecal IgA were recorded in aged mice compared to the response 
observed in young mice. Serum IgA levels in sera of aged mice were comparable to that of 
young mice. Interestingly, fecal IgA and serum IgA were detectible in sera of aged mice as 
early as one week following first immunization. These differences were attributed to 
alterations that occur in the mucosal immune system of aged individuals. In accordance with 
observations reported by other studies, we showed by examining levels of total IgGia and 
IgGi in aged and young mice that aged mice responded with more of Th-2 type immune 
response. This observation might relate to the faster IgA response in aged mice. The results 
of this study evidenced the following; 1) immune memory forms upon administration of 
antigens produced in palatable parts of plants when they are delivered through feeding, 2) 
lower levels of fecal IgA and serum IgG observed in sera of aged mice suggest that LT-B 
may not be an efficient adjuvant in aged individuals when used for the first time. 
Expression of CT-B in com seeds, biochemical characterization of com derived CT-B 
and its immunogenic properties are reported in Chapter 3. Our results indicated that CT-B 
can be expressed at high levels in com seeds. It was shown via ganglioside dependent ELISA 
that com derived CT-B forms pentamers as its bacterial counterpart. Com derived CT-B is 
also capable of inducing CT-B specific IgG. We also wanted to address whether com derived 
CT-B and com derived LT-B would work synergistically to induce higher levels of 
antibodies when given together. Our results were suggestive of this interaction on certain 
days of sample collection. An interesting outcome of our mice feeding study was that 
antibodies raised against com derived CT-B do not cross react significantly with bacterial 
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LT-B. This observation may be explained by possible structural differences of corn derived 
CT-B when compared with bacterial CT-B. Western blot analysis of corn derived CT-B 
suggested that the bacterial signal is not cleaved. Therefore corn derived CT-B may have 
different epitopes leading to presence of new structures on anti-CT-B antibodies which do 
not recognize the bacterial LT-B. Partial protection against toxin challenges observed in our 
treatment groups may also be explained due to this structural difference. Further studies need 
to be conducted to address this observation. To test this hypothesis, a transgenic corn line 
transformed with CT-B gene encoding a mature peptide (without signal peptide) should be 
produced and this corn should be evaluated in mice. In this mice experiment one should 
compare immunogenicity of mice fed with 1) corn-derived CT-B mature protein, 2) corn-
derived CT-B (with bacterial signal peptide, as this chapter) and 3) bacterial CT-B spiked 
corn meal. This comparison will be helpful to address importance of the bacterial signal 
peptide in immunogenicity of the subunit. 
Our efforts to produce a corn derived vaccine against Alzheimer's disease (AD) are 
presented in Chapter 4. Amyloid beta protein (AP42) plays a critical role in pathogenesis of 
Alzheimer's disease. Active immunizations with amyloid beta and passive immunizations 
with anti-amyloid beta antibodies were shown to treat and prevent induction of the disease in 
mice models of AD. LT-B and CT-B have been shown to act as carriers for unrelated 
antigens. We generated fusion genes with amyloid beta protein to use LT-B and CT-B as 
carrier for this antigen. Analysis of calli transformed with LT-B- A^ fusion gene indicated 
expression of LT-B and correct assembly of pentamers. However although mRNA was 
detectable for the whole fusion gene, we failed to detect AP42 protein. Analysis of protein 
extracts from transformed calli indicated that transgenic protein (product of the fusion gene) 
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moves along with pentameric LT-B. This suggests that amyloid beta protein was either 
cleaved from the fusion protein by an unknown protease or the part of mRNA encoding for 
amyloid beta might not be stable. Our second approach utilized an internal permissive site (a 
site in surface exposed part of CT-B which allows insertion of foreign epitopes) to express 
amyloid beta epitopes on CT-B. We generated two versions of the gene with N-terminal and 
middle epitopes of amyloid beta protein. Our gene design failed to produce pentameric or 
monomeric CT-B. We also failed to detect epitopes of amyloid beta. While we followed the 
recombinant protein strategies used successfully by other groups, we did not produce 
functional fusion proteins that would allow us to continue the experiments. Success of fusion 
strategies has to be evaluated on a case by case basis. For the LT-B Ap42 fusion a new 
construct without any hinge and with different hinges might be tested. In addition, N-
terminal fusion of A|^ to LT-B may yield to different outcomes. For insertion of epitopes 
into the permissive site of CT-B shorter fragments might be tested because we had 
introduced neighboring amino acids around the epitopes. 
Ever since the StarLink corn incidence, the potential of genetically modified food 
crops to trigger allergies has become a great concern. Analysis of allergenic potential of 
model antigens used in this study at amino acid sequence level was described in Chapter 5. 
We wanted to include analysis of transgenic crops which are already in food chain and 
deregulated to infer insights regarding usefulness of this analysis. Sequences of CrylAb 
(insecticidal protein from Bacilllus thrungiensis) and cp4 epsps (herbicide tolerant enzyme, 
5 -enolpyruvylshikimate-3 -phosphate synthase from Agrobacterium tumefaciens) which are 
recombinantly produced in Bt com and Roundup Ready soybean respectively were selected 
to serve as controls. FAO/WHO guidelines were followed and two publicly available 
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databases (FARRP and SDAP) were used for the analysis. Potential N-glycosylation sites on 
the sequences were also determined since these sites might possess allergenic a(l-3)-fucosyl 
and P(l,2)-xylose glycosyl groups. Varying numbers of 6 contiguous amino acids 
homologous to known allergens and N-glycosylation sites were found in all sequences 
analyzed. These findings suggest that further analysis of transgenic corn lines transformed 
with LT-B and CT-B are required. Protein extract from these lines should be tested against 
sera of individuals with food allergies. A broader analysis should be performed with sera of 
individuals who have different classes of allergies. Interestingly, despite the presence of a 
high number of 6 contiguous amino acids homologous to known allergens and N-
glycosylation sites, similar analysis with sera of individuals with food allergies indicated that 
Bt corn and Roundup Ready soybean protein extracts do not cross react with IgEs. This 
comparion may suggest that LT-B and CT-B corn itself may or may not cause food allergy. 
However, because LT-B and CT-B are known to be strong immunogens, similar analysis 
with LT-B and CT-B com may yield different outcomes. Therefore full analysis following 
F AO/WHO guidelines should be conducted. If negative results are obtained from serum 
screening, pepsin digestion and animal models should be utilized. 
Enterotoxigenic strains of E. coli is a leading cause for diarrhea in humans, it also 
causes severe diarrhea in pigs. A pig feeding experiment with LT-B com was carried out and 
results are presented in Chapter 6. We fed newly weaned pigs with two doses of com derived 
LT-B (IxLTB: 8.83 gg/kg of body weight; 2xLTB: 17.76pg/kg of body weight) four times. 
Elevated anti-LT-B specific IgG antibodies were detectable in sera of 50% of the subjects in 
treatment groups. Fifty percent of the subjects in IxLTB group produced detectable levels of 
serum IgA with respect to the WT group. Anti-LTB IgA antibodies were recorded in 75% of 
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the subjects in 2xLTB group. These preliminary results suggest that LTB-corn produced in 
our lab is capable of inducing serum IgG and IgA in pigs. Therefore LTB-corn has potential 
to serve as a vaccine for pigs against diarrhea and it might also be utilized as carrier for 
antigens to treat other pig diseases. 
Major conclusions inferred from the work presented in this dissertation can be 
summarized as follows. Plant derived vaccines are capable of inducing immune memory 
which strengthens the potential of immunizations through feeding to be part of clinical 
practices. Administration of corn derived CT-B and LT-B in combination has potential to 
induce higher levels of protective antigens. This outcome suggests that a mixture of these 
two components may be used in vaccine preparations targeting protection against both 
cholera and ETEC. Ability of corn seeds to allow expression of high levels of recombinant 
proteins and ability of LT-B and CT-B to serve as carrier for unrelated antigens makes them 
attractive candidates to produce fusion proteins. Many versions of the peptides have to be 
tested because not all fusion strategies lead to functional proteins. A transient corn expression 
system for screening of high number of constructs should be developed. Use of corn leaf as 
transient testing system for this purpose is being investigated in our lab. Amino acid 
sequences of LT-B and CT-B show similarities to short fragments found in a few known 
allergens. There are also potential N-glycosylation sites on these two proteins. Complete 
analysis of allergenic potential of these two transgenic com lines has to be conducted 
following F AO/WHO guidelines. Testing immunogenic potential of LT-B com in pigs has 
also indicated its usefulness of com derived LT-B in vaccine preparations for preventing 
diarrhea in pigs. Our results strengthen the potential of com to be used as production and 
delivery vehicle for antigens through oral immunization. 
